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i 
ABSTRACT 
 
The cell wall mycolyl-arabinogalactan-peptidoglycan complex is essential in mycobacterial 
species, such as Mycobacterium tuberculosis and is the target of several antitubercular drugs. 
Arabinofuranosyltransferase enzymes, such as EmbA, EmbB, and AftA, play pivotal roles in the 
biosynthesis of arabinogalactan. The anti-tuberculosis agent ethambutol (EMB) targets 
arabinogalactan biosynthesis through inhibition of Mt-EmbA and Mt-EmbB and also targets the 
biosynthesis of the important immunomodulatory molecule lipoarabinomannan (LAM), through 
inhibition of Mt-EmbC. 
 
A bioinformatics approach identified putative integral membrane proteins in Mycobacterium 
smegmatis, M. tuberculosis and the closely related species Corynebacterium glutamicum, with 
features common to the GT-C superfamily of glycosyltransferases. A novel 
arabinofuranosyltransferase, AftC, was deleted from both M. smegmatis and C. glutamicum and 
shown to be an internal branching α(1→3) arabinofuranosyltransferase involved in 
arabinogalactan biosynthesis.   Further studies revealed a truncated LAM whereby the arabinan 
domain was severely reduced and consisted of a simple linear arabinan of approximately 12-15 
α(1→5) linked Araf residues. This mutant LAM was also shown to be a potent stimulator of 
TNF-α production using a human macrophage cell line, thus illustrating that masking of the 
mannan core by arabinan in wild type LAM alters its ability in the production of this cytokine. 
We also describe a further arabinofuranosyltransferase, AftB. Deletion of its orthologue in C. 
glutamicum resulted in a viable mutant and biochemical analysis revealed the complete absence 
of terminal β(1→2)-linked arabinofuranosyl residues. Further analysis confirmed AftB as a 
terminal β(1→2) arabinofuranosyltransferase, which was also insensitive to EMB. 
 
The bioinformatic search for cell wall glycosyltransferases led to the identification of a 
rhamnosyltransferase in C. glutamicum, RptA. Deletion resulted in a reduction of terminal-
rhamnopyranosyl linked residues and as a result, a corresponding loss of branched 2,5-linked 
arabinofuranosyl residues. Furthermore, analysis of base-stable extractable lipids from C. 
glutamium revealed the presence of decaprenyl-monophosphorylrhamnose, a putative substrate 
for the cognate cell wall transferase. Altogether, these studies have shed further light on the 
complexities of Corynebacterianeae cell wall biosynthesis, and represent potential new drug 
targets. 
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1.1. Mycobacterial Classification and Phylogenetic Analysis 
Tuberculosis (TB) has been a prominent human disease for several thousand years.  
Mycobacterium tuberculosis, the aetiological agent of TB, belongs to the genus 
Mycobacterium, which is presumed to have originated more than 150 million years ago 
(Daniel, 2006; Hayman, 1984).  Phylogenetic analysis of bacilli isolated from patients living 
in remote East African villages, suggest that these isolates predate the modern M. 
tuberculosis complex (MTBC) members, representing the ancestral species from which these 
modern members may have evolved (Gutierrez et al., 2005). This has led to the assumption 
that an ancient predecessor co-existed and co-evolved nearly 3 million years ago with early 
East African Hominids. The organism which later underwent an “evolutionary bottleneck”, 
some 20,000 years ago, resulting in the present strains that account for the majority of TB 
worldwide (Brosch et al., 2002; Daniel, 2006; Kapur et al., 1994; Sreevatsan et al., 1997a).    
1.1.1. The Genus Mycobacterium  
Members of the MTBC include M. tuberculosis, Mycobacterium bovis, Mycobacterium bovis 
BCG, Mycobacterium africanum, Mycobacterium canettii, Mycobacterium leprae and 
Mycobacterium pinnipedii (Brosch et al., 2002), which belong to the genus Mycobacterium.  
At present over 100 species have been recognised in this genus, the majority of which are 
saprophytic soil species (Brown-Elliott et al., 2002); however, a minority are pathogenic to 
humans, such as M. tuberculosis and M. leprae, causing TB and leprosy, respectively.  In 
addition, Mycobacterium kansasii, Mycobacterium fortuitum and Mycobacterium avium 
complex (MAC) members cause illness and fatalities in immunocompromised individuals 
(Kiehn et al., 1985).  The Mycobacterium genus belongs to the family Mycobacteriaceae, 
positioned in the suborder Corynebacterineae, which is included in the suprageneric 
Acinomycete taxon.   Corynebacterineae also includes Corynebacterium, Nocardia and 
Rhodococcus, all of which are classified as Gram-positive, non-motile, aerobic, rod-shaped 
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bacteria, with characteristically high proportions of guanine and cytosine in their genomes.  
One of the foremost defining features of this suborder is the existence of mycolic acids 
(Minnikin & Goodfellow, 1980), unique β-hydroxy-α-alkyl branched long chain fatty acids, 
which are specific constituents of the cell envelope (Daffé & Draper, 1998; Dover et al., 
2004).  This distinctive ‘waxy’ cell wall is highly impermeable and is the basis for M. 
tuberculosis’ intrinsic resistance to common antibiotics (Brennan & Nikaido, 1995; Nguyen 
et al., 2006) and its formidable strength against the bactericidal activities of the macrophage.    
Species within the Mycobacterium genus exhibit variable growth rates and are classified as 
either slow or rapid growers (Table 1.1) (Lewin & Sharbati-Tehrani, 2005). A characteristic 
feature of highly pathogenic species such as M. tuberculosis and M. leprae is their slow 
growth rate and fastidious culturing processes. M. tuberculosis divides every 15 to 20 hours, 
taking between 4-6 weeks to obtain visual colonies, which is extremely slow compared to 
other bacteria, for instance Escherichia coli has a doubling time of 20 minutes (Lewin & 
Sharbati-Tehrani, 2005). 
Mycobacterium smegmatis is classified as a fast-growing species, with a doubling time of 
approximately 3 hours, producing visible colonies in 3-5 days.  It is generally considered 
non-pathogenic in immunocompetent individuals, and thus does not require the Category 3 
safety laboratory. There are many similarities between M. smegmatis and the much more 
virulent pathogens, with more than 2000 homologous genes shared with M. tuberculosis. 
These properties make it a very useful model organism for M. tuberculosis and other 
mycobacterial pathogens.   
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Table 1.1:  Mycobacterium genus with representative slow-growing and fast-growing bacilli. 
Slow Growers Fast Growers 
Mycobacterium africanum Mycobacterium marinum Mycobacterium aurum 
Mycobacterium avium Mycobacterium microti Mycobacterium chelonae 
Mycobacterium bovis Mycobacterium scrofulaceum Mycobacterium chitae 
Mycobacterium intracellulare Mycobacterium simiae Mycobacterium fortuitum 
Mycobacterium farcinogenes Mycobacterium szulgai Mycobacterium phlei 
Mycobacterium gastri Mycobacterium tuberculosis Mycobacterium porcinum 
Mycobacterium kansasii Mycobacterium ulcerans Mycobacterium pulveris 
Mycobacterium leprae Mycobacterium xenopi Mycobacterium smegmatis 
 
1.2. History of tuberculosis  
Mycobacterial DNA has been detected in numerous archaeological specimens, proving that 
TB is an ancient disease, which plagued the prehistoric man. Molecular identification of 
human TB from 4500 year old Egyptian mummies (Zink et al., 2001) and further 
palaeomicrobiological evidence (Donoghue et al., 2004) from the United Kingdom (Taylor et 
al., 2005), South America (Salo et al., 1994), Borneo (Donoghue et al., 2004) and numerous 
other world-wide locations, illustrate the wide geographical distribution of the disease.   
During 460 BC, the first documented account of TB emerged; the term phthisis (to waste 
away) was introduced into Ancient Greek literature by Hippocrates, who recognised how 
widespread and prevalent the disease was (Coar, 1982). It wasn’t until the writings of 
Clarissimus Galen (131-201 AD) that Phthisis or ‘consumption’ was described as ulceration 
of the lungs, along with wasting away of the body, fever and cough.  TB persisted throughout 
the ages, surging into 17th century Europe, becoming the principal cause of death. Mortality 
rates reached their pinnacle in the 18th and 19th centuries and TB gained the title the “Great 
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White Plague”.   The name ‘tuberculosis’ was introduced into the medical language after 
Gaspard Laurent Bayle (1774-1816) proved that tubercles present on the lungs of TB 
sufferers were the cause of illness. 
1.2.1.  Discovery of the tubercle bacillus and initial therapies 
In 1720, Benjamin Marten, a prominent English Physician, published work proposing that 
TB was infectious, stating that these ‘minute, living creatures’ enter the body and induce 
formation of lesions, producing the symptoms of Phthisis (Doetsch, 1978).   In 1882, Robert 
Koch provided unequivocal proof that TB was in fact caused by a bacterium, M. tuberculosis, 
which could be isolated and stained (Koch, 1931). This significant discovery awakened the 
scientific community to the prospect that this age-old disease could be treated, and research 
concentrated on producing effective chemotherapeutic agents. 
The mid 19th century was accompanied by a decrease in TB mortality rates and a lesser 
incidence of disease, which may have coincided with the establishment of Hermann 
Brehmer’s sanatoriums in 1859.  These establishments promoted good nutrition, exercise, 
rest and fresh air (Cox, 1923; Daniel, 2006), providing the first widely practiced anti-
tuberculosis treatment. The introduction of active therapy soon followed in the form of 
pneumothorax and thoracoplasty procedures that collapsed part of the infected lungs with the 
intention of closing the cavities (Daniel, 2006).  Nonetheless, these invasive early therapies 
seemed to do little to alleviate the symptoms, and are now deemed dangerous and 
controversial.  Albert Calmette and Camille Guerin, inspired by Edward Jenner’s discovery, 
that humans could be immunised against smallpox following cowpox infection, began 
developing a vaccine against M. tuberculosis using M. bovis, the aetiological agent of bovine 
TB.  In 1921, after successful attenuation of the strain, the Bacille Calmette-Guerin (BCG) 
vaccine was administered to humans (Calmette, 1928) and remains the only vaccine in use 
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today regardless of reports on it’s variable efficacy (Brewer & Colditz, 1995; Colditz et al., 
1994).   
1.3. Pathogenesis of tuberculosis 
Transmission of M. tuberculosis begins with the inhalation of infective droplet nuclei 
expelled from the respiratory tract of an active TB sufferer.  The nasopharynx and the upper 
respiratory tract trap larger particles; however, droplets with a diameter as large as 5µm may 
enter the alveoli, whereby they are ingested by the alveolar macrophages (Lurie, 1950). 
Receptor-mediated phagocytosis of the invading bacteria involves several major host cell 
surface receptors, such as, complement receptors (CR1, CR2, and CR3), mannose receptors 
(MR), surfactant protein receptors, CD14, and scavenger receptors (Ernst 1998). Following 
phagocytosis, the bacteria continue to reside within the membrane-bound vacuole called the 
phagosome, which matures to form the phagolysosome (Figure 1.1). This process subjects 
the internalised bacilli to attack from hydrolytic enzymes delivered by the lysosome. These 
initial microbicidal defenses may destroy the invading bacilli, yet some are able to evade this 
outcome by inhibiting the maturation process of the phagosome, as well as modulating the 
internal environment allowing logarithmic growth, leading to lysis of the immune cell.  The 
released bacteria, chemoattractants, and cellular debris draw in other macrophages and 
monocytes from the bloodstream. The logarithmic bacterial growth terminates when T-
lymphocytes, attracted by interleukin-8, arrive at the lesions. The lesions then undergo 
caseous necrosis due to the amplified immune response, resulting in a build up of acidic 
necrotic material in the centre, predominantly made up of macrophage debris (Dannenberg & 
Rook, 1964; Dannenberg & Sugimoto, 1976). This acidic, anoxic environment does not 
support bacterial growth, although the bacteria can survive in the destroyed tissue.  
Eventually, the copious amounts of released antigen stimulate the cell-mediated immune 
response; cytokines activate macrophages, which are then capable of killing bacilli ingested 
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from the edges of the lesion. In most cases the disease enters a period latency with the 
formation of a granulomatous lesion, named a ‘tubercule’.  
             
 
Figure 1.1: The intracellular existence of M. tuberculosis. This figure illustrates the influence of M. 
tuberculosis on the phagosome and endosome maturation processes. Specialised cell types — the so-called 
‘professional’ phagocytes, engulf larger particles. Numerous cell-surface receptors participate in the interaction 
between M. tuberculosis and the macrophages, facilitated by Cholesterol.  M. tuberculosis resides in a 
phagosome, the maturation of which is inhibited at an early stage. The early mycobacteria-containing 
phagosome retains tryptophan-aspartate containing coat protein TACO, which apparently prevents its further 
maturation.  M. tuberculosis inhibits phagosomal acidification (which normally occurs via recruitment of Vo–H+ 
ATPase) and prevents fusion with the endosomal pathway. Rab5 is involved in regulation of the fusion with 
vesicles of the endosomal-lysomal pathway. Phagosomal maturation is not always successfully halted, allowing 
some phagosomes to mature into phagolysosomes. Phagosome maturation is promoted in activated 
macrophages, particularly after stimulation by IFN-γ.  CR, complement receptor; FcR, receptor for the constant 
fragment of immunoglobulin; LAMP-1 lysosomal-associated membrane protein 1; LBPA, lysobiphosphatic 
acid; MR, mannose receptor; Rab5 and Rab7, members of the small GTPase family; SPR, surfactant protein 
receptor; TACO, tryptophane, aspartate-containing coat protein; TLR, Toll-like receptor; V–H+ATPase, 
vacuolar ATP-dependent proton pump (Adapted from Kaufmann, 2001).  
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Figure 1.2 Overview of TB infection and host defence.  There are three potential outcomes of infection of the 
human host in M. tuberculosis. a) The frequency of spontaneous healing is unknown, but is assumed to be rare 
b) Disease progression immediately after infection in the immunocompromised host. c) In the majority of cases, 
mycobacteria are initially contained and disease progresses later due to reactivation. The granuloma is the major 
site of infection, which develops from infected macrophages that become surrounded by lymphocytes. Effector 
T cells (CD4+ and CD8+ T cells, and double-negative or CD4/CD8 single-positive T cells that recognise antigen 
presented by CD1) and macrophages participate in the control of TB. Crucial macrophage activators interferon-
γ (IFN-γ) and tumour-necrosis factor-α (TNF-α) are produced by T cell and macrophages respectively. 
Macrophage activation permits phagosomal maturation and the production of antimicrobial molecules such as 
reactive nitrogen intermediates (RNI) and reactive oxygen intermediates (ROI). LT-3, lymphotoxin-3 (Adapted 
from Kaufmann, 2001). 
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It is estimated that only 1 in 10 infected individuals will go on to develop clinical symptoms 
due to reactivation of TB, and the lifetime risk of this is 5-10% (Figure 1.2).  The strongest 
risk factor for reactivation of TB is an impaired immune system, for instance, as a result of 
HIV infection, malnutrition, advanced malignancy or old age (Kaufmann, 2001). HIV 
infected individuals have a 7-10% annual risk of latent disease progressing into active TB.   
Their incompetent immune cells ingest the bacilli from the edges of the caseous regions, yet 
they are unable to halt growth, thus the delayed-type hypersensitivity response continues to 
destroy tissue.  This results in lymphohematogenous dissemination, whereby escaping 
bacteria are free to form multiple lesions throughout the body (Kaufmann, 2001; Raupach & 
Kaufmann, 2001). 
1.4. Epidemiology of tuberculosis 
By the mid 20th century, with the onset of improved public health services, the BCG vaccine 
and the use of specific drug therapies, TB prevalence had declined dramatically in 
industrialised countries, so much so, that the disease was considered to be close to 
elimination.  The resurgence of TB occurred during the 1980s, exacerbated by several 
factors, such as the HIV/AIDS pandemic, the variable effectiveness of the BCG vaccine, lax 
drug adherence resulting in the emergence of multi-drug resistant strains (MDR-TB) and 
increased immigration from developing countries where TB has continued to be endemic 
(Figures 1.3 & 1.4).  In fact, the concept of TB’s imminent eradication cannot be further from 
reality (Murray & Salomon, 1998).  In 1993 the World Health Organisation declared TB a 
global emergency, estimating that a third of the world’s population are infected, equating to 2 
billion people.  With 8 million new cases reported each year and 2 million fatalities annually, 
M. tuberculosis is the biggest global killer amongst infectious diseases (Dye & Raviglione, 
2005).   These alarming statistics and the emergence of MDR-TB strains and extensively-
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drug resistant (XDR-TB) strains have highlighted the urgency for the development of newer, 
more efficient antimicrobial agents (Blanchard, 1996; Pablos-Mendez et al., 1998).  
 
Figure. 1.3: Estimated TB incidence rates in the year 2009 (WHO, 2010). 
 
 
 
Figure. 1.4: Estimated HIV prevalence in new TB cases in the year 2009 (WHO, 2010). 
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1.5. TB drug treatments 
The most commonly used TB drug regimens include the so-called front-line drugs, 
rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (EMB) as shown in 
Table 1.2.   
Table 1.2: Commonly used TB drugs and their targets.  Adapted from Kremer & Besra, (2002); Nachega & 
Chaisson, (2003). 
Drug Drug mechanism of action 
Genes involved in 
resistance Function of gene 
Isoniazid (INH) 
(1952) 
 
 
Inhibition of mycolic 
acid biosynthesis 
and other multiple 
effects on DNA, 
lipids, carbohydrates 
and NAD metabolism 
 
 
katG 
 
inhA 
 
ndh 
 
oxyR-aphC 
 
Catalase-peroxidase 
 
Enoyl-Acp reductase 
 
NADH dehydrogenase II 
 
Alkyl hydroperoxidase 
 
 
Ethionamide (ETH) 
(1956) 
 
 
 
Inhibition of mycolic 
acid biosynthesis 
 
ethA 
 
inhA 
 
Flavin mono-oxygenase 
 
Enoyl-Acp reductase 
 
Ethambutol (EMB) 
(1961) 
 
 
 
Inhibition of cell wall 
arabinogalactan 
(AG) biosynthesis 
 
embCAB Arabinosyltransferases 
 
Rifampicin (RIF) 
(1966) 
 
 
Inhibition of 
transcription 
 
rpoB RNA polymerase 
Pyrazinamide 
(PYR) 
(1952) 
 
 
Acidification of 
cytoplasm and de-
energising the 
membrane 
 
pncA Nicotinamidase/pyrazinamide 
 
Streptomycin (STREP) 
(1944) 
 
 
Inhibition of protein 
synthesis 
 
rpsL 
 
rrs 
 
S12 ribosomal protein 
 
16S rRNA 
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In cases where INH resistance has occurred, streptomycin (STRP) is used as a replacement, 
although it is not preferred since there is a higher toxicity and a high incidence of STRP-
resistant TB.  The most effective drug regimen is endorsed by the WHO and is called 
Directly Observed Treatment, Short-course (DOTS), developed to fully supervise those 
patients deemed high-risk for non-drug adherence. This course consists of a 6-month 
treatment plan, where the initial phase is 2 months, involving the administration of INH, RIF, 
EMB and PZA.  The remaining four months is known as the continuation phase, during 
which time different regimens may be followed depending on any resistance profiles, but 
generally involves taking RIF and INH (Farmer & Kim, 1998). 
1.5.1.  TB Drug resistance  
The global problem of TB has been worsened by the development of drug resistant M. 
tuberculosis strains and is generally attributed to poor compliance with treatment. Lax drug 
adherence is associated with either lengthy duration of TB therapy, the tendency of patients 
to feel free of previous disease-like symptoms before course completion, therapy termination 
due to certain side effects, or unreliable drug supplies, all of which have accelerated MDR- 
and XDR-TB strains (Munro et al., 2007).  MDR-TB is defined as TB that is resistant to at 
least INH and RIF, the two most powerful first-line anti-TB drugs.  Treatment in the case of 
MDR-TB can exceed 2 years, in comparison to drug-senstive TB, which can be effectively 
treated with a 6-month regimen, thus significantly increasing costs and side effects. The 
incidence rates are inceasing with 424,000 cases in 2004, up from 273,000 in 2000 (Aziz et 
al., 2006; Zignol et al., 2006), and a mortality rate of 27% in those infected with MDR-TB 
compared to 18% for drug-sensitive TB infections (World Health Organisation (WHO) 
2007).   XDR-TB has now disturbingly emerged; defined as MDR-TB that has developed 
additional resistance to three injectable second-line drugs (aminoglycosides) and one of the 
fluoroquinolones (CDC, 2006; World Health Organisation (WHO) 2007).  Worryingly, 
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XDR-TB has been detected in 45 countries as disclosed by the WHO/IUATLD report for 
2008, and is untreatable so far.  This shows that control of drug-resistant TB incidence is 
somewhat inadequate, especially in regions with a high prevalence of HIV cases, where TB-
HIV co-infections increase the susceptibility to re-infection, relapse and treatment failure 
(Nations et al., 2006; Omerod, 2005).  Therefore, there is a necessity to discover new specific 
antimicrobial compounds against M. tuberculosis.  
1.6. The mycobacterial cell wall  
The compositional complexity of the mycobacterial cell wall (Figure 1.5) distinguishes 
Mycobacterium species from the majority of other prokaryotes.  Classified as Gram-positive 
organisms, their envelopes do in fact share notable features with Gram-negative cell walls, 
such as an outer permeability barrier acting as a pseudo-outer membrane (Brennan & 
Nikaido, 1995; Minnikin, 1982).  Much of the early structural definition of the cell wall was 
conducted in the 1960s and 1970s (Lederer et al., 1975; Petit et al., 1969; Adam et al., 1969). 
Minnikin, in 1982, proposed the currently accepted structural model for the cell wall 
architecture that was later supported by McNeil and Brennan (McNeil & Brennan, 1991; 
Minnikin, 1982; Minnikin et al., 2002) and numerous further investigations (Besra & 
Brennan, 1995; Brennan & Nikaido, 1995; Minnikin, 1991; Nikaido et al., 1993).    
The structural features of the cell envelope can be divided into three major components;  
1. the plasma membrane 
2. the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex (Besra & Brennan, 
1997), consisting of three covalently linked macromolecules, peptidoglycan (PG), 
arabinogalactan (AG) and hydrophobic mycolic acids which decorate the non-
reducing terminus of the arabinan domains 
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3. lipoarabinomannan (LAM), lipomannan (LM), non-covalently bound lipids and 
glycolipids. 
 
 
Figure 1.5: Schematic model of the mycobacterial cell wall. The major structural features of the cell wall of 
M. tuberculosis as proposed by Minnikin et al. (2002) and modified from Dmitriev et al. (2000).  The cell 
envelope consists of a plasma membrane, a cell wall core, an outer membrane and a capsule. 
Lipoarabinomannan (LAM), mycolyl-arabinogalactan-peptidoglycan (mAGP), phthiocerol dimycocerosates 
(PDIM), peptidoglycan (PG), plasma membrane (PM), sulfated tetra-acyl trehalose (SL), diacyl trehalose 
(DAT), penta-acyl trehalose (PAT), trehalose monomycolate (TMM), trehalose dimycolate (TDM), N-
acetylglucosamine (NAG), N-acetylmuramic acid (NAM), arabinogalactan (AG). 
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1.6.1. The cell wall of M. tuberculosis as a drug target 
Mycobacterial diseases are especially problematic to treat owing to this unique cell wall 
architecture. This tightly packed, lipid rich envelope accounts for the inherent resistance of 
M. tuberculosis to various hydrophilic antimicrobials, as well as lipophilic molecules that 
have difficulty passing through this highly ordered mycolic acid layer.  The cell wall is 
essential for growth and survival and cell wall inhibitors have been one of the most active 
agents of chemotherapy, and as such, the majority of front-line drugs target its biosynthesis 
(Zhang, 2005). Drug regimens employ at least one cell wall biosynthetic inhibitor, for 
instance INH and ETH, which target mycolic acid biosynthesis or EMB which inhibits 
arabinan biosynthesis, taken in combination with other chemotherapeutic agents that have 
intracellular targets (Nikaido & Jarlier, 1991). However, due to the emergence of various 
drug resistant strains as discussed previously, there is a need for the discovery of novel drug 
targets and the development of active compounds against them (Heymann et al., 1999; 
Sreevatsan et al., 1997b; Telenti et al., 1997). In this regard, the biosynthetic machinery of 
mycobacterial cell wall represents an attractive target and numerous research studies have 
been and are being conducted, delving into the intricacies of the mycobacterial cell wall 
assembly (Bhatt et al., 2007b; Bhowruth et al., 2007; Brennan & Crick, 2007; Dover et al., 
2008).  
1.6.2. Plasma membrane 
The plasma membrane acts as a boundary between the cytosol and the periplasmic space, but 
it also harbours a number of substrates required by cell wall biosynthetic enzymes (Berg et 
al., 2007), thus playing a crucial role in the biogenesis of the cell wall.  A group of 
glycosylphosphoprenols associated with the plasma membrane have been identified and 
operate as sugar donor substrates for many of the TB glycosyltransferases.  For instance, 
activated forms of D-ribofuranose (Wolucka et al., 1994; Wolucka & de Hoffmann, 1995), 
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D-mannopyranose (Takayama & Goldman, 1970) and D-arabinofuranose (Wolucka & de 
Hoffmann, 1994; Wolucka et al., 1994) have been identified. Many of the involved 
glycosyltransferases are either embedded in the lipid bilayer as integral membrane proteins, 
or associated with the membrane surface by hydrophobic and/or electrostatic interactions. For 
instance, topology studies of the EmbCAB proteins, the putative arabinofuranosyltransferases 
revealed 13 transmembrane domains (Telenti et al., 1997).  In addition, Alderwick et al. 
(2006b) recently discovered a further arabinofuranosyltransferase AftA, which also contains 
integral transmembrane spanning domains. It is believed that glycosyltransferases involved in 
the biosynthesis of the arabinans of both AG and LAM are all integral membrane proteins 
and are therefore classified as members of the glycosyltransferase family C (GT-C) (Berg et 
al., 2007).  With the exception of phosphatidylinositol mannosides (PIMs), which are 
constrained to Actinomycetales, the lipid composition of this biomembrane is similar to that 
of other prokaryotes, suggesting that the general properties of lipid bilayers are applicable for 
mycobacteria. 
1.6.3. Structure and biosynthesis of peptidoglycan 
Peptidoglycan (PG) is a complex macromolecular structure situated on the outside of the 
plasma membrane of almost all eubacteria (Schleifer & Kandler, 1972; van Heijenoort, 
2001a, 2001b). Its mesh-like arrangement confers rigidity to the cell, allowing it to withstand 
osmotic pressure maintaining cell integrity and cellular shape.  Relatively little is known 
about M. tuberculosis PG synthesis, although it is generally assumed to be akin to that of E. 
coli (van Heijenoort, 2001a, 2001b), also being classified as A1γ according to the 
classification system of Schleifer & Kandler (1972).  Mycobacterial PG forms the backbone 
of the mAGP complex, composed of alternating N-acetylglucosamine (GlcNAc) and 
modified muramic acid (Mur) residues, linked in a β(1→4) configuration  (Lederer et al., 
1975).  Unlike E. coli PG, the muramic acid residues in M. tuberculosis and M. smegmatis 
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for instance, contain a mixture of N-acetyl and N-glycolyl derivatives, whereby the N-acetyl 
function has been oxidised to a N-glycolyl function to form MurNGly (Mahapatra et al., 
2005a; Mahapatra et al., 2005b; Raymond et al., 2005).  These additional glycolyl containing 
residues result in extra hydrogen bonding, strengthening the mesh-like structure (Brennan & 
Nikaido, 1995), as well as possibly protecting the organism from lysozyme degradation.  
Tetrapeptide side chains consisting of L-alaninyl-D-isoglutaminyl-meso-diaminopimelyl-D-
alanine (Petit et al., 1969) cross-link with identical short peptides of neighbouring glycan 
chains (van Heijenoort, 2007).  These cross-links include the expected meso-diaminopimelic 
acid (DAP) and D-alanine bond, common to most prokaryotes, but also a high degree of 
bonds between two residues of DAP (Ghuysen, 1968; Wietzerkin et al., 1974).  The 
proportion of cross-linking in Mycobacterium species is 70-80%, significantly more so than 
E. coli, with only 50% (Vollmer, 2004).  An additional deviation from E. coli PG, is the use 
of the muramic acid residues as attachment sites for the galactan domain of the 
arabinogalactan, whereby carbon-6 of some of the muramic acid residues form a 
phosphodiester bond and are linked to the α-L-rhamnopyranose–(1→3)-α-D-GlcNAc(1→P) 
linker unit of AG (Hancock et al., 2002; McNeil et al., 1990).  
One model proposed for the three-dimensional topology of the mAGP complex, consistent 
with the traditional models of PG architecture  (Ghuysen, 1968; McNeil & Brennan, 1991), 
suggests that the PG and the galactan moiety run parallel to the plasma membrane.  However, 
an opposing model put forward by other modeling studies predict that the PG and the AG 
polymers may in fact be coiled and are thus orientated perpendicular to the plane of the 
plasma membrane (Dmitriev et al., 2000; Dmitriev et al., 2003).  Minnikin and colleagues 
(2002) proposed that AG as well as LAM form coiled strands and integrate with PG.  
Although, recent published nuclear magnetic resonance (NMR) data concluded that the PG 
glycan strand is orthogonal to the plane of the membrane, thus the overall three-dimensional 
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structure and topology remains open to debate (Meroueh et al., 2006).  The biosynthesis of 
mycobacterial PG is comparable to that of E. coli and is shown in Figure 1.6. 
 
Figure 1.6:  Biosynthesis of peptidoglycan in M. tuberculosis. The synthesis of the disaccharide-peptide 
monomer unit is initiated in the cytoplasm, catalysed by six enzymes, MurA to MurF.  MurA transfers 
enolpyruvate from phosphoenolpyruvate to the 3-OH of UDP linked GlcNAc, which is reduced to form UDP-
MurNAc by MurB (De Smet et al., 1999; Goffin & Ghuysen, 2002).  The UDP-MurNAc-pentapeptide is then 
formed via the sequential addition of L-alanine, D-glutamic acid, DAP and a D-alanyl-D-alanine dipeptide, to 
MurNAc, by MurC, MurD, MurE and MurF, repectively (Mahapatra et al., 2000).  Lipid I synthesis involves 
MraY (MurX) transferring the modified MurNAc residue to a polyprenyl phosphate carrier lipid, followed by 
addition of GlcNAc by MurG (Ikeda et al., 1991). The product, GlcNAc-MurNAc(pentapeptide)-diphosphoryl-
undecaprenol (Lipid II) is then translocated across the membrane and incorporated into the growing PG by 
transglycosylases and further modified by transpeptidases (Bhakta & Basu, 2002; Goffin & Ghuysen, 2002).  
 
1.6.4. Biosynthesis of the linker unit 
Mycobacterial viability rests heavily on the structural integrity of the cell wall, thus the 
attachment of which the AG proper is hinged to the PG layer is pivotal.  Amar & Vilkas 
(1973), initially reported that AG is tethered to PG at intervals by a phosphodiester bond, 
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supported by the presence of muramyl-6-phosphate in the cell wall preparations from several 
mycobacterial species (Kanetsuna, 1968; Liu & Gotschlich, 1967).  The fundamental 
question of the chemical nature of this link wasn’t answered until 20 years later when 
oligosaccharides containing galactofuranose (Galf) from the galactan domain were isolated 
along with rhamnose (Rha) residues (McNeil et al., 1990).   The further discovery of the 
disaccharide L-Rhap-(1→3)-D-GlcNAc (Figure 1.7) led to the conclusion that these 
constituents make up the linkage unit and the inference that the GlcNAc is directly attached 
to the 6-position of a proportion of the muramyl residues of PG (McNeil et al., 1990).   
 
Figure 1.7:  The Rha-GlcNAc linker unit.  The molecular structure of the LU, the conduit between AG 
and PG.  The reducing end of AG consists of the terminal sequence →5)-D-Galf-(1→4)-L-Rhap-(1→3)-D-
GlcNAc, attached to muramyl-6-P. 
The crucial structural role of the linker unit (LU) (Figure 1.7) in the attachment of AG to PG, 
as well as the presence of L-Rhamnose, a sugar absent in humans, makes the biosynthetic 
machinery of the mycobacterial LU (Figure 1.8) an attractive drug target (Ma et al., 2002).   
In M. tuberculosis, synthesis is initiated on the acceptor decaprenyl-phosphate (Dec-P or C50-
P), whereby GlcNAc-phosphate is transferred from UDP-GlcNAc, forming C50-P-P-GlcNAc, 
referred to as glycolipid 1 (GL-1) (Mikusova et al., 1996).   The enzyme formerly known as 
Rfe (Rv1302, WecA) has been implicated as a decaprenyl-phosphate α-N-
acetylglucosaminyltransferase by its significant homology to the E. coli WecA protein (Amer 
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& Valvano, 2002; Dal Nogare et al., 1998), although there are no biochemical data as yet to 
definitively prove this supposition.   The linkage region is completed by the subsequent 
addition of the Rha residue by the recently defined rhamnosyltransferase, WbbL (Rv3265c), 
to the 3-position of the GlcNAc of GL-1, forming glycolipid 2 (GL-2) (Figure 1.8) (Mills et 
al., 2004). The key to these studies was with the successful complementation of an E. coli 
mutant with Rv3265c (wbbL) and subsequent restoration of rhamnosyltransferase activity 
(McNeil, 1999). Moreover, investigations from M. smegmatis have highlighted the 
essentiality of wbbL for bacterial viability  (Mills et al., 2004).  
           
 
Figure 1.8: Formation of the linker unit - glycolipid-1 (GL-1) and glycolipid-2 (GL-2).  α-GlcNAc-1-P is 
transferred from UDP-GlcNAc to decaprenol (DP) by the GlcNAc-1-phosphate transferase Rfe (Rv1302, 
WecA), followed by the attachment of a rhamnosyl residue from dTDP-Rha catalysed by WbbL (Rv3265c) 
(Mills et al., 2004), resulting in Rha-GlcNAc-P-P-decaprenyl. 
 
 
The wbbL gene product utilises the nucleotide donor dTDP-rhamnose for the formation of 
GL-2, so it stands to reason that the rhamnosyl biosynthetic pathway has come under scrutiny 
and a number of inhibitors have been described (Babaoglu et al., 2003; Kantardjieff et al., 
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2004; Ma et al., 2001).  Synthesis of dTDP-Rha occurs via a linear 4-stage pathway utilising 
the gene products of rmlABCD as depicted in Figure 1.9.   
Recognition of the genes involved transpired by comparison to known polysaccharide 
biosynthetic enzymes found in other bacteria, namely E. coli (Ma et al., 1997; Stevenson et 
al., 1994; Weston et al., 1997).  RmlA (Rv0334) sets in motion the sequence of reactions, 
converting dTTP + α-D-glucose 1-phosphate to dTDP-glucose + PPi (Ma et al., 1997).  The 
enzyme was cloned from M. tuberculosis and transformed into an E. coli strain devoid of 
four TDP-Rha biosynthetic genes.  Cellular extract analysis revealed an abundance of α-D-
Glc-P thymidylyltransferase activity confirming its proposed function (Ma et al., 1997).  The 
product of RmlA activity is then shuttled through three sequential reactions catalysed by 
dTDP-D-glucose 4,6-dehydratase (Rv3464, RmlB), dTDP-4-keto-6-deoxy-D-glucose 3,5 
epimerase (Rv3465, RmlC) and dTDP-Rha synthase (Rv3266, RmlD) (Hoang et al., 1999; 
Ma et al., 2001; Stern et al., 1999).  Li et al (2006) demonstrated that rmlB and rmlC genes 
are also essential for mycobacterial growth.  
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Figure 1.9: Biosynthetic pathway of dTDP-rhamnose.  A series of enzymes converts glucose-1-phosphate  
(α-D-Glc-1-P) to dTDP-Rha. RmlA (Rv0334) = α-D-glucose-1-phosphate thymidylyl transferase (Ma et al., 
1997), RmlB (Rv3464) = dTDP-D-glucose 4,6-dehydratase (Ma et al., 2001), RmlC (Rv3465) = dTDP-4-keto-
6-deoxy-D-glucose (Stern et al., 1999), and RmlD (Rv3266c) = dTDP-rhamnose synthetase (Hoang et al., 
1999). 
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1.6.5. Arabinogalactan 
1.6.5.1. Structural features of arabinogalactan 
Exclusive to the Actinomycetales, the mAG complex is a key structural component which 
makes up the bulk of the cell wall (Minnikin et al., 2002).  Arabinogalactan (AG), the unique 
heteropolysaccharide, is covalently tethered to the PG via a phosphodiester bond to 
approximately 10-12% of the muramic acid residues of PG (Amar & Vilkas, 1973; Misaki et 
al., 1974).   Collectively, PG and AG, form a covalently linked network positioned between 
the plasma membrane and the mycolic acid layer, resulting in an exceptionally robust cell 
wall. Early work demonstrated that the polymer was composed predominantly of arabinose 
and galactose (Azuma et al., 1968; Kanetsuna, 1968; Kanetsuna et al., 1969; McNeil et al., 
1987; Misaki et al., 1966). Both sugars are in the furanoid ring form, D-galactofuranosyl 
(Galf) and D-arabinofuranosyl (Araf), which are extremely rare in nature (McNeil et al., 
1987).  Detailed characterisation of oligomers generated from partial depolymerisation of 
per-O-alkylated AG and the use of methylation analysis, gas-chromatography-mass 
spectrometry (GC-MS), fast atom bombardment-mass spectrometry (FAB-MS) and NMR 
spectroscopy established the detailed structure of this complex and the fact that unlike most 
bacterial polysaccharides, AG lacks repeating units being composed of a few distinct 
structural motifs (Besra et al., 1995; Daffé et al., 1990; McNeil et al., 1990; McNeil et al., 
1991; Vilkas et al., 1973).  The use of endo-arabinofuranosidases secreted from a 
Cellomonas species provided additional support for the obtained structural data as well as 
revealing further insights (McNeil et al., 1994). AG consists of a linear galactan composed of 
30 linear alternating β(1→5) and β(1→6) Galf residues (Abou-Zeid et al., 1982; McNeil et 
al., 1987; Vilkas et al., 1973), attached to the rhamnosyl residue of the linker unit.  Three 
apparently similar D-arabinan chains comprised of 22 or 23 Araf residues are affixed to the 
C-5 of the β(1→6) linked Galf (Besra et al., 1995).  Recent studies by Alderwick et al (2005) 
ascertained that the arabinan chains are attached specifically to the 8th, 10th and 12th Galf 
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residue, data congruent with Besra et al. (1995) who recognised long stretches of unbranched 
galactan, leading to the prediction that the chains are attached near the reducing end.  It 
seems that the arabinan domain is present as a highly branched network built on a backbone 
of α(1→5) linked sugars with a number of α(1→3) linked residues forming  3,5-Araf branch 
points  (Daffé et al., 1990).  Further α(1→5)  linked Araf sugars are attached subsequent to 
this branch point with the non reducing ends terminated by β(1→2) Araf residues.  The final 
structural motif is the distinctive hexa-arabinoside (Ara6) (McNeil et al., 1994) present as 
(Araf-β(1→2)-Araf-α(1-)2 → 3,5-Araf-α(1→5)-Araf-α(1→5), of which  two-thirds are 
mycolated (Figure 1.10).  
                       
Figure 1.10:  Structural features of arabinogalactan.  Pictorial representation of the arabinogalactan of M. 
tuberculosis as defined by McNeil et al. (1987), Daffé et al. (1990), McNeil et al. (1994) and Besra et al. 
(1995). Three chains of arabinan are attached to each galactan chain, of which two-thirds are substituted with 
mycolic acids.  
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Research emphasis has now shifted somewhat from structural analysis to biosynthesis. The 
complete sequencing of the mycobacterial genome has provided major impetus in the 
identification and the study of the enzymes involved in the biosynthesis of this exceptional 
structure, with the hope of uncovering new drug targets.        
1.6.5.2. Synthesis of arabinogalactan biosynthetic precursors 
1.6.5.2.1. Galactan precursor synthesis 
D-galf residues, the main constituents of the galactan component of the mAGP complex, do 
not exist in mammalian metabolism, thus their biosynthesis constitutes an appealing target 
for chemotherapy without any deleterious side effects.  Galf residues of the galactan domain 
are incorporated from the high-energy sugar nucleotide donor UDP-Galf, which is formed via 
two reactions.  In E. coli, galactosyl residues in the pyranose ring form (UDP-Galp) are 
synthesised by the action of UDP-glucose 4-epimerase on UDP-glucopyranose (UDP-Glcp), 
the protein of which is encoded by the galE gene (Lemaire & Muller-Hill, 1986).  Weston et 
al. (1997) assayed for the reverse reaction in M. smegmatis using radiolabeled UDP-Galp and 
UDP-glucose 4-epimerase activity was observed, of which the purified protein and its N-
terminal sequence was shown to be similar to M. tuberculosis Rv3634.  Conversion of UDP-
Galp to the furanose form occurs via ring contraction catalysed by the enzyme UDP-
galactopyranose mutase (Glf) that was first recognised in E. coli (Nassau et al., 1996) and 
subsequently in M. smegmatis and M. tuberculosis (Rv3809c) (Weston et al., 1997) and is 
summarised in Figure 1.11.  Allelic exchange experiments of glf in M. smegmatis highlighted 
the essentiality of this gene (Pan et al., 2001). 
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Figure 1.11:  Formation of galactan precursors.  Adapted from Pan et al. (2001).  UDP-glucose (UDP-Glc) is 
converted to UDP-galactopyranose (UDP-Galp), catalysed by UDP-galactopyranose epimerase (Rv3634) 
(Weston et al. 1998). Glf, a UDP-galactopyranose mutase (Rv3809c), subsequently converts UDP-Galp to 
UDP-Galf. 
 
 
1.6.5.2.2. Arabinan precursor synthesis 
Endeavours to uncover sugar nucleotides of Araf have proven unsuccessful.  Arabinan 
biosynthesis in the Actinomycetales involves β-D-arabinofuranosyl-1-
monophosphodecaprenol (DPA), the only known donor of Araf residues (Alderwick et al., 
2005; Wolucka et al., 1994; Xin et al., 1997).  Synthetically derived DP[14C]A and an array 
of synthetic acceptors have determined that DPA provides Araf units in the in vitro formation 
of 2-linked and 5-linked arabinofuranosyl linkages present in the arabinans of AG and LAM 
(Belanger et al., 1996; Lee et al., 1997; Xin et al., 1997). The use of DPA and endogenous 
acceptors from membrane preparations produced a structure identical to the natural polymer, 
with equal distribution of radiolabel, highlighting that the lack of 3-linked linkages was not 
due to another unidentified activated donor and most likely the inability of the α(1→3) AraT 
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to recognise the acceptor. Subsequent assays discovered other DPA dependent AraTs, the so-
called “priming” enzyme AftA (Rv3792), was responsible for the addition of the first AraT to 
the galactan domain, as well as demonstrating conclusively that DPA is the only donor in the 
related organism C. glutamicum (Alderwick et al., 2005).    
Due to the important role of DPA, elucidation of its biosynthetic pathway has received much 
attention.  The recognised biosynthesis of such polyprenylphosphate sugars chiefly involves 
the donation of a glycosyl residue from a sugar nucleotide to the polyprenylphosphate, 
interestingly the sugar nucleotides of arabinose (UDP-Ara or GDP-Ara) have not been 
identified.  The carbon skeleton of the arabinosyl residues (Figure 1.12) are derived from the 
non-oxidative pentose shunt (Scherman et al., 1995), after which, ribose 5-phosphate and 
ATP react with the assistance of a pRpp synthetase to produce pRpp (Wolucka et al., 2008).  
The 5-phospho-α-D-ribose 1-pyrophosphate:decaprenyl phosphate 5-phosphoribosyl 
transferase (Rv3806c), or UbiA  transfers ribose-5-phosphate from pRpp to 
decaprenylphosphate to form DPPR (Huang et al., 2005). The final stages involve 
dephosphorylation of DPPR and epimerisation at the C-2 anomeric hydroxyl of the ribose 
moiety by Rv3790 (DprE1) forming the putative intermediate, decaprenylphosphoryl-2-keto-
β-D-erythro-pentofuranose (DPK) (Mikusova et al., 2005).  Subsequent reduction by Rv3791 
(DprE2) results in the completed arabinose donor DPA.  Studies on the enzymes involved in 
the complete pathway to D-arabinose await thorough biochemical characterisation. 
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Figure 1.12: Formation of arabinan precursor DPA. The carbon atoms of the Araf residues are derived from 
the pentose shunt pathway.  α-D-ribose-5-phosphate (R5P) is then acted on by PrsA a pRpp synthetase, which 
catalyses the addition of a diphosphate moiety from ATP to the carbon-1-OH (Alderwick et al., 2010). The 
formation of decaprenylphosphoryl-D-arabinose (DPA) then proceeds with the transfer of ribose-5-phosphate 
from pRpp to decaprenylphosphate to form decaprenylphosphoryl-5-phosphoribose (DPPR).  DPPR then 
undergoes dephosphorylation to decaprenol-1-monophosphoribose (DPR) and epimerisation of the ribosyl unit 
at carbon 2-OH position. DprE1 (Rv3790), a FAD-containing oxidoreductase is responsible for oxidising the 
ribosyl carbon-2-OH producing the keto sugar decaprenol-1-monophosphoryl-2-keto-β-erythro-pentofuranose 
(DPX).  This is the reduced to DPA DprE2 (Rv3791, a decaprenylphosphoryl-2-keto-D-erythropentose 
reductase (Mikusova et al., 2005).  
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1.6.5.3. Galactan biosynthesis 
The assortment of glycosyl linkages within the galactan moiety leads to the supposition that 
at least two to four Galf transferases (GalTs) are involved in its biosynthesis (Crick et al., 
2001). It was predicted that one GalT could be specifically designed to recognise the LU 
(C50-P-P-GlcNAc-Rha or GL2) catalysing the β(1→4) linkage allowing galactan formation to 
begin and then another to add the following Galf units.  Indeed, Mikusova et al. (2000, 2006) 
recognised Rv3782 (GlfT1) as the putative GalT responsible for the initial transfer of 
possibly two Galf residues from UDP-Galf, forming C50-P-P-GlcNAc-Rha-Galf (GL-3) and 
C50-P-P-GlcNAc-Rha-Galf-Galf (GL-4) (Alderwick et al., 2008; Mikusova et al., 2006).   
 
 
Figure 1.13:  Polymerisation of galactan - biosynthesis of GL-4.  The first two galactosyl sugars are added to 
the rhamosyl residue of the linker unit via GlfT1 (Rv3782) (Mikusova et al., 2006).  
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Rv3782 was implicated as a possible GalT due to the observations that there is significant 
sequence identity with portions of Rv3808c a known GalT (discussed below), which is 
classified as an inverting glycosyltransferase-2 (GT-2) of the GT-A superfamily. In addition, 
Rv3782 is also situated in the putative “AG biosynthetic gene cluster” (Mikusova et al., 
2006). Kremer et al. (2001a) reported the first GalT with the identification of Rv3808c 
(GlfT1) through the use of a novel neoglycolipid acceptor assay, together with UDP-Galf and 
isolated E. coli membranes expressing the aforementioned gene (Kremer et al., 2001a).  It 
was demonstrated that the enzyme has dual functionality, acting both as a UDP-Galf:β-D-
(1→5) GalT and the UDP-Galf:β-D-(1→6) GalT, responsible for the polymerisation of 
approximately 30 Galf residues with alternating β(1→5) and β(1→6) linkages (Kremer et al., 
2001; Rose et al., 2006).  
        
Figure 1.14:  Polymerisation of galactan.  The bifunctional galactosylfuranosyl transferase GlfT2 (Rv3808c) 
adds the remaining alternating β(1→5) and β(1→6) galactosyl residues to GL-4.  
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1.6.5.4.     Arabinan biosynthesis 
1.6.5.4.1. Ethambutol inhibition and its use in the identification of the Emb proteins 
The arabinan homopolymer is a pivotal structure in both AG and LAM, the two major cell 
wall polysaccharides. Accordingly, it is considered one of the most prominent mycobacterial 
structures being targeted by the frontline drug EMB ((S,S’)-2,2’(ethylenediimino)di-1-
butanol). EMB is a synthetic compound that was first recognised as an anti-mycobacterial 
agent in 1961 (Thomas, 1961).  Early work by Kilburn & Greenberg observed an 
unanticipated increase in viable cells during the initial four hours after addition of EMB to M. 
smegmatis cultures.  It was postulated that large bacillary clusters disaggregated due to a 
possible reduction in lipid content, which would lead to the apparent increase in colony-
forming units (CFU) (Kilburn & Greenberg, 1977).  This theory was supported by Takayama 
and coworkers who conducted a series of early studies into the effects of the EMB on M. 
smegmatis, reporting that inhibition of mycolic acid transfer into the cell wall and the 
simultaneous accumulation of trehalose-monomycolate (TMM), trehalose-dimycolate 
(TDM), and free mycolic acids occurred within 15 minutes of drug administration (Kilburn & 
Takayama, 1981; Takayama et al., 1979). This suggested that the target might be a 
mycolytransferase responsible for the transfer of mycolic acids onto the arabinan polymer. 
However, it was later discovered that the earliest point of drug inhibition occurred during 
arabinan synthesis demonstrated by the immediate inhibition of incorporated label from 
[14C]-glucose into the cell wall D-arabinose monomers (Takayama & Kilburn, 1989), whilst 
synthesis of the galactan of AG remained unaffected (Mikusova et al., 1995). Furthermore, 
the arabinans of both AG and LAM were disturbed, although inhibition of label into the latter 
was less pronounced and at a later stage of its biosynthesis (Deng et al., 1995; Mikusova et 
al., 1995).  
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The generation of EMB-resistant M. smegmatis mutants greatly aided the discovery of the 
primary EMB target, implicating it as an arabinan specific inhibitor.  This was illustrated by 
Mikusova et al., (1995), who subjected an EMB-resistant strain to sub-inhibitory levels of 
EMB (10µg/ml) showing that the resistant mutant produced “normal” cell wall AG but a 
truncated version of LAM due to arabinan inhibition. Extending this observation using higher 
concentrations of EMB, Khoo et al. (1996) reported that the degree of truncation in LAM 
was dose dependent and at higher concentrations, the arabinan of AG was also impaired.  
Collectively, these studies indicate that the effects of EMB on the synthesis of both arabinan 
moieties are uncoupled, and the time difference of inhibition implies that synthesis occurs via 
distinct pathways, involving multiple AraT targets with varying EMB sensitivities. A number 
of concurrent EMB studies provided evidence of an accumulation of DPA, the source of Araf 
residues in arabinan biosythesis, confirming that EMB effects were not due to inhibition of 
Araf donor synthesis but rather its utilisation (Lee et al., 1995; Wolucka et al., 1994).  Taken 
together, all the evidence points to arabinan polymerisation, specifically the arabinan of AG, 
as the primary target of EMB.  
A major breakthrough in the discovery of the precise EMB cellular target arose through 
exploitation of a moderately resistant strain from the related M. avium species.  The genomic 
library from the aforementioned strain was screened and over-expressed in an otherwise 
susceptible M. smegmatis host, leading to the identification of a resistance conferring region 
encompassing three complete open reading frames (ORFs), embR, embA and embB (Belanger 
et al., 1996).  Moreover, use of an EMB-sensitive cell-free arabinan biosynthetic assay 
demonstrated that arabinosyltransferase activity was restored with embAB over-expression.  
Interestingly, neither embA or embB alone was sufficient to confer multi-copy resistance, thus 
supporting the supposition that they are translationally coupled forming a multienzyme 
complex (Belanger et al., 1996). EMB resistance was also used to identify the embCAB gene 
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cluster from M. smegmatis, which was subsequently characterised in M. tuberculosis and M. 
leprae, all of which possess the same syntenic organisation (Lety et al., 1997; Telenti et al., 
1997) and encode homologues of the embA and embB genes from M. avium.  Escuyer et al. 
(2001) created individual genetic knockouts in M. smegmatis, embC, embA and embB, all of 
which were viable, with the most profound affects observed in the embB mutant.  Individual 
inactivation of embA, and embB resulted in the diminished incorporation of arabinose into 
AG, specifically, the terminal disaccharide β-D-Araf –(1→2)-α-D-Araf, normally situated on 
the 3-OH of the 3,5-linked Araf residue.    
       
 
Figure 1.15: Schematic presentation of arabinogalactan biosynthesis. 
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Thus, a substantial amount of the otherwise Ara6 motifs were present as terminal linear Ara4 
structures akin to the terminal motif of LAM (Escuyer et al., 2001), also leading to a loss of 
cell wall bound mycolates.  Based on the above observations, it appears that the Emb proteins 
could be involved in Ara6 biosynthesis, with the authors suggesting that the EmbA/EmbB 
proteins could both act as α(1→3) AraTs.  Indeed, Khasnobis et al. (2006), assayed for the 
putative activity of EmbA/EmbB, using cell-free preparations from wild-type M. smegmatis 
and demonstrated the formation of the non-reducing terminal disaccharide, which were 
absent in both embA and embB mutants. Moreover, the transferase activity was re-established 
upon mixing the membrane preparations from the disrupted strains with wild-type 
membranes.   
1.6.5.4.2. EMB resistance  
Identification of the emb gene cluster has provided the opportunity to analyse the molecular 
basis of resistance of mycobacteria to EMB.  Telenti et al. (1997) demonstrated that high-
level resistance to EMB in M. smegmatis could be related to either overproduction of the 
Emb protein(s), a structural mutation in a conserved region of EmbB, or both.  A number of 
reports presented additional genetic evidence for a key role of the EmbB protein in cell wall 
biosynthesis highlighting the fact it is the most EMB-sensitive protein in the gene cluster 
(Alcaide et al., 1997).  Mutations in EmbB have been recorded in up to 65% of EMB 
resistant clinical isolates of M. tuberculosis, with the majority of mutations present at codon 
306 or in the immediate surrounding area (Lety et al., 1997; Ramaswamy et al., 2000).  This 
region is highly conserved amongst mycobacteria and topological analysis of the Emb 
proteins (Telenti et al., 1997) positioned this EMB resistance-determining region (ERDR) in 
the second intracellular loop of EmbB (Sreevatsan et al., 1997b). Five distinct mutations have 
been recognised at codon 306, resulting in a subsitution of the wild-type methionine with 
isoleucine, leucine or valine (Sreevatsan et al., 1997b).  Other mutations have been identified 
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in the second intracellular loop region and the large-C terminal globular region of EmbB 
(Ramaswamy et al., 2000).  It should be noted that there are a number of EMB resistant 
strains that do not possess ERDR mutations, thus other genes may be involved in EMB 
resistance.  
1.6.5.4.3.  Identification of novel arabinofuranosyltransferases and the use of C.   
glutamicum as a model organism 
Efforts to generate viable embA/embB mutants in M. tuberculosis and an embAB double 
mutant in M. smegmatis have so far proven unfruitful, highlighting their essentiality (Mills et 
al., 2004; Pan et al., 2001; Vilcheze et al., 2000). The Corynebacterianeae taxon, as 
previously discussed, encompasses Mycobacterium species as well as Corynebacterium 
species, such as C. diphtheriae and C. glutamicum. The corynebacteria possess a comparable 
cell wall core and have previously been shown to serve as a useful model organism in the 
study of essential orthologous M. tuberculosis genes (Gande et al., 2004; Gibson et al., 2003; 
Radmacher et al., 2005).  Centred on this observation, Alderwick et al. (2005) successfully 
constructed a C. glutamicum mutant with its singular emb gene disrupted (Cg-emb). 
Corynebacterium are deemed the archetype of Corynebacterianeae since they maintain a low 
frequency of gene duplications and modifications, thus it is reasonable that C. glutamicum 
possesses only one emb gene. Surprisingly, Cg-emb exhibited higher identity to embC, even 
though C. glutamicum lacks an elaborately arabinosylated LM product (Dover et al., 2004; 
Tatituri et al., 2007a).  Chemical analyses of the tolerable Cg-emb deletion mutant revealed 
an almost total loss of cell wall arabinan, except terminal t-Araf residues decorating the 
galactan backbone (Alderwick et al., 2005).  Moreover, EMB treatment of wild-type C. 
glutamicum produced an identical profile to that of the mutant, illustrating that Cg-emb is 
indeed the target of EMB and furthermore, there is another AraT responsible for “priming” 
the galactan backbone.  Disruption of the decaprenyl transferase orthologue Cg-ubiA, 
involved in formation of the lipid-linked sugar donor DPA, resulted in total ablation of Araf 
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residues indicating that the unidentified AraT was also DPA dependent (Alderwick et al., 
2005). 
 
By virtue of DPA’s role as the only arabinose donor, it follows that all of the AraTs will be 
dependent on this polyprenyl-linked sugar. The Emb proteins, although novel, possess 
membrane topologies consistent with other glycosyltransferases (GTs) that use lipid-linked 
precursors, and do not resemble the more typical nucleotide-diphosphate (NDP) sugar donor 
requiring GTs.  The Carbohydrate-Active enZymes (CAZy) have classified GTs into 
approximately 87 families with 3 large structural superfamilies, GT-A, GT-B and GT-C 
(Berg et al., 2007; Unligil and Rini, 2000; Liu and Mushegian, 2003). GT-A and GT-B are 
NDP-sugar utilising, predominantly soluble and peripheral membrane proteins.  The GT-C 
superfamily embody polyprenyl-linked sugar donor dependent, integral membrane proteins, 
all of which contain 8-13 predicted transmembrane (TM) domains, with typically low 
sequence similarity, but a conserved amino acid motif, called the DxD motif, generally 
positioned in the first or second predicted extracytoplasmic loop.  The modified DxD motif 
(e.g., DxE, ExD, DDx, DEx, or EEx) lies upstream of a conserved proline motif, both of 
which are located in the same predicted loop and have been so called the “GT-C motif” (Berg 
et al., 2007). The actual mechanism is unknown but this motif may be responsible for the 
binding of a lipid-linked sugar donor and/or catalytic activity.  The Emb proteins have been 
classifed as GT-Cs, comprising approximately 1100 amino acids and 12-13 TM spanning 
regions (Berg et al., 2005).  Considering the other putative AraTs will utilise the same 
substrate, it follows that they will share these structural similarities. 
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1.6.5.4.4. Identification and functional role of AftA 
The identity of the novel “priming” AraT, arabinofuranosyltransferase AftA (Rv3792), which 
is responsible for priming the 8th, 10th and 12th Galf residues for further attachment of 
α(1→5)-linked Araf units, was addressed by Alderwick et al. (2006b).   
 
Figure 1.16: Early arabinogalactan formation.  The biosynthesis of the arabinan of AG is initiated by AftA 
(Rv3792), an integral membrane protein responsible for priming the decaprenyl-PP-galactan for further 
elaboration by arabinosyltransferases (Alderwick et al., 2005). The Araf residues derived from DPA are affixed 
to the carbon-5 hydroxyl of the 8th, 10th and 12th β-(1→6) linked Galf residues of the galactan chain.   
Genome comparisons of the Corynebacterianeae emb locus revealed a highly conserved gene 
situated after the DPPR epimerising enzymes and adjacent to embC. Although AftA proteins 
show no significant sequence identity to the Emb proteins, they do possess a notably similar 
domain organisation and localisation to that of EmbC, with an array of conserved amino 
acids comparable to the GT-C motif.   Contrary to the Emb proteins, AftA only encodes for 
643 amino acids with 11 predicted TM domains; however, it is proposed to contain an Emb 
analogous C-terminal region directed towards the periplasm.  AftA is essential for M. 
tuberculosis (Sassetti et al., 2003); hence its orthologue was successfully disrupted in C. 
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glutamicum producing a cell wall lacking Araf units (Alderwick et al., 2005). Furthermore, E. 
coli membranes expressing M. tuberculosis AftA exhibited AraT activity, specifically 
transferring arabinose from DPA to a galactan acceptor, which was shown to be EMB 
resistant (Alderwick et al., 2006b).  
1.6.6. Mycolic acids 
Mycolic acids and their homologs have been defined as high molecular weight α-alkyl, β-
hydroxy fatty acids (Asselineau & Lederer, 1950).  These fatty acids differ in length across 
species, consisting of 70-90 carbons in mycobacteria (Goodfellow & Minnikin, 1981; 
Lechevalier et al., 1986) and 22-38 carbons in their corynebacterial counterparts, the 
corynomycolic acids.   In M. tuberculosis, these long chain fatty acids are extremely 
hydrophobic, containing a meromycolate chain (up to C56) with a saturated α-side chain (C24-
C26).  Studies have shown that there are three distinct structural categories of mycolic acids, 
depending on the chemical modifications present in the meromycolate chain.  These include 
the α- mycolates, which are the most abundant form, containing no oxygenated functional 
groups in the meromycolate branch and two cyclopropane rings that are in the cis 
configuration (Minnikin et al., 2002; Qureshi et al., 1978; Yuan et al., 1995).  Ketomycolates 
and methoxymycolates on the other hand, are oxygenated species with only one 
cyclopropane ring in the cis and trans configuration, respectively (George et al., 1995).  The 
cyclopropane rings contribute to the structural integrity of the cell wall complex (George et 
al., 1995), and protect the bacillus from oxidative stress by hydrogen peroxide (Yuan et al., 
1995).  Deletion of the methoxy- and ketomycolates (Dubnau et al., 2000) and removal of the 
proximal cyclopropane ring of the α-mycolic acids (Glickman et al., 2000) leads to 
considerable attenuation of virulence in mouse models.  Thus, the fine structure of mycolic 
acids is coupled to the virulence of M. tuberculosis. 
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Figure 1.17: Structures of representative mycolic acids from M. tuberculosis. Modified from Minnikin et al. 
(2002). 
1.6.6.1. Biosynthesis of mycolic acids 
The fatty acid synthase-I (FAS-I) and fatty acid synthase-II (FAS-II) pathways are the two 
systems responsible for the biosynthesis of the mycolic acids (Bloch, 1977; Bloch & Vance, 
1977).   FAS-I is a multifunctional polypeptide encoded by the gene fas (Rv2524c) (Smith et 
al., 2003).  This single polypeptide contains all the functional domains required for the 
generation of short chain acyl-Coenzyme A (acyl-CoA) primers, which are either fed into the 
FAS-II pathway or become the C26 α-alkyl branch of the mycolic acids.  FAS-I begins de 
novo fatty acid synthesis by utilising acetyl-CoA and malonyl-CoA, elongating the acetyl 
group by two carbons in each cycle (Heath & Rock, 2002).   These substrates are only 
available for the FAS-I pathway upon activation via a thioester linkage to the prosthetic 
group of Coenzyme A. The intermediates remain associated to the polypeptide during the 
complete process; transacylation passes them from one active site of one domain to the active 
site of the next in the following sequence: acyltransferase, enoyl reductase, dehydratase, 
malonyl/palmitoyl transferase, acyl carrier protein (ACP), β -ketoacylreductase and β -keto 
synthase (Smith et al., 2003).    
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The FAS-II system is not capable of de novo fatty acid synthesis, thus relying on FAS-I for 
its acyl-CoA substrate.   An additional FAS-II substrate is malonyl-AcpM, an activated 
primer (Kremer et al., 2001; Schaeffer et al., 2001).  Malonyl-AcpM is synthesised by the 
malonyl-CoA:AcpM transacylase mtFabD from malonyl-CoA and phosphopantothenylated 
holo-AcpM.  AcpM has the vital role of steering acyl intermediates between enzymes, 
initially shuttling malonyl-AcpM to an acyl-CoA primer derived from the FAS-I pathway, 
allowing the two substrates to undergo a condensation reaction catalysed by mtFabH (Choi et 
al., 2000).    The AcpM-acyl precursor, β-ketoacyl-ACP is then reduced by MabA/FabG1 to 
β-hydroxyacyl-AcpM (Banerjee et al., 1998; Marrakchi et al., 2002), which is subsequently 
dehydrated by a β-hydroxyacyl-AcpM dehydratase (Rv0636) (Sacco et al., 2007; Brown et 
al., 2007).  InhA, an enoyl-AcpM reductase; the target of the INH, performs the enoyl-
reduction, resulting in an AcpM-bound acyl chain, which is now two carbon units longer 
through the complete enzyme cycle.  The cycle is then repeated several times, except for the 
substitution of mtFabH with the β -ketoacyl-AcpM synthases, KasA (Rv2245) or KasB 
(Rv2246), which catalyse the condensation of the acyl-AcpM and the new malonyl-AcpM, 
further elongating the chain by two carbon units (Figure 1.15) (Bhatt et al., 2005; Bhatt et al., 
2007; Gao et al., 2003; Kremer et al., 2002a; Schaeffer et al., 2001b; Slayden & Barry, 
2002).  
The final step in the synthesis of the mycolic acids was proposed by Walker et al. (1973) 
using a C. diptheriae model, and later in M. tuberculosis by Takayama & Qureshi (1975).   
The proposed Claisen-type condensation of C26-S-CoA and meromycolyl-AMP has been 
described as the final step carried out by Pks13, the type I polyketide synthase family protein.  
Prior to the participation of Pks13, each meromycolyl-S-AcpM from the FAS-II pathway are 
converted into meromycolyl-AMP by FadD32 (Triverdi et al., 2004), a specific fatty acyl-
AMP ligase. 
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Figure 1.18: Mycolic acid biosynthesis in M. tuberculosis (Adapted from Bhowruth et al., 2008). mtFabD 
converts malonyl-CoA to malonyl-AcpM, which is then ligated by mtFabH to FAS-I derived C14–CoA.  The 
FAS-II system (KasB/A, MabA, InhA, and Rv0636) continues to process the C16 acyl-AcpM product producing 
mercomycolates (C56). The meromycolic acid precursors are ligated to a FAS-I synthesised C26 fatty acid that 
constitutes the α-branch of the final mycolic acid. Mycolic acids are then formed via the condensation of the α-
branch and the meromycolate by polyketide synthase Pks13.  
 
The C26-S-CoA released from FAS-I is carboxylated by AccD4 (Rv3799c) and AccD5 
(Rv3280), the acyl-CoA carboxylases, yielding 2-carboxyl-C26-CoA.   This is followed by 
Pks13 thioester binding of the two substrates, C52-meromycolyl and 2-carboxyl-C26-acyl 
group to the N-terminus and C-terminus PPB domains, respectively (Takayama et al., 2005).  
Subsequent reactions occur generating the mature C78-mycolate (Lea-Smith et al., 2007) (as 
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shown in Figure 1.18). A series of mycolyltransferases are believed to be involved in the 
transfer of mycolic acids to their outer cell wall position.  Mycolates are also present in free, 
solvent-extractable trehalose conjugates TMM and TDM (Asselineau & Lederer, 1950; 
Minnikin, 1982; Minnikin et al., 2002), of which TMM is present both intra- and 
extracellulary, leading to the possible implication that it is responsible for the transport of 
extracellular mycolates and mycolyl components of the mAGP (Takayama et al., 2005). 
TMM, a key precursor for the biosynthesis of TDM is dephosphorylated and translocated 
across the membrane, whereby three mycolyltransferases Ag85A, Ag85b and Ag85c 
synthesise TDM and transfer mycolic acids to the arabinan termini (Belisle et al., 1997; 
Takayama et al., 2005). 
 
Figure 1.19: Structure of TDM 
 
1.6.7. Structural features of lipoarabinomannan (LAM) and related biosynthetic 
precursors (LM and PIMs) 
The mycobacterial cell wall’s core framework, the mAGP complex, provides a template for 
the insertion of an abundance of mannosylated molecules, such as lipoarabinomannan (LAM) 
and its structurally related glycolipids, lipomannan (LM) and phosphatidylinositol 
mannosides (PIMs) (Besra et al., 1997; Brennan & Ballou, 1967; Brennan & Ballou, 1968b; 
Brennan & Nikaido, 1995; Hill & Ballou, 1966; Morita et al., 2004).  These highly complex 
immunomodulatory lipoglycans are found ubiquitously in the envelopes of all mycobacterial 
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species, non-covalently associated to the plasma membrane and/or the mycolic acid layer via 
a conserved phosphatidyl-myo-inositol (PI) anchor (Hunter & Brennan, 1990), which extends 
to the exterior of the cell wall (Besra & Brennan, 1997; Belanger & Iamine, 2000; Nigou et 
al., 2003).  LAM is composed of numerous structural domains, the aforementioned PI 
anchor, as well as a polysaccharidic backbone consisting of D-mannan and D-arabinan and 
several distinct capping motifs.  
1.6.7.1. Phosphatidyl-myo-inositol mannosides (PIMs) 
The PI linker is based on a sn-glycero-3-phospho-(1-D-myo-inositol) unit, whereby, the 
glycerol phosphate component is attached to the L-1-position of myo-inositol (Ballou et al., 
1963; Ballou & Lee, 1964) and  mannopyranosyl (Manp) residues decorate positions C-2 and 
C-6 of the inositol ring, constituting phosphatidylinositol dimannoside (PIM2).  This anchor 
shows a high degree of heterogeneity with regard to its multiple acylation states, with four 
potential sites, two of which are present on the glycerol unit, one on the Manp unit linked to 
C-2 of myo-inositol and the fourth at the C-3 position of myo-inositol (Brennan & Ballou, 
1968; Khoo et al., 1995).  Ac1PIM2 and Ac1PIM6 are the major PIM species, existing as a 
diacylglycerol with a further fatty acid attached to the Manp residue at C-2 of myo-inositol. 
Ac2PIM2 and Ac2PIM6 also exist, but Ac1PIM2 is believed to be the preferred precursor upon 
which higher PIMs(3-6) are built, as well as LAM, and its arabinose-free counterpart LM 
(Chatterjee et al., 1992a).  
1.6.7.2. Characterisation of LM and LAM 
The mannan of LM and LAM is an extension of the PIMs, containing on average 20-30 
residues, emanating from the C-6 position of the inositol ring (Chatterjee et al., 1991; Khoo 
et al., 1996).  This α(1→6)-linked mannan backbone is adorned with single Manp sugars at 
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C-2 of the occasional α(1→6)-linked mannose in all mycobacterial species examined, with 
the exception of M. chelonae, which contains C-3-linked branching (Guerardel et al., 2002).  
 
Figure 1.20: Current structural model of mycobacterial LAM. The MPI anchor is linked to a mannan 
backbone with a α(1→6)Manp core branched frequently at the 2-position with a single α-Manp. Attached to the 
mannan core is an arabinan domain (approximately 50–70 residues in total). The point of attachment of arabinan 
to the mannan has not been elucidated. The non-reducing termini of the arabinan are capped with species 
specific sugars (Lee et al., 2005). 
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LM is further glycosylated with an arabinan domain similar to, but more variable than, that in 
AG.  Shi et al. (2006) identified the occurrence of an Ara18-22 motif in M. smegmatis that 
resembled the internal structure of the arabinan of AG, however, the terminal extensions at 
the non-reducing end varied.  The basic structure of the polymer consists of a linear α(1→5)-
linked arabinosylfuranosyl backbone with branched hexa-Araf (Ara6) and linear tetra-Araf 
(Ara4) terminal moieties (Chatterjee et al., 1991; 1993), equating to between 50-80 Araf 
residues (Khoo et al., 1996). 
1.6.7.3. Characterisation of LAM capping 
Mycobacterial species differ in the nature and extent of the capping motifs modifying the 
nonreducing termini of the arabinan chains, specifically, the β(1→2)-linked terminal Araf 
units. To date, three structural families have been recognised, mannose capped LAM (Man-
LAM), PI capped LAM (PI-LAM) and non capped LAM (Ara-LAM), of which “Man-caps” 
are an important feature of the LAM of pathogenic species or slow growing mycobacteria, 
such as M. tuberulosis, M. bovis, M. bovis BCG, M. leprae, M. avium, M. xenopi, M. 
marinum, and M. kansasii.  The caps may be present as single Manp capping residues, di or 
tri-mannosides, of which di-mannosides predominate. (Delmas et al., 1997; Guerardel et al., 
2003).  Fast growing mycobacteria such as M. smegmatis and M. fortuitum possess PI caps, 
and M. chelonae is the only known example of Ara-LAM.  
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Figure 1.21: Structural model of mycobacterial ManLAM, PILAM and AraLAM highlighting the 
different capping motifs found in all mycobacterial LAM. The non-reducing termini of arabinan are 
decorated with species specific sugars; 1–3 mannose units in M. tuberculosis and M. bovis, phosphatidylinositol 
in M. smegmatis (Nigou et al., 2003). 
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1.6.7.4.     Biosynthesis of PIMs, LM and LAM 
1.6.7.4.1. Synthesis of precursors 
1.6.7.4.2. GDP-Manp biosynthesis 
Mannose is a key component in numerous cell wall and intracellular molecules present in 
mycobacteria, including the mannolipids PIMs, LM and LAM and has been shown to be 
essential for the growth and viability of M. smegmatis (Patterson et al., 2003).  Mycobacteria 
can obtain mannose via two distinct pathways (Figure 1.21).  The first relies on 
phosphorylation by a hexokinase (Rv2702) to produce mannose-6-phosphate from 
exogenously obtained mannose (Hsieh et al., 1996).  The second is carried out by ManA 
(Rv3255c), a phosphomannose isomerase (PMI), which synthesises mannose-6-phosphate by 
converting fructose-6-phosphate obtained from the glycolytic pathway.  Patterson et al. 
(2003), demonstrated the essentiality of PMI in vitro in an M. smegmatis mutant, which was 
unable to synthesise mannose-containing molecules in the absence of an extracellular source 
of mannose (Patterson et al., 2003). Mannose-6-phosphate is subsequently converted into 
mannose-1-phosphate by a phosphomannomutase (PMM) encoded by manB (Rv3257c) 
(McCarthy et al., 2005).  Indeed, accumulation of PIMs, LM, and LAM was observed in a  
M. smegmatis strain overexpressing M. tuberculosis ManB, which intimates its role in the 
biosynthesis of these mannolipids (McCarthy et al., 2005). Finally, mannose-1-phosphate is 
modified by GDP-mannose pyrophosphorylase, ManC (Rv3264c) to GDP-Manp the 
nucleotide sugar donor of mannose (Ma et al., 2001; Ning & Elbein, 1999).  
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Figure 1.22: Pathway of mannose biosynthesis in mycobacteria. Two sugar donors are accessible to 
mycobacteria, GDP-Man and C50-P-Man (DPM), playing a separate role in mannan biosynthesis. Abbreviations: 
P = phosphate. Adapted from McCarthy et al. (2005) and Patterson et al. (2003). 
1.6.7.4.3. β-D-Mannosyl-1-monophosphoryldecaprenol (PPM) biosynthesis 
Takayama & Goldman (1970) presented initial reports characterising mannolipids potentially 
involved in mannan biosynthesis. They identified a C50-polyprenol based mannolipid (C50-P-
Man) in M. tuberculosis, followed by the characterisation of a M. smegmatis specific alkali 
stable, C35-octahydroheptaprenyl-phospho-mannose (C35-P-Man) (Takayama & Goldman, 
1970).  It was later demonstrated by Besra et al. (1997) that Ac1PIM2 is specifically extended 
by the addition of Manp residues from the alkali-stable sugar donor, polyprenol-
monophosphomannose (PPM), to form higher PIMs and linear LM. Gurcha et al. (2002) 
identified a polyprenol monophosphomannose synthase, Rv2051 (Ppm1) from M. 
tuberculosis by means of a combined genomics and biochemical approach, derived from 
similarities to the known eukaryotic dolichol monophosphomannose (DPM) synthases 
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(Gibson et al., 2003; Gurcha et al., 2002). It was discovered that PPM is generated from 
GDP-Man and the corresponding polyprenol phosphate via Ppm1. Therefore the PPM 
synthase is a key enzyme in the generation of PPM, which is subsequently utilised in the 
biosynthesis of LM and LAM, thus making it a potential drug target.  
1.6.7.4.4. Synthesis of PI 
Phosphatidyl-myo-inositol (PI) is the component upon which PIMs, LM and LAM are built 
and is the linkage to the plasma membrane. The initial step in the synthesis of PI is the 
phosphorylation of diacylglycerol (DAG) by a DAG Kinase (Rv2252) to form phosphatidic 
acid (Owens et al., 2006; Salman et al., 1999).  A CDP-DAG synthase (Rv2881c), activates 
phosphatidic acid with CTP forming cytidine diphosphate-diacylglycerol (CDP-DAG) 
(Nigou & Besra, 2002b), which later reacts with Myo-inositol forming PI. Recently, the gene 
encoding the PI synthase (Rv2612c) was identified and shown to be essential in M. 
tuberculosis (Jackson et al., 2000).  
1.6.7.5. Biosynthesis of PIMs 
The currently accepted model for PIM biogenesis follows a linear pathway 
PI→PIM2→PIM4→PIM6 (Figure 1.23).  In M. tuberculosis PimA (Rv2601) catalyses the 
glycosylation of PI by the transference of Manp from GDP-Manp to the 2-position of PI 
forming PIM1 (Kordulakova et al., 2002), which is subsequently acylated by Rv2611c at the 
6-position (Kordulakova et al., 2003). A Rv2611c mutant of M. smegmatis exhibited severe 
growth defects and accumulation of non-acylated PIM1 and PIM2. Furthermore, in a cell-free 
assay utilising membrane preparations from M. smegmatis, overexpression of Rv2611c 
increased the incorporation of [14C]-palmitate into PIMs (Kordulakova et al., 2003). Both of 
these enzymes are part of a conserved gene cluster of six ORFs in an operon, which is present 
in all members of Corynebacterineae (Cole & Barrell, 1998; Cole et al., 1998).  
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Figure 1.23: Pictorial depiction of PIM, LM and LAM biosynthesis. The three first mannosylations of PI 
in biosynthesis of PIMs involve the GDP-Man dependent PimA, PimB, and PimC, which are believed 
to occur on the cytoplasmic face of the plasma membrane. Rv2611c is responsible for the acylation of 
PIM1. PIM3 or PIM4 is translocated across the bilayer by an unidentified flippase, where it then acts as 
a substrate for PimE towards biosynthesis of the polar PIM6 and as a precursor in the formation of 
LM. The ManT(s) involved in the synthesis of the mannan backbone of LM (MptA and MptB) are 
believed to be C50-P-Man dependent, as was suggested for Rv2181, the α1,2-ManT responsible for the 
LM branching. LAM is generated via the further elaboration of LM with Araf units forming an 
arabinan domain. As yet, only the EmbC protein has been recognised, but the exact activity 
remains to be ascertained.  
 
 
PimB (Rv0557) was originally proposed as an α-D-mannose-α(1→6)-phosphatidyl-myo-
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inositol-mannopyranosyltransferase (PimB) responsible for the formation of Ac1PIM2  
through the transference of  mannose from GDP-Manp to Ac1PIM1 (Schaeffer et al., 1999). 
However, it was later found that disruption of pimB in M. tuberculosis did not affect the 
biogenesis of PIMs (Torrelles et al., 2009) suggesting that either complementary activities 
existed in the form of gene duplications or PimB is responsible for another function (Kremer 
et al., 2002a). Recent investigations have identified Rv2188c, now termed PimB’, as the 
protein involved in the second mannosylation step responsible for Ac1PIM2 formation (Lea-
Smith et al., 2008; Mishra et al., 2008b; Mishra et al., 2009). Indeed, work carried out by 
Tatituri et al. (2007) demonstrated PimB’s role in the biosynthesis of a novel mannolipid, 
ManGlcAGroAc2 and a LM-like molecule in C. glutamicum, and has since been renamed 
MgtA (Tatituri et al., 2007b).   Ac1PIM2 can remain unmodified, accumulating as an end 
product or be acylated to Ac2PIM2 and/or mannosylated forming the higher PIMs (Ac1PIM3- 
Ac1PIM6/Ac2PIM3-Ac2PIM6), or LM and LAM.  Research using cell free extracts has 
identified the mannosyltransferase PimC from M. tuberculosis strain CDC1551 implicating it 
as the ManT responsible for Ac1PIM3 /Ac2PIM3 formation from Ac1PIM2 /Ac2PIM2 (Kremer 
et al., 2002a). However, a M. bovis BCG pimC deletion mutant continued to produce normal 
levels of PIMs/ LM/LAM implying reduncancy of genes or compensatory pathways (Kremer 
et al., 2002b). In fact, there is no strong homologue of pimC in M. tuberculosis H37Rv or M. 
smegmatis, thus it remains to be identified along with the ManT accountable for α(1→6) 
mannosylation of Ac1/Ac2PIM3 yielding Ac1/Ac2PIM4. This product is believed to be an 
intermediate at the branch point at which polar PIMs and LM/LAM biosynthesis diverges 
(Mishra et al., 2008a; Morita et al., 2004; Morita et al., 2006). It is proposed that up until this 
branch point, mannose residues have been provided by the nucleotide-derived sugar substrate 
GDP-Man, characterising the earlier ManTs as members of the GT-A/B superfamily of 
glycosyltransferases. It has been hypothesised that Ac1/Ac2PIM4 is translocated across the 
plasma membrane, where it becomes available for Rv1159 (PimE), the recently identified 
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α(1→2)-mannopyranosyltransferase which utilises the polyprenylphosphate sugars PPM/C50-
P-Man as a substrate, adding an α(1→2)-Manp residue resulting in the synthesis of 
Ac1/Ac2PIM5 (Morita et al., 2006).  This transition to the GT-C superfamily of 
glycosyltransferases, which utilise polyprenylphosphate sugars (Liu & Mushegian, 2003), has 
been supported by a number of inhibition studies in which amphomycin, an inhibitor of the 
mannose donor PPM/C50-P-Man,  was shown to halt the synthesis of PIM4-PIM6 (Besra et 
al., 1997; Morita et al., 2006) and effect elongation and branching of LM and LAM (Morita 
et al., 2006). The biosynthesis of the final product Ac1/Ac2PIM6 has not been deduced, 
although the involvement of PimE cannot be ruled out.  
Chapter 1     Introduction 
 53 
   
 
Figure 1.24 Biogenesis of PIM, LM and LAM.   A schematic representation of the current understanding of 
the PIM, LM and LAM biosynthetic pathways in M. tuberculosis.  
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1.6.7.6. Biosynthesis of LM and LAM 
1.6.7.6.1. The role of MptA, MptB and Rv2181 
The mannan of LM/LAM is believed to be an extension of the PIMs, specifically 
Ac1/Ac2PIM4, and is composed of a linear α(1→6) mannan backbone, punctuated 
occasionally at C-2 with single α(1→2)-linked mannoses, resulting in a mannan  of 
approximately 25-30 residues (Figure 1.24) (Chatterjee et al., 1991; Khoo et al., 1996).  
Mishra et al. (2007, 2008a) recently identified two α(1→6) mannopyranosyltransferases, 
mannopyranosyltransferase A and B, named MptA and MptB, using C. glutamicum as a 
model organism.  It was elucidated that MptA (NCgl2093 and M. tuberculosis homolog, 
Rv2174) are concerned with the biosynthesis of the distal end of the α(1→6) mannan 
backbone of LM (Mishra et al., 2007; Kaur et al., 2007) and MptB (Rv1459c) is involved in 
the synthesis of the proximal end of the mannan backbone. A reduction in α(1→6)-
mannopyranosyltransferase activity, with complete loss of LM and LAM, was observed in a 
MptB-deletion mutant in C. glutamicum.  Further evidence from cell free C. glutamicum 
assays utilising C50-P-Manp and expressing Rv1459c and/or its M. smegmatis homologue 
MSMEG_3120 showed that these enzymes possess α(1→6)-mannopyranosyltransferase 
activity.  However, M. tuberculosis and M. smegmatis MptB proteins are unable to 
complement the C. glutamicumΔmptB mutant, suggesting substrate specificity differences.  It 
is proposed that MptB catalyses the addition of further Manp residues (12-15 sugars) to 
Ac1PIM4, which has been transported across the plasma membrane by an as yet unidentified 
flippase (Mishra et al., 2008a). 
Kaur et al. (2006) recently identified the putative integral membrane proteins, MSMEG4250 
in M. smegmatis and Rv2181 in M. tuberculosis as potential polyprenol-dependent 
glycosyltransferases based on shared characteristics with previously identified enzymes. A 
knock-out of MSMEG4250 in M. smegmatis possessed a truncated version of LAM with a 
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decrease in the number of α(1→2)-Manp branching residues and altered growth with an 
inability to synthesise LM. Complementation of the mutant with the corresponding ortholog 
of M. tuberculosis (Rv2181) restored normal LM/LAM synthesis. However, regulation of 
LM and LAM biosynthesis in M. smegmatis appears to differ somewhat with M. tuberculosis, 
as M. tuberculosisΔRv2181 produced truncated versions of LM and Man-LAM (Kaur et al., 
2008).  
Table 1.3:  Genes involved in biosynthesis of LAM and related glycoconjugates (Mishra et al., 2009) 
Protein Function Role References 
PgsA 
(Rv2612c) PI synthase PI synthase Jackson et al. 2000 
PimA 
(Rv2610c) Synthesis of PIM1 
α(1→2)- 
Mannopyranosyltransferase Kordulakova et al. 2003 
Rv2611c Synthesis of Ac1/Ac2PIM1 Acyl transferase Kordulakova et al. 2003 
PimB 
(Rv2188c) Synthesis of Ac1/Ac2PIM2 
α(1→6)- 
Mannopyranosyltransferase 
Lea-Smith et al. 2008; 
Mishra et al., 2008; 2009 
MgtA 
(Rv0557) 
Synthesis of Gl-X and 
Ac1/Ac2PIM2 
α(1→6)- 
Mannopyranosyltransferase 
Tatituri et al. 2007a; 
Mishra et al., 2008 
PimC (RvD2-
ORF1) Synthesis of Ac1/Ac2PIM3 
α(1→6)- 
Mannopyranosyltransferase Kremer et al., 2002 
PimE 
(Rv1159) Synthesis of Ac1/Ac2PIM5 
α(1→2)- 
Mannopyranosyltransferase Morita et al., 2006 
MptB 
(Rv1459c) 
Synthesis of proximal 
mannan backbone i.e. 
Ac1/Ac2PIM12-17 
α(1→6)- 
Mannopyranosyltransferase Mishra et al.,2008 
MptA 
(Rv2174) 
Synthesis of distal mannan 
backbone i.e. 
Ac1/Ac2PIM22-25 
α(1→6)- 
Mannopyranosyltransferase Mishra et al.,2007. 
MptC 
(Rv2181) 
Adds α(1→2)-Manp units on 
mannan backbone, and also 
adds second mannose cap 
on ManLAM 
α(1→2)- 
Mannopyranosyltransferase Kaur et al., 2008; 2010 
EmbC 
(Rv3793) 
Involved in the synthesis of 
α(1→5)-arabinan backbone 
α(1→5)- 
Arabinofuranosyltransferase Zhang et al., 2003 
AftC 
(Rv2673) 
Adds Araf on α(1→5)-
arabinan backbone in 
α(3→5)-direction 
α(1→3)- 
Arabinofuranosyltransferase Birch et al., 2010 
AftD 
(Rv0236c) 
Either adds α(1→3)-Araf 
units to the non-reducing 
end of α(1→5)- arabinan 
branch or synthesize 
α(1→3) or α(1→5)- 
Arabinofuranosyltransferase Skovierova et al., 2009 
CapA 
(Rv1635c) 
Adds first mannose cap on 
ManLAM 
α(1→5)- 
Mannopyranosyltransferase Appelmelk et al., 2008 
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1.6.7.7. Arabinan biosynthesis in lipoarabinomannan 
1.6.7.7.1. The role of EmbC 
LAM is generated via the further elaboration of LM with Araf units forming an arabinan 
domain akin to that found in AG (Besra et al., 1997).  The linkage pattern of Araf residues 
and the Ara6 non-reducing end are also present in AG (as discussed in section 1.6.5.1); 
however, the arabinans also differ in a number of ways.  Firstly, LAM also contains a linear 
tetra-arabinoside (Ara4) as well as the Ara6 motif, with a major difference being that the non-
reducing end of the LAM arabinan is substituted with α-mannosyl residues rather than with 
mycolic acids (Chatterjee et al., 1992b).  The arabinan structure is also more variable in 
LAM, with a recent study suggesting that the precise Ara18 arrangement is not always 
present, but rather chains of differing lengths extend from the interior 3,5-Araf residues (Shi 
et al., 2006). It is theorised that at least five distinct arabinofuranosyltransferases are required 
for the generation of mature LAM, based on the linkages present; as yet only the EmbC 
protein has been recognised, but the exact activity remains to be ascertained (Zhang et al., 
2003).  Although EmbC is an essential enzyme in M. tuberculosis (Goude et al., 2008), 
inactivation of the gene in M. smegmatis produced a viable mutant, with lack of 
arabinosylation in LAM but AG remained largely unaffected (Escuyer et al., 2001; Zhang et 
al., 2003).  This knockout strain did possess two to three single Araf residues secured to the 
mannan backbone, suggesting the existence of an additional AraT, analogous to the priming 
enzyme AftA (Zhang et al., 2003). However, despite extensive analyses, the arabinan chain 
attachment sites have not been defined (Chatterjee & Khoo, 1998).  
The EmbC protein is predicted to contain 13 transmembrane helices and a modified DxD 
motif, which is expected to play a role in carbohydrate binding and is thus classified as a 
member of the GT-C super-family of integral membrane glycosyltransferases (Berg et al., 
2005). The characteristic GT-C motif of EmbC may be responsible for the chain elongation 
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of α (1→5)-Araf residues, where the arabinan units are linked to each other creating 3,5-α-
Araf branches on 5-linked chains or by transferring the residues directly on to the mannan 
backbone (Berg et al. 2005). Thus, embC inhibition appears to be parallel to the emb 
mediated inhibition of arabinosylation of galactan in corynebacterial AG, conferring the 
α(1→5) transferase activity.  Point mutations introduced into the conserved proline motif 
proximal to the large carboxyl-terminal globular region, resulted in the biosynthesis of 
shorter arabinan domains thus this region seems to control chain length extension of the 
arabinan domain of LAM (Shi et al., 2006).  
1.6.7.8. Mannose - capping of LAM 
The arabinan domain of LAM is further modified by the addition of α-mannosyl residues, 
resulting in capping with either one, two or three Manp residues.  The total extent of capping 
is about 70%, with a di-mannoside cap being the most abundant (Chatterjee et al., 1992; 
Chatterjee et al., 1993).  It is predicted that synthesis would require at least two ManTs, one 
that should recognise the arabinan domain and thus add the primary α(1→5)-mannose and a 
further ManT for the elongation of this mannose with a second α(1→2)-mannose. Mannose-
capped LAM (Man-LAM) is a feature of all pathogenic strains of the Mycobacterium genus 
and is, hence, responsible for some of the immuno-modulatory properties of these strains 
(Briken et al., 2004). Subtractive genomics of the M. tuberculosis genome, with those species 
of the genus that do not contain mannose-capped LAM, such as M. smegmatis, highlighted 
the GT-C enzyme Rv1635c (Dinadayala et al., 2006).  A transposon mutant strain of M. 
tuberculosis CDC1551 with an ineffective copy of MT1671 (Rv1635c), did indeed produce 
LAM devoid of Manp capping (Dinadayala et al., 2006). Moreover, an M. smegmatis strain 
expressing MT1671 resulted in a hybrid LAM, possessing single mannose caps. Further 
studies supported this finding, with Rv1635c mutants in M. marinum and M. bovis BCG 
showing that Rv1635c encoded for a mannopyranosyltransferase involved in the addition of 
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the first Manp residue on the non-reducing arabinan termini of LAM (Appelmelk et al., 
2008). More recently, Kaur et al. (2008) have shown that Rv2181c possesses varied substrate 
specificity, capable of adding α(1→2)-Manp residues onto the mannan backbone, as well as 
the non-reducing end of LAM in combination with Rv1635c (Kaur et al., 2008).  
 
1.6.7.9. Immunomodulatory properties of LAM & LM 
LAM and related lipoglycans are not only essential for mycobacterial growth and survival 
(Haites et al., 2005; Kovacevic et al., 2006), but have also been implicated in a broad 
spectrum of immunomodulatory activities. During the last decade, investigators have studied 
LAM and LM isolated from a multitude of mycobacterial organisms with various capping 
motifs, hoping to gain insight into the nature of these host-pathogen interactions and the 
importance of these complex heteropolysaccharides in pathogenesis (Dao et al., 2004; Garton 
et al., 2002; Gibson et al., 2003; Gibson et al., 2004; Gibson et al., 2005; Maeda et al., 2003; 
Quesniaux et al., 2004a, 2004b).  
The ability of mycobacteria to persist in host tissues is central to the disease. One strategy for 
survival is phagosomal maturation inhibition (Armstrong & Hart, 1971; Nguyen & Pieters, 
2005; Russell, 2001); another is the suppression of the cell-mediated host immune response 
after infection.  Several studies using purified LAM have highlighted a major role for this 
lipoglycan in both of these phenomena.  
1.6.7.9.1. Phagosome maturation arrest  
ManLAM has been implicated in inhibition of phagosome maturation (Jo, 2008; Quesniaux 
et al., 2004a) and infection induced apoptosis (Rojas et al., 2000).  Man-LAM blocks the 
increase of macrophage cytosolic Ca2+ that normally occurs upon infection, thereby 
inhibiting Ca2+/calmodulin-dependent PI3-kinase hVPS34 (Chua and Deretic, 2004; Malik et 
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al., 2001; Vergne et al., 2004a, 2004b). PI3-Kinase is necessary for the production of PI3-
phosphate on the phagosomal membrane, which is subsequently involved in the recruitment 
of the Rab5 effector EEA1 to the early endosome. This is required for the delivery of 
lysosomal components from the trans-Golgi network (TGN) to the phagosome and regulation 
of fusion with vesicles of the endosomal-lysomal pathway, as discussed in section 1.3 
(Simonsen et al., 1999; Vergne et al., 2003). ManLAM is able to suppress cytosolic Ca2+-
increase and therefore restrict generation of PI3-phosphate (Fratti et al., 2003; Vergne et al., 
2003b).  Indeed, Fratti et al. (2001) reported that ManLAM-coated beads behaved similarly 
to M. bovis BCG LAM, in that they resided in early endosomes that failed to recruit EEA1. 
Thus, M. tuberculosis ManLAM may contribute to the maturation arrest of bacillus-
containing phagosomes by virtue of its ability to attenuate hVPS34 and to inhibit EEA1 
recruitment.  The inhibition of Ca2+ increase appears to be specific for ManLAM, as LAM, 
lacking terminal mannose capping, from non-pathogenic Mycobacterium does not affect Ca2+ 
levels (Vergne et al., 2003). At present, the mechanism by which ManLAM alters Ca2+ fluxes 
remains to be established (figure 1.25).  
 
It has also been reported that p38 mitogen-activated protein kinase (p38 MAPK) contributes 
to phagosome maturation arrest in a way distinct from the inhibition of cytosolic Ca2+ 
increase. ManLAM has been implicated as a trigger for an increase in p38 MAPK activation, 
which contributes to phagosome maturation arrest through modulation of EEA1 recruitment 
(Fratti et al., 2003) and downstream trafficking events. However, Welin et al. (2008) recently 
published contrasting results demonstrating that ManLAM did not effect p38 MAPK 
activation.  
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Figure 1.25: The role of ManLAM and PIMs in phagosome maturation arrest.  Fusion with early 
endosomes required for nutrient acquisition is promoted by PIMs. ManLAM inhibits lysosomal fusion and 
acidification by inhibiting cytosolic-Ca2+ increase and thereby blocks the successive steps of hVPS34 kinase 
activity at the phagosomal membrane, the recruitment of Rab5, EEA1 and Syn6 to the phagosome, and the 
delivery of cathepsins and VoH+ ATPase. TGN = trans-Golgi network, CaM = calmodulin, PI(3P) = 
phosphatidylinositol (3-phosphate), Syn = syntaxin, EEA1 = early endosome autoantigen. 
 
Another process of maturation arrest involves the incorporation of ManLAM, via its GPI 
anchor, into so-called lipid rafts or membrane rafts of the macrophage cell membrane. These 
are cholesterol and glycosphingolipid-rich domains that act as docking sites for cell 
signalling processes (Welin et al., 2008).  The insertion of ManLAM is reported to reorganise 
the phagosomal membrane in such a way as to disrupt access to the molecules essential for 
maturation (Hayakawa et al., 2007). The overall effect is that the mycobacteria can survive in 
their self-created phagosomal niche. 
 
In contrast to ManLAM, its biosynthetic precurser LM does not affect phagolysosomal 
development (Kang et al., 2005; Vergne et al., 2004b).  PIMs, however, have been found to 
specifically stimulate early endosomal fusion through incorporation into the membrane rafts 
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and thus competitively inhibiting insertion of LAM (Welin et al., 2008). Therefore PIM 
generates a bypass mechanism allowing endosome fusion necessary for nutrient delivery to 
the bacilli residing in the phagosome (Kelley and Schorey, 2003; Vergne et al., 2004b). 
Torrelles et al. (2006), reported that the MR has a high affinity for higher-order PIMs (PIM5 
and PIM6) while lower-order PIMs (PIM2) are not recognised. Thus, although ManLAM and 
PIMs influence the phagosome maturation by distinct mechanisms, both may involve ligation 
to the mannose receptor (MR) (Vergne et al., 2004b).  
 
1.6.7.9.2. Lipoglycan interaction with the host cell 
While LM is mainly associated with toll-like receptor (TLR)-signalling, the higher-order 
PIMs and ManLAM are recognised by the C-type lectins DC-SIGN and the macrophage MR 
(Tailleux et al., 2005). Both C-type lectins show comparable recognition specificities for the 
mannosylated glycolipids, and, as receptors CD14 and pulmonary surfactant protein (SP)-A 
and SP-D also bind ManLAM (Ernst, 1998; Pugin et al., 1994; Sidobre et al., 2000; Torrelles 
et al., 2008), interactions of mycobacteria with all these pattern recognition receptors may 
enhance or dampen inflammatory signals and thereby determine the nature of the immune 
response. Anti-inflammatory signaling, via the interaction of the glycolipids with the host 
immune system, can be regarded as strategies of mycobacteria to escape immune surveillance 
(Torrelles & Schlesinger, 2010), but may be also vital in prevention of an exaggerated 
inflammatory response (Jo, 2008).  
1.6.7.9.3. LAM and the Mannose receptor 
The ManLAM-mediated phagosome maturation delay is dependent on the MR present on the 
macrophage membrane. Indeed, Kang et al. (2005) demonstrated the reversal of delayed 
phagolysosome fusion by use of a MR-blocking antibody alongside LAM-coated 
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microspheres. Further supporting evidence was presented by Ferguson et al. (2006), 
demonstrating that coating M. tuberculosis with the mannose cap binding C-type lectin 
surfactant protein D (SP-D),  increases phagolysosome fusion in infected macrophages.  
Given that the macrophage MR only recognises the mannose-capped ManLAM and not 
AraLAM or PILAM (Schlesinger et al., 1994), this is further evidence that ligation to the 
macrophage MR is required for the phagosome maturation block, which appears to be 
restricted to the more virulent Mycobacterium species. This receptor is distinguished by the 
fact that it mediates the engulfment of microbes without necessarily inciting a 
proinflammatory response and thereby has long been postulated to enhance early intracellular 
survival of the microbe. This receptor has also been implicated in intracellular trafficking of 
LAM to the late endosomal compartments for loading onto CD1b molecules for LAM 
presentation to T cells (Prigozy et al., 1997).  Some species of PIMs expressed by M. 
tuberculosis have been shown to engage the MR and illicit an MR-dependent delay in 
phagolysosome fusion (Torelles et al., 2006), whereas PILAM and AraLAM did not effect 
maturation (Kang et al., 2005). 
1.6.7.9.4. Modulation of DC-SIGN activity 
Immature DCs are seeded throughout peripheral tissues to act as sentinels against invading 
pathogens.  Indeed, immature DCs internalise M. tuberculosis derived LAMs and present 
these structures via the CD1b-presentation pathway to LAM specific T cells.   DC-SIGN has 
a high affinity for mannose-containing carbohydrates.  It was demostrated by Geitjenbeek et 
al. (2003), that mycobacteria specifically target DC-SIGN through ManLAM to impair DC 
maturation and to induce production of the anti-inflammatory cytokine IL-10.  These 
conditions promote immunosuppression.   
DC-SIGN only recognises LAM if it is mannose-capped (Geijtenbeek et al., 2003; Maeda et 
al., 2003) and it has been shown to have a strong affinity for increasing chain lengths of 
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α(1→2)-linked mannosyl residues (Koppel et al., 2004). Unsurprisingly, PIM5 and PIM6 are 
recognized by DC-SIGN with a higher affinity then lower order PIMs, most likely due to 
terminal α(1→2)-linked mannosyl residues similar to the mannose cap of ManLAM 
(Boonyarattanakalin et al., 2008; Driessen et al., 2009). On the other hand, a BCG mutant 
producing a mannose-cap devoid LAM still bound DC-SIGN to the same extent as wild-type 
BCG (Appelmelk et al., 2008); thus, other DC-SIGN ligands must be present in the 
mycobacterial cell envelope.   
ManLAM binding to LPS-activated DCs increases the secretion of pro-inflammatory IL-12 
and IL-6 as well as IL-10 (Gringhuis et al., 2009); therefore, this suggests that DC-SIGN 
binding may function primarily in the protection of the host (Ehlers, 2009).  
1.6.7.9.5. Toll-like receptors 
PILAM and LM stimulate innate immunity via signaling through TLR2, which differs from 
that of ManLAM.  TLR2 signalling has been demonstrated for PI-anchored mannosylated 
lipoglycans; however, it is dependent on their degree of acylation and mannosylation (Doz et 
al., 2007; Gilleron et al., 2006; Nigou et al., 2008). For instance, lipoglycan-induced 
signaling occurs via the TLR1/TLR2-heterodimer complex, which recognises tri-acylated 
lipoglycans (Elass et al., 2005; Gilleron et al., 2006; Nigou et al., 2008). The degree of 
mannosylation also affects the ability of the lipoglycan to activate TLR2, with a higher level 
of activation accompanying an increasing length of mannan chain (Nigou et al., 2008). LM 
presents the largest accessible mannan chain, since it does not possess a masking arabinan 
domain; it did indeed show increased TLR2-signalling (Quesniaux et al., 2004b), although 
this activity is restricted to the tri- and tetra-acylated forms (Ac1/Ac2-LM) (Doz et al., 2007; 
Gilleron et al., 2006). Ac1/Ac2PIM2, PILAM and AraLAM have been shown to be poor 
inducers of TLR2-signalling in comparison to LM and Ac1/Ac2PIM6 (Nigou et al., 2008), 
highlighting the need for a large unmasked mannan chain. Vignal et al. (2003) also presented 
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supporting evidence, showing that in contrast to LM, neither AraLAM from M. chelonae nor 
ManLAM and Ac1/Ac2PIM2 from M. kansasii mediate a TLR2-dependent activation (Vignal 
et al., 2003). Moreover, chemical degradation of the arabinan domain of ManLAM from M. 
kansasii restored its ability to induce cytokine secretion via TLR2, which suggests that the 
arabinan domain prevents proper interaction of ManLAM with TLR2 (Vignal et al., 2003). 
This was confirmed in this thesis (Chapter 3) in which LAM containing a truncated arabinan 
domain from a M. smegmatis AftC knock-out mutant, showed enhanced TLR2-signalling as 
compared to wild-type LAM (Birch et al., 2010). Overall, the data indicate that LM, and in a 
minor respect PIM6, are the only significant TLR2-ligands from this group of mycobacterial 
lipoglycans. 
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1.7. Project aims 
Mycobacterial diseases are especially problematic to treat owing to the unique lipid-rich cell 
wall architecture. The cell wall is essential for growth and survival and the majority of front-
line drugs target its biosynthesis (Zhang, 2005). In particular, EMB and INH inhibit 
biosynthesis of arabinan and mycolic acids, respectively. Nonetheless, the global problem of 
TB has been worsened in recent years by the emergence of MDR- and XDR-TB cases, 
leading to a necessity to discover novel drug targets and specific antimicrobial compounds 
against them (Sreevatsan et al., 1997b; Telenti et al., 1997). In this regard, the biosynthetic 
machinery of the mycobacterial cell wall and associated lipoglycans represent attractive 
targets (Bhatt et al., 2007b; Bhowruth et al., 2007; Brennan & Crick, 2007; Dover et al., 
2008).  
The structural basis of the arabinan of both AG and LAM is now well defined (Besra et al., 
1995; Daffé et al., 1990; McNeil et al., 1990), conversely, aspects of its biosynthesis 
remained poorly resolved. Upon commencing this study, only EmbA, EmbB and the newly 
identified AftA were implicated in AG arabinan biosynthesis and only EmbC as the AraT 
involved in LAM biosynthesis (Alderwick et al., 2006; Mikusova et al., 1995; Zhang et al., 
2003). Given that the arabinan domains utilise several different Araf linkages clearly suggests 
that additional AraTs must be required to form a fully matured arabinan.  All of these 
recognised AraTs are classified as members of the GT-C superfamily of integral membrane 
proteins. Liu and Mushegian (2003) identified members of this superfamily, representing 
potential candidates involved in the biosynthesis of cell wall related components. The major 
hindrance for the study of these genes, adopting a “reverse-genetics” approach, is the 
essentiality of arabinan in M. tuberculosis. For instance, a direct knock out embA, embB or 
embC resulted in non-viable mutants of M. tuberculosis. Furthermore, the study of M. 
tuberculosis has posed a formidable challenge as a result of its long generation time, 
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fastidious growth requirements, and high risk of contagion. M. smegmatis and C. glutamicum 
share similar genomic organization and cell wall biosynthetic machinery, and are 
nonpathogenic, fast-growing organisms that can tolerate deletion of some cell wall 
biosynthetic genes that are essential in M. tuberculosis (Alderwick et al., 2005b; Alderwick 
et al., 2006c; Gande et al., 2004).  The aim of this thesis was to study the direct effects of 
Corynebacteriaceae glycosyltransferases which represent the orthologous genes and enzymes 
of M. tuberculosis, in the model organisms C. glutamicum and M. smegmatis. More 
specifically: 
• Bioinformatic investigation of the published Corynebacterineae genomes using 
comparative genomics to identify putative glycosyltransferases involved in cell wall 
AG and LAM biosynthesis. 
• Deletion of selected genes from M. smegmatis and C. glutamicum that encode 
putative GT-C glycosyltransferases involved in AG and LAM biosynthesis.  
• Subsequent phenotypic characterization of strains deleted of putative GT-C 
glycosyltransferase encoding genes which includes 
• Carbohydrate and lipid chemical compositional analysis of purified cell wall 
material. 
• Biochemical investigation into consequential effects of AraT activity in 
isolated membranes using a range of neoglycolipid acceptor analogues. 
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2. Identification and characterisation of AftB and AftC arabinotransferases involved 
in arabinogalactan biosynthesis 
2.1. Introduction 
TB is currently the leading cause of mortality from a single infectious agent, responsible for 
1.8 million fatalities annually, as well as latently infecting a third of the world’s population.   
Mycobacterial diseases, such as TB and leprosy, consequently still represent a global health 
problem (Gupta et al., 2001). For instance, the recent emergence of MDR-TB strains and, 
more recently, XDR-TB clinical isolates (Singh et al., 2007; Zignol et al., 2006), has 
prompted the need for new drugs and drug targets. The causative agent of these diseases, M. 
tuberculosis and M. leprae, respectively, are members of the Corynebacterianeae, a group of 
atypical Gram-positive bacteria characterised by an intricate cell envelope (Besra et al., 
1995; McNeil et al., 1990; McNeil et al., 1991).  
 
This distinctive mycobacterial cell envelope is composed of three macromolecules, LAM, 
mycolyl-AG and PG (Besra et al., 1995; Chatterjee et al., 1991; McNeil et al., 1990; McNeil 
et al., 1991). The galactan domain of AG is linked to PG via a specialised “linker unit”, L-
Rhap-(1→4)-α-D-GlcNAc, and its distal arabinan domain to mycolic acids, forming mAGP 
complex (Besra et al., 1995; McNeil et al., 1990; McNeil et al., 1991). The arabinan domain 
contains α(1→5), α(1→3) and β(1→2) Araf linkages, arranged in several distinct structural 
motifs (Alderwick et al., 2005b; Besra et al., 1995; Daffé et al., 1990). The non-reducing 
arabinan termini of AG consists of t-Araf, 2-Araf, 5-Araf, and 3,5-Araf residues arranged into 
a characteristic terminal Ara6 motif, with the 5-OH of the t-Araf and 2-Araf residues 
representing sites of mycolylation (McNeil et al., 1991). The packing and ordering of 
mycolic acids within the mAGP and additional lipids within the outer envelope results in a 
highly impermeable barrier (Minnikin et al., 2002), which is essential for bacterial survival. 
Chapter 2  
 69 
It is interesting to note that several front-line anti-tubercular drugs, such as ethambutol 
(EMB) (Belanger et al., 1996; Takayama & Kilburn, 1989; Telenti et al., 1997) and isoniazid 
(INH) (Banerjee et al., 1994; Winder & Collins, 1970), target aspects of the biosynthesis of 
the mAGP complex.  
 
The structural basis of AG is now well defined (Besra et al., 1995; Daffé et al., 1990; McNeil 
et al., 1990), conversely, aspects of its biosynthesis remain poorly resolved. The biosynthesis 
of AG involves the formation of a linear galactan chain, with alternating β(1→5) and 
β(1→6)-D-galactofuranosyl (Galf) residues of approximately 30 residues in length, from the 
specialised ‘linker unit’, L-Rhap-(1→4)-α-D-GlcNAc (Kremer et al., 2001; Mikusova et al., 
2000), attaching the AG to the PG via the C-6 of some of the MurNGly residues. MALDI-
TOF MS analyses of per-O-methylated AG of C. glutamicum, deleted of its single 
arabinofuranosyltransferase Cg-emb, revealed that the 8th, 10th and 12th Galf residue 
possessed singular Araf residues (Alderwick et al., 2005b). These specific Araf residues were 
recently shown to be transferred by a specialised arabinofuranosyltransferase AftA, whose 
gene in all Corynebacterianeae analysed to date is adjacent to the emb cluster (Alderwick et 
al., 2006c). These initial Araf residues “prime” the galactan backbone for further attachment 
of α(1→5) linked Araf residues. These reactions require the arabinofuranosyltransferase 
activities of Mt-EmbA and Mt-EmbB, or Cg-Emb, respectively; these are also targets of 
EMB (Alderwick et al., 2005b; Radmacher et al., 2005; Telenti et al., 1997), which 
eventually result in mature AG.  
 
Disruption of either embA or embB, in M. smegmatis, produced an impairment of the 
terminal Ara6 motif, resulting in a linear terminal motif (Escuyer et al., 2001). The Emb and 
AftA proteins utilise the specialised sugar donor, β-D-arabinofuranosyl-1-monophosphoryl-
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decaprenol (DPA) (Lee et al., 1995b; Lee et al., 1997; Wolucka et al., 1994b), and is a 
characteristic feature found only in Corynebacterianeae (Alderwick et al., 2006a; Huang et 
al., 2005; Mikusova et al., 2005). In addition, these proteins also belong to the GT-C 
superfamily of integral membrane glycosyltransferases (Liu & Mushegian, 2003). A recent 
topological analysis of Cg-Emb (Seidel et al., 2007c), together with a mutational study of 
Mt-EmbC (Berg et al., 2005), revealed for the first time a clear domain organisation of these 
proteins. The glycosyltransferase DDX signature is evident in the extracellular loop which 
connects helixes III-IV and the chain elongation “Pro-motif”, is in the extracellular loop 
connecting helixes XIII-XIV (Berg et al., 2005). 
It is interesting to note that the arabinan domain of AG utilises several different Araf 
linkages, which suggests that additional arabinofuranosyltransferases must be required to 
form a fully matured AG. Moreover, initial Araf residues at branching sites could require 
specialised arabinofuranosyltransferases, as already observed for AftA (Alderwick et al., 
2006c). Clearly additional arabinofuranosyltransferases still remain to be identified in 
Corynebacterianeae. Liu and Musheginan (2003) identified fifteen members of the GT-C 
superfamily, representing candidates involved in the biosynthesis of cell wall related glycans 
and lipoglycans in M. tuberculosis. In order to study the direct effects of Corynebacteriaceae 
arabinofuranosyltransferases, we have attempted to identify and delete genes, which 
represent the orthologous genes and enzymes of M. tuberculosis, in the model organisms C. 
glutamicum and M. smegmatis.  The study of M. tuberculosis has posed a formidable 
challenge as a result of its long generation time, fastidious growth requirements and high risk 
of contagion.  M. smegmatis and C. glutamicum, on the other hand, are non-pathogenic, fast-
growing organisms that can tolerate deletion of some cell wall biosynthetic genes that are 
essential in M. tuberculosis (Alderwick et al., 2005b; Alderwick et al., 2006c; Gande et al., 
2004).  Herein, we present the identification of two novel arabinofuranosyltransferases of the 
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GT-C superfamily, arabinfuranosyltransferase B (AftB) and arabinofuranosyltransferase C 
(AftC).  The latter is responsible for the transfer of Araf residues from DPA to the arabinan 
domain to form α(1→3)-linked Araf residues, which result in the branched arabinan domain 
distal to the non-reducing terminal Ara6 motif characteristic of mycobacterial AG.  AftB is 
responsible for the transfer of Araf residues from DPA to the arabinan domain to form 
terminal β(1→2) linked Araf residues, which marks the “end-point” for AG arabinan 
biosynthesis before decoration with mycolic acids.  
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2.2. Results 
2.2.1. Genome comparison of the aftB locus 
With the recent identification of AftA as a novel arabinofuranosyltransferase present in 
Corynebacterianeae (Alderwick et al., 2006c), and based on the fact that it is present in a 
highly conserved cell wall locus (Alderwick et al., 2006c), we concentrated our studies to 
identify other cell wall related genes. Subsequently, we identified Rv3805c (Figure 2.1A), 
which is located in close proximity to the antigen 85 complex-encoding genes fbpA and fbpD 
(Belisle et al., 1997). Furthermore, Rv3805c is likely to form an operon together with ubiA, 
which is required for prenyl transfer to 5-phosphoribose pyrophosphate (PRPP) to form 
decaprenylphosphoryl-5-phosphoribose (DPPR), before conversion to DPA (Huang et al., 
2005; Mikusova et al., 2005), and glfT, which is responsible for establishing the galactan 
backbone of AG (Kremer et al., 2001; Mikusova et al., 2000). The apparent fundamental 
function of aftB is indicated by the fact that the genome organisation of this particular region 
is syntenic in Corynebacterianeae, including all Mycobacterium and Corynebacterium 
species analysed to date (Figure 2.1A, B) and also in Norcardia farcinica IFM 10152 and 
Rhodococcus sp. RHA1. 
The gene product of Rv3805c, termed AftB, is predicted to form nine transmembrane (TM) 
spanning helixes, in its amino-terminal part, whereas a 237 amino acid carboxy-terminal part 
is directed towards the periplasm (Figure 2.1C). Interestingly, AftB shows no obvious 
sequence similarity to the previously identified arabinofuranosyltransferases, such as Emb 
(Alderwick et al., 2005b) and AftA (Alderwick et al., 2006c), although the topology, with the 
C-terminus directed towards the periplasmic side, is to some degree comparable. However, 
the intrageneric similarity of the AftB proteins is very high, even for the most distant pairs, 
M. tuberculosis and C. diphtheriae, exhibiting 33% identity over the entire length of  
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Figure 2.1: Comparison of the aftB locus within Corynebacterianeae. A) The locus consists in M. 
tuberculosis (M. tub.) of aftB with the upstream located ubiA gene product catalysing prenylation of 5-
phosphoribose pyrophosphate (PRPP) (Huang et al., 2005)), and glfT (Kremer et al., 2001) and UDP-Galp 
mutase enzyme glf (Pan et al., 2001). Downstream of aftB the genes fbpA, and fbpD are located which encode 
mycolyltransferases (Belisle et al., 1997). The organisation of these genes is largely retained in a number of 
Corynebacterianeae indicative for a basic functional unit. In N. farcinica (N. far.), a third paraloguous 
mycolyltransferase is present, and in C. glutamicum (C. glu.) a transposon is inserted between the two 
mycolyltransferases. Orthologous genes are shaded accordingly.  M. bovis (M. bov.), M. avium paratuberculosis 
(M. av. p.), M. leprae (M. lep.), Rhodococcus sp. RHA1 (R. spe.), C. efficiens (C. eff.), and C. diphtheriae (C. 
dip.). B) Partial sequence comparison of the first loop region of AftB. The conserved charged residues possibly 
involved in glycosyltransferase activity are shaded in grey, and the adjacent aspartate residues possibly directly 
involved in glycosyl transfer are in white on black background (Liu & Mushegian, 2003).  On top are the 
predicted structural properties of the peptide with E indicating β-sheet, and H α-helix structure. C) Topology of 
Mt-AftB based on dense alignment surface (DAS) analysis (Cserzo et al., 1997). The membrane spanning 
helixes are given in Roman numbers, and their amino acyl residues in Arabic.  
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the proteins. Even stronger conservation is found in the first periplasmic loop region (Figure 
2.1B), exhibiting a modified motif of the GT-C superfamily of glycosyltransferases 
consisting of two adjacent aspartic acid residues (Liu & Mushegian, 2003). Also, the 
periplasmic loop regions following helix V and VII are strongly conserved, which may play a 
role in presenting the nascent arabinose domain to the catalytic glycosyltransferase site. 
Taken together, the features of AftB and the locus where the gene is localised suggests that it 
represents a glycosyltransferase involved in AG biosynthesis. 
2.2.2. Construction of C. glutamicumΔaftB 
In an attempt to delete aftB in C. glutamicum the non-replicative plasmid 
pK19mobsacB∆aftB was constructed carrying sequences adjacent to Cg-aftB. The vector was 
introduced into C. glutamicum and in several electroporation assays kanamycin resistant 
clones were obtained, indicating integration of pK19mobsacB∆aftB into the genome by 
homologous recombination (Figure 2.2A). The sacB gene enables for positive selection of a 
second homologous recombination event, which can result either in the original wild-type 
genomic organisation or in clones deleted of aftB (Schafer et al., 1994). Forty-eight clones 
exhibiting the desired phenotype of vector-loss (KanS, SucR) were analysed by PCR and 
twenty-one of them were found to have Cg-aftB excised. These numbers indicate that the loss 
of Cg-aftB is apparently not a serious disadvantage for viability, in contrast with Cg-aftA, 
where deletion was rather difficult to obtain (Alderwick et al., 2006c). As a result, one clone 
was subsequently termed C. glutamicum∆aftB and confirmed by PCR to have Cg-aftB 
deleted, whereas controls with C. glutamicum wild type and genes adjacent to Cg-aftB 
resulted in the expected amplification products (Figure 2.2A).  
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Figure 2.2: Construction and characteristics of C. glutamicumΔaftB.  A) Genomic illustration of Cg-aftB 
with its adjacent genes ubiA and cmt2, which is the orthologue of mycobacterial fbpA, and the strategy to delete 
Cg-aftB using the deletion vector pK19mobsacBΔaftB. This vector carries 18 nucleotides of the 5´-end of Cg-
aftB and 36 nucleotides of its 3´-end thereby enabling the in-frame deletion of almost the entire Cg-aftB gene. 
The arrows marked P2 locate the primers used for the PCR analysis to confirm the absence of Cg-aftB. Primers 
P1 were used to detect ubiA, and P3 to detect cmt2. Distances are not drawn to scale. The results of the PCR 
analysis are shown on the right, where the results obtained with the corresponding primer pairs are marked 
accordingly. Samples were applied pair wise with the amplification products obtained from the wild type 
applied in the left lane, and that of the deletion mutant in the right lane. St marks the standard, where the 
arrowheads are located at 10, 3, 2, 1, and 0.5 kb, respectively. B) Phenotype of C. glutamicumΔaftB cells spread 
on BHI medium and incubated for 3 days. On the left is shown wild type C. glutamicum (Cg-WT) and on the 
right the deletion mutant C. glutamicumΔaftB (Cg-∆aftB). The picture shows an area of about 1.5 cm square. 
 
2.2.3. In vitro growth analysis of C. glutamicumΔaftB 
Growth of wild type C. glutamicum and C. glutamicum∆aftB were compared in BHI medium 
as well as salt medium CGXII (Eggeling & Bott, 2005). Both strains exhibited comparable 
growth rates and the final cell densities reached were comparable. Single colonies of the 
deletion mutant appeared less glossy. In streak-outs on BHI plates, the surface of the deletion 
mutant appeared rough with a coarsely granular surface, as compared to wild type C. 
glutamicum (Figure 2.2B). Taken together C. glutamicum∆aftB possesses only a slight 
growth defect, under the conditions assayed, indicating a degree of tolerance to the deletion 
of Cg-aftB. Complementation of C. glutamicumΔaftB with either pMSX-Cg-aftB or pMSX-
Mt-aftB restored the mutant to a wild type phenotype. For the purpose of significance, C. 
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glutamicumΔaftB complemented with Mt-aftB was used throughout this investigation to 
study the corresponding mutant phenotype; however, similar results were also obtained with 
C. glutamicumΔaftB complemented with Cg-aftB. 
2.2.4. Analysis of cell wall associated lipids and bound corynomycolic acid  
The initial qualitative investigations involved the analysis of cell wall associated lipids and 
release of bound corynomycolic acids as cornomycolic acid methyl esters (CMAMEs) 
following by TLC analysis. Analysis of free lipids from other previously identified cell wall 
mutants, such as C. glutamicumΔemb (Alderwick et al., 2005b) and C. glutamicumΔaftA 
(Alderwick et al., 2006c), highlighted an apparent increase in trehalose monocorynomycolate 
(TMCM) indicating a defect in cell wall biosynthesis. This phenotype was also consistently 
observed for the aftB deletion mutant (Figure 2.3). Quantitative free lipid analysis used [14C]-
acetate labeled cultures and equal loading of radioactivity based on the extractable free lipids 
for C. glutamicum, C. glutamicumΔaftB and the complemented C. glutamicumΔaftB pMSX-
Mt-aftB strains.  Typically, C. glutamicum exhibited the known free lipid profile for wild 
type C. glutamicum, including phospholipids (3945 cpm), TMCM (3217 cpm), trehalose 
dicorynomycolate (TDCM) (8619 cpm) and non-polar lipids migrating at the solvent front 
(8753 cpm) (Figure 2.3, lane 1). In contrast, following equivalent loading of radioactivity and 
quantitative analysis by phosphoimager analyses, C. glutamicumΔaftB possessed an 
approximate significant three-fold increase in TMCM (10185 cpm) and a decrease in TDCM 
(6539 cpm), phospholipids (1275 cpm) and non-polar lipids (5439 cpm) (Figure 2.3, lane 2). 
Complementation of C. glutamicumΔaftB with pMSX-Mt-aftB, reverted the deletion mutant 
back to a phenotype similar to the wild type, TMCM (3331 cpm), TDCM (9123 cpm), 
phospholipids (4011 cpm) and non-polar lipids (8901 cpm) (Figure 2.3, lane 3).  
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Figure 2.3: Quantitative analysis of extractable [14C]lipids from C. glutamicum, C. glutamicun∆aftB and 
C. glutamicum∆aftB pMSX-Mt-aftB. Lipids were extracted from cells by a series of organic washes as 
described in “Materials and methods”. An aliquot (25,000 cpm) from each strain was subjected to TLC using 
silica gel plates (5735 silica gel 60F254, Merck) developed in CHCl3/CH3OH/H2O (60:16:2, v/v/v) and either 
charred using 5% molybdophosphoric acid in ethanol at 100 oC to reveal the extracted lipids and compared to 
known standards (Alderwick et al., 2005; Gande et al., 2004) or quantified using a phosphorimager following 
exposure to Kodak X-Omat film for 24 h. The TLC-autoradiogram is representative of 3 independent 
experiments. Lane 1, C. glutamicum; lane 2, C. glutamicum∆aftB; and lane 3, C. glutamicum∆aftB pMSX-Mt-
aftB. 
To relate the above growth phenotypic changes of C. glutamicumΔaftB to its cellular 
composition, C. glutamicumΔaftB and C. glutamicumΔaftB pMSX-Mt-aftB, along with wild 
type C. glutamicum, were analysed for arabinogalactan esterified corynomycolic acids 
released from the above [14C]-delipidated cells. As expected, the wild type exhibited a typical 
profile of CMAMEs (Figure 2.4, lane 1, 28562 cpm), whereas these products were 
significantly reduced in C. glutamicum∆aftB (Figure 2.4, lane 2, 8947 cpm). In addition, 
complementation of C. glutamicum∆aftB with pMSX-Mt-aftB (Fig. 2.4, lane 3, 27523 cpm) 
led to the restoration of normal ‘levels’ of cell wall bound corynomycolic acids. These results 
suggested that Mt-aftB was involved in a key aspect of arabinan biosynthesis, whereby 
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deletion perturbs tethering of corynomycolic acids to AG, but not as severely as in C. 
glutamicum∆emb and C. glutamicum∆aftA mutants (Alderwick et al., 2005b; Alderwick et 
al., 2006c).   
 
                                  
Figure 2.4: Quantitative analysis [14C]CMAMEs from C. glutamicum, C. glutamicun∆aftB and C. 
glutamicum∆aftB pMSX-Mt-aftB. The bound [14C]corynomycolic acids from [14C] delipidated extracts were 
released by the addition of TBAH at 100 °C overnight and methylated as described in “Materials and Methods”. 
A 5% aliquot from each strain was subjected to TLC using silica gel plates (5735 silica gel 60F254, Merck) 
developed in petroleum ether/acetone (95:5, v/v) and either charred using 5% molybdophosphoric acid in 
ethanol at 100 oC to reveal [14C]CMAMEs and compared to known standards (Alderwick et al., 2005; Gande et 
al., 2004)) or quantified using a phosphorimager following exposure to Kodak X-Omat film for 24 h. The TLC-
autoradiogram is representative of 3 independent experiments. Lane 1, C. glutamicum; lane 2, C. 
glutamicum∆aftB; and lane 3, C. glutamicum∆aftB pMSX-Mt-aftB. 
 
 
2.2.5. Cell wall glycosyl compositional and linkage analysis of cell walls 
Alditol acetate derivatives of highly purified mAGP from C. glutamicum, C. 
glutamicumΔaftB and C. glutamicumΔaftB pMSX-Mt-aftB were prepared for glycosyl 
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compositional analysis. All strains exhibited a similar Ara:Gal ratio of 3.7:1. However, 
glycosyl linkage analysis of per-O-methylated alditol acetate derivatives of mAGP extracted 
from these strains highlighted an obvious difference in linkage profiles (Figure 2.5).  
All glycosyl linkages could be accounted for in wild type C. glutamicum (Figure 2.5A) as 
described previously (Alderwick et al., 2005b; Alderwick et al., 2006c), however, mAGP 
from C. glutamicumΔaftB was devoid of β(1→2) Araf linkages (Figure 2.5B). 
Complementation of C. glutamicumΔaftB with pMSX-Mt-aftB restored the β(1→2) Araf 
linkage thus reverting the deletion mutant to a wild type phenotype (Figure 2.5C). Further to 
this, we analysed the cell wall glycosyl composition of C. glutamicumΔaftB complemented 
with either pMSX-Mt-aftB-D29A or pMSX-Mt-aftB-D30A. Each of these complemented 
stains exhibited a phenotype identical to that of C. glutamicumΔaftB, with a complete loss of 
2-Araf linkages.  
As confirmed by SDS-PAGE (Figure 2.6) the Mt-AftB muteins are synthesised in vivo and 
the failure to establish the β(1→2) Araf linkage is therefore most likely due to a catalytically 
inactive AftB,  thus highlighting the importance of these particular aspartic acid residues in 
enzyme function. 
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Figure 2.5: Glycosyl linkage analysis of cell walls of C. glutamicum (A), C. glutamicun∆aftB (B), C. 
glutamicum∆aftB pMSX-Mt-aftB (C). Cell walls were per-O-methylated, hydrolysed using 2M TFA, reduced 
and per-O-acetylated. The resulting partially per-O-methylated, per-O-acetylated glycosyl derivatives were 
analysed by GC/MS as described previously (Alderwick et al. 2005; Besra et al., 1995; Daffé et al., 1990). 
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Figure 2.6. Formation of Mt-AftB in C. glutamicum. Extracts of C. 
glutamicumΔaftB expressing His-tagged M. tuberculosis AftB and 
AftB muteins were subjected to Ni2+-NTA chromatography and 
analysed by SDS-PAGE. Lane 1, 20 µg of clarified extract of C. 
glutamicumΔaftB pMSX-Mt-aftB prior to chromatography. Lane 2-5 
received the entire protein isolated from a 2 L culture of the 
respective recombinant strain via Ni2+-NTA chromatography, which 
was approximately 20 µg in each case. Lane 2 C. glutamicumΔaftB 
pMSX-Mt-aftB; lane 3, C. glutamicumΔaftB pMSX-Mt-aftB-D29A; 
lane 4, C. glutamicumΔaftB pMSX-Mt-aftB-D30A; and lane 5, C. 
glutamicumΔaftB pMSX (control). Standards (Std) along with their 
molecular weights in kDa are shown. The expected molecular weight 
for Mt-AftB is 72 kDa and the faint band at this location in lanes 2-4     
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxis shown by an arrow and was verified by peptide mass 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxfingerprinting as M. tuberculosis AftB. 
 
 
2.2.6. Endogenous in vitro arabinofuranosyltransferase activity of C. glutamicum, C. 
glutamicumΔaftB and C. glutamicumΔaftB complemented with Mt-aftB and 
product analysis. 
We assessed the capacity of membrane preparations from C. glutamicum, C. 
glutamicumΔaftB and C. glutamicumΔaftB, complemented with pMSX-Mt-aftB, to catalyse 
arabinofuranosyltransferase activity in the presence of an exogenous synthetic α -D-Araf-
(1→5)-α-D-Araf-O-C8, neoglycolipid acceptor (Lee et al., 1997) and DP[14C]A (Lee et al., 
1998).  TLC analysis of the products, when assayed with wild type C. glutamicum 
membranes, resulted in the formation of two products (A and B) (Figure 2.7A) when 
analysed by TLC (Figure 2.7B). The enzymatic synthesis of products A and B are consistent 
with previous studies (Lee et al., 1997) using mycobacterial membrane preparations resulting 
in trisaccharide products as a result of the addition of α(1→5) and β(1→2) linked Araf 
residues to the disaccharide acceptor (Figure 2.7A) (Lee et al., 1997). Addition of EMB in 
several experiments, even at high concentrations of up to 1 mg/ml to the reaction mixture, 
resulted in the complete loss of only product A. However, when assays were performed using  
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Figure 2.7: Arabinofuranosyltransferase activity in membranes prepared from C. glutamicum, C. 
glutamicun∆aftB and C. glutamicum∆aftB pMSX-Mt-aftB. A, Biosynthetic reaction scheme of products 
formed in arabinofuranosyltransferase assays using α-D-Araf-(1→5)-α-D-Araf-O-C8. B, 
Arabinofuranosyltransferase activity was determined using the synthetic α -D-Araf-(1→5)-α-D-Araf-O-C8 
acceptor in a cell-free assay as described previously (Lee et al., 1997). The products of the assay were 
resuspended prior to scintillation counting and subjected to TLC using silica gel plates (5735 silica gel 60F254, 
Merck) in CHCl3:CH3OH:H2O:NH4OH (65/25/3.6/0.5, v/v/v/v) with the reaction products visualised by 
autoradiography. 
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Membranes, prepared from C. glutamicum∆aftB, only a single band migrating to a position 
akin to that of product A could be observed and no product formation could be identified 
upon the addition of 100 µg/ml of EMB (Figure 2.7B). Membranes prepared from C. 
glutamicumΔaftB, complemented with pMSX-Mt-aftB, restored product A and B formation 
back to that of the wild type (Figure 2.7B) and only product B was synthesised when EMB 
(up to 1 mg/ml) was added to the reaction mixture. 
2.2.7. ES-MS and GC/MS analysis of product A and B 
Newly synthesised products A and B prepared using C. glutamicum treated with EMB and C. 
glutamicumΔaftB membranes, as described above, were further characterised. ES-MS 
analysis of the reaction products A and B extracted through preparative TLC (Figure 2.8A), 
revealed a strong molecular ion m/z 549.3 (M+Na+), which corresponds to a trisaccharide 
product Araf-(1→?)-Araf-(1→5)-α-D-Araf-O-C8. GC/MS analysis of the partially per-O-
methylated, per-O-acetylated alditol acetate derivative of product A, synthesised in assays 
with C. glutamicumΔaftB membranes revealed the addition of only an α(1→5) linked Araf 
residue (Figure 2.8B and Figure 2.7A) (Lee et al., 1997). However, GC/MS analysis of the 
partially per-O-methylated, per-O-acetylated alditol acetate derivative of product B, 
synthesised in enzyme assays utilising membranes from C. glutamicum and EMB, identified 
the new glycosyl linkage as a β(1→2)-linked Araf residue (Figure 2.8C and Figure 2.7A). By 
analogy, this new glycosidic linkage corresponds to a terminal β(1→2) linked Araf residue 
(Lee et al., 1997).  Finally, the results clearly establish, both from in vivo and in vitro 
experiments, that Mt-AftB catalyses the addition of a β(1→2) Araf unit, and that this enzyme 
is resistant to EMB (Figure 2.7B). 
Chapter 2  
 84 
                                   
Figure 2.8: ES-MS and GC/MS characterisation of products A and B. A, ES-MS analysis of products from 
assays containing membranes prepared from C. glutamicum treated with EMB and C. glutamicumΔaftB. B, 
GC/MS analysis of the partially per-O-methylated, per-O-acetylated alditol acetate derivative of product A 
obtained from assays containing membranes prepared from C. glutamicumΔaftB. C, GC/MS analysis of the 
partially per-O-methylated, per-O-acetylated alditol acetate derivative of product B obtained from assays 
containing membranes and EMB prepared from C. glutamicum. 
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2.2.8. Genome comparison of the AftC locus 
In silico analysis of one of the putative glycosyltransferases of M. tuberculosis, Rv2673, 
highlighted that orthologues are present in a range of species belonging to the sub-order 
Corynebacterianeae, including the families Mycobacteriaceae, Corynebacteriacea and 
Nocardiaceae (Figure 2.9A).  
 
Figure 2.9: Comparison of the aftC locus within the Corynebacterianeae. A) The locus in the bacteria 
analysed consists of aftC which in M. tuberculosis has the locus tag Rv2673 and in C. glutamicum NCgl1822. 
The genomic region displayed encompasses 7 kb, and orthologous genes are highlighted accordingly. 
Abbreviations: M. marinum, Mycobacterium marinum; M. av subsp. par., Mycobacterium avium subsp. 
paratuberculosis; C. efficiens, Corynebacterium efficiens; C. jeikeium, Corynebacterium jeikeium; Nocardia 
farcina, Nocardia farcina IFM 10152; Rhodococcus, Rhodococcus sp. strain RHA1. B) AftC is a hydrophobic 
protein predicted to span the membrane 10 times and the transmembrane helices are numbered accordingly. The 
lower part of the figure shows the degree of conservation of the orthologues given in A as analysed by the 
DIALIGN method (Brudno et al., 2003). Also shown is the approximate position of the fully conserved aspartyl 
and glutamyl residues. 
Furthermore, the organisation of the gene locus is largely retained. The adjacent genes are 
largely of unknown function. RibD encodes a bifunctional deaminase-reductase domain, 
followed by a gene product containing a hydrolase domain, which is however absent in 
Corynebacterium, and downstream of Rv2673 a domain of unknown function is present. The 
wide distribution of Rv2673, its syntenic organisation, and the fact that it is retained even in 
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M. leprae, strongly indicates a fundamental function of its product. According to our 
experimental analysis we annotated this gene arabinofuranosyltransferase C (aftC). 
AftC of M. tuberculosis is 433 amino acid residues long. It is a hydrophobic protein and is 
predicted to possess 10 transmembrane-spanning segments (Figure 2.9B). However, in 
contrast to AftA, AftB or EmbC, it is characterised by the absence of a periplasmic 
carboxyterminal extension. The amino acid sequence among the Corynebacterianeae is very 
well conserved, and there are 43% identical residues shared by the M. tuberculosis and C. 
glutamicum proteins. The degree of conservation is particularly high in the loop regions, for 
instance between helix 1 and 2, 3 and 4, or 6 and 7 (Figure 2.9B). The fully conserved 
aspartyl and glutamyl residues, which we propose to be involved in catalysis or substrate 
binding, are located in the first extended loop region (Liu & Mushegian, 2003) as 
demonstrated earlier with AftB. Interestingly, the long transmembrane helix 8 is well 
conserved and it is within this region that there is a strong identity to a membrane protein of 
Vibrio parahaemolyticus (CpsG). Furthermore, this gene is located in a gene cluster involved 
in the biosynthesis of a capsular polysaccharide within this pathogen (Guvener & McCarter, 
2003). 
2.2.9. Construction and growth of mutants 
In order to delete aftC and study possible consequences, we generated a null mutant of M. 
smegmatis mc2155 MSMEG2785 (homologue of Rv2673) using specialised transduction 
(Figure 2.10A). In contrast to our C. glutamicum studies (see below), growth of M. 
smegmatis∆aftc, in comparison to M. smegmatis, was poor in liquid media (Figure 2.10B) 
and sensitive to the addition of Tween-20 on agar plates (>0.005%). In addition, on solid 
media, M. smegmatis∆aftc had a smooth appearance in comparison to the typical crenulated 
colony morphology found for wild type M. smegmatis (Figure 2.11). Complementation of M. 
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smegmatis∆aftC with either pMV261-Ms-aftC or pMV261-Mt-aftC restored the mutant to a 
wild type phenotype (Figure 2.10B).  
 
Figure 2.10: Generation of a MSMEG2785 null mutant.  A) A map of the MSMEG2785 region in the 
parental M. smegmatis strain and its corresponding region in the ΔMSMEG2785 mutant. res, γδ resolvase site; 
hyg, hygromycin resistance gene from Streptomyces hygroscopicus; sacB, sucrose counter-selectable gene from 
Bacillus subtilis. Digoxigenin-labelled probes were derived from ~1kb upstream and downstream flanking 
sequences that were used to construct the knockout plasmid, and are indicated by thick lines with square ends. 
SacI digested bands expected in a Southern blot are indicated in roman numerals with sises in brackets. The 
inset shows the Southern blot of SacI digested genomic DNA from the two strains with expected bands 
indicated by arrows. B) Growth of wild type of M. smegmatis (), M. smegmatis∆aftC (), M. 
smegmatis∆aftC pMV261-Ms-aftC (∆), and M. smegmatis∆aftC pMV261-Mt-aftC () on TSB medium.  
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Figure 2.11: Colony morphology of wild-type M. smegmatis and M. smegmatis∆aftC on TSB-agar plates. 
Black bar represents 1 mm. 
 
To study the function of the corynebacterial AftC the non-replicative plasmid 
pK19mobsacBΔaftC was constructed. This was used to transform C. glutamicum to 
kanamycin resistance, indicating integration in its chromosome (Figure 2.12). Loss of vector 
was obtained by selection for sucrose-resistance yielding clones with aftC deleted. A PCR 
analysis with primer pairs P5 and P6 resulted in the expected fragment of 2160 bp for the 
wild type and of 1065 bp for the deletion mutant, which was termed C. glutamicumΔaftC 
(Figure 2.12A).  In contrast to M. smegmatis∆aftC, the growth of the C. glutamicumΔaftC 
mutant on the salt medium CGXII possessed only a slightly reduced growth rate of 0.32 h-1, 
whereas, that of the wild type C. glutamicum was 0.39-1h (Figure 2.12B).  
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Figure 2.12: Strategy to delete Cg-aftC using the deletion vector pK19mobsacB ∆aftC. A) This vector 
carries 18 nucleotides of the 5' end of Cg-aftC and 36 nucleotides of its 3' end thereby enabling the in-frame 
deletion of almost the entire Cg-aftC gene. The arrows marked P5 and P6 locate the primers used for the PCR 
analysis to confirm the absence of Cg-aftC. Distances are not drawn to scale. The results of the PCR analysis 
with the primer pair P5/P6 are shown on the right. Amplification products obtained from the wild type (wt) 
were applied in the middle lane and that of the deletion mutant in the right lane. ‘St’ marks the standard, where 
the arrowheads are located at 1 and 0.5 kb. B) Growth of the wild type of C. glutamicum () and C. 
glutamicumΔaftC (∆) on salt medium CGXII with glucose as carbon source.  
 
2.2.10. Analysis of cell wall bound mycolic acids 
To study the function of mycobacterial AftC deletion, defatted cells were analysed 
qualitatively for AG esterified mycolic acids from an equivalent starting amount of biomass 
for each strain, due to differences in growth rate (Figure 2.12B). As expected, M. smegmatis 
exhibited a typical profile of α, α’ and epoxy-mycolic acid methyl esters (MAMEs), 
whereas, these products were drastically reduced in M. smegmatis∆aftC (Figure 2.13). In 
addition, complementation of M. smegmatis∆aftC with either pMV261-Ms-aftC or pMV261-
Mt-aftC (Figure 2.13), led to the restoration of normal ‘levels’ of cell wall bound mycolic 
acids. These results demonstrated that Ms-aftC and Mt-aftC are involved in a key aspect of 
arabinan biosynthesis, whereby deletion substantially perturbs tethering of mycolic acids to 
AG. 
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Figure 2.13: Analysis of cell wall bound MAMES from M. smegmatis, M. smegmatis∆aftC, M. 
smegmatis∆aftC pMV261-Ms-aftC and M. smegmatis∆aftC pMV261-Mt-aftC. The bound mycolic acids 
from an equivalent amount of freeze-dried cells (100 mg), which were initially de-lipidated using two 
consecutive extractions of CHCl3:CH3OH:H2O (10/10/3; v/v/v/v) at 50oC for 4 h, were released by the addition 
of tetra-butylammonium hydroxide at 100°C overnight, and methylated as described in the “Materials and 
methods” Chapter 6. An equivalent aliquot from each strain was subjected to TLC using silica gel plates (5735 
silica gel 60F254, Merck), and developed in petroleum ether/acetone (95:5, v/v) and charred to reveal MAMEs 
and compared to known standards (Gande et al., 2004). 
 
In contrast to the mycolic acid studies performed with the mycobacterial AftC deletion 
mutant, C. glutamicum∆aftC cells were analysed quantitatively for AG esterified 
corynmycolic acids due to similar growth rates between strains (Figure 2.11B). Wild type C. 
glutamicum exhibited the known profile of corynomycolic acid methyl esters (CMAMEs, 
35,345 cpm) (Figure 2.14), whereas, cell wall bound CMAMEs were significantly reduced in 
C. glutamicum∆aftC (8023 cpm). The above data were reassuring, as the qualitative (M. 
smegmatis∆aftC) and quantitative (C. glutamicum∆aftC) analyses were comparable in terms 
of a reduction in cell wall bound mycolic acids (Figure 2.13 and Figure 2.14). Importantly, 
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these results have also shown that Cg-aftC is involved in a key aspect of arabinan 
biosynthesis, whereby deletion perturbs tethering of corynomycolic acids to AG. 
                                       
Figure 2.14: Analysis of cell wall bound CMAMES from C. glutamicum and C. glutamicun∆aftC. The 
bound [14C]-labeled corynemycolic acids from de-lipidated [14C]-labeled cell of pulse-labeled 5 ml cultures 
were released by the addition of tetra-butyl ammonium hydroxide at 100°C overnight and methylated as 
described in the “Materials and methods”. An equivalent aliquot from each strain was subjected to 
TLC/autoradiography using silica gel plates (5735 silica gel 60F254, Merck), and developed in petroleum 
ether/acetone (95:5, v/v) reveal CMAMEs and compared to known standards. 
 
 
2.2.11. Glycosyl compositional analysis of cell walls from M. smegmatis, M. 
smegmatis∆aftC and complemented strains 
The cell wall core (mAGP) was prepared from M. smegmatis and M. smegmatis∆aftC as 
described (Alderwick et al., 2005b; Besra et al., 1995; Daffé et al., 1990) and the ratio of Ara 
to Gal in mAGP determined by gas chromatography (GC) analysis of alditol acetates 
(Alderwick et al., 2005b; Besra et al., 1995; Daffé et al., 1990) (Figure 2.15). The glycosyl 
compositional analysis revealed an Ara:Gal ratio of 2.45:1 for M. smegmatis. The M. 
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smegmatis∆aftC yielded an AG with a significant reduction in cell wall Ara with an Ara:Gal 
ratio of 0.45:1. Complementation of M. smegmatis∆aftC with either pMV261-Ms-aftC or 
pMV261-Mt-aftC, restored the Ara:Gal ratio to that of the wild type M. smegmatis (Figure 
2.15, Ara:Gal, 2.40:1). 
                                
Figure 2.15: GC analysis of cell walls of M. smegmatis, M. smegmatis∆aftC, M. smegmatis∆aftC pMV261-
Ms-aftC and M. smegmatis∆aftC pMV261-Mt-aftC. Samples of purified cell walls were hydrolysed with 2M 
TFA, reduced, per-O-acetylated and analysed as described under “Materials and Methods” (Alderwick et al., 
2005b; Besra et al., 1995). 
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2.2.12. Glycosyl linkage analysis of cell walls 
Gas chromatography mass spectrometry (GC/MS) analysis of per-O-methylated alditol 
acetate derivatives prepared from M. smegmatis and M. smegmatis∆aftC indicated the 
complete absence of 3,5-Araf branching residues, with a significant reduction in t-Araf, 2-
Araf and 5-Araf-linkages (Figure 2.16). Complementation of M. smegmatis∆aftC with either 
plasmid encoding Ms-aftC or Mt-aftC restored the glycosyl linkage profile to that of wild 
type M. smegmatis (Figure 2.16). These results demonstrate that MSMEG2875 and Rv2673, 
are functionally equivalent and are involved in the synthesis of 3,5-Araf branching residues.  
The GC/MS profiles of per-O-methylated alditol acetate derivatives of C. glutamicum and C. 
glutamicum∆aftC are shown in Figure 2.17 with C. glutamicum∆aftC also clearly devoid of 
3,5-Araf branching residues.   
 
Figure. 2.16: GC/MS analysis of cell walls of M. smegmatis, M. smegmatis∆aftC, M. smegmatis∆aftC pMV261-Ms-aftC 
and M. smegmatis∆aftC pMV261-Mt-aftC. Per-O-methylated cell walls were hydrolysed with 2M TFA, reduced, per-O-
acetylated and analysed as described under “Materials and methods” (Alderwick et al., 2005b; Besra et al., 1995). 
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Figure 2.17: GC and GC/MS analysis of cell walls of C. glutamicum and C. glutamicum∆aftC. Samples of 
either purified cell walls or per-O-methylated, hydrolysed using 2M TFA, reduced, per-O-acetylated and 
analysed as described under “Materials and methods”. 
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2.2.13. In vitro arabinofuranosyltransferase activity with extracts of M. smegmatis, M. 
smegmatis∆aftC and complemented strains 
Initial attempts to develop an in vitro assay using either purified recombinant expressed AftC 
or E. coli membranes expressing aftC, have thus far proved unsuccessful, probably due to the 
hydrophobic nature of the protein. In an alternative approach, we assessed the capacity of 
membrane preparations from M. smegmatis, M. smegmatis∆aftC and M. smegmatis∆aftC 
complemented with pMV261-Mt-aftC to catalyse arabinofuranosyltransferase activity in the 
presence of exogenous synthetic acceptors (Lee et al., 1997; Seidel et al., 2007b). 
We first assessed whether M. smegmatis∆aftC was deficient in α(1→5) and β(1→2) 
arabinofuranosyltransferase activity, using an α-D-Araf-(1→5)-α-D-Araf-O-(CH2)7CH3 
(Ara2) synthetic acceptor (Lee et al., 1997) and DP[14C]A as a sugar donor based on an 
established assay format for determining α(1→5) and β(1→2) arabinofuranosyltransferase 
activities (Lee et al., 1998). TLC/autoradiographic analysis of the products, which were only 
synthesised in the presence of Ara2, when assayed with M. smegmatis membranes resulted in 
the formation of two products (A and B) (Figure 2.18A and B). The enzymatic synthesis of 
products A and B are consistent with previous studies using mycobacterial (Lee et al., 1997) 
membrane preparations resulting in trisaccharide products as a result of α(1→5) and β(1→2) 
Araf linkages to the Ara2 acceptor (Figure 2.18A) (Lee et al., 1997). Addition of EMB in 
several experiments, even at high concentrations of up to 1 mg/ml, to the reaction mixture, 
resulted in a decrease in only the in vitro synthesised α-D-[14C]Araf-(1→5)-α-D-Araf-
(1→5)-α-D-Araf-O-(CH2)7CH3 product A (Figure 2.18A and B). Assays performed with 
membranes from M. smegmatis∆aftC and the pMV261-Mt-aftC complemented strain using 
the Ara2 synthetic acceptor gave a similar profile to that of wild type M. smegmatis (Figure 
2.18B). The data clearly show that the M. smegmatis∆aftC strain possesses comparable levels 
of EMB-sensitive α(1→5) and EMB-resistant β(1→2) arabinofuranosyltransferase activity. 
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Figure 2.18: Arabinofuranosyltransferase activity utilising an Ara2 acceptor and membranes prepared 
from M. smegmatis, M. smegmatis∆aftC and M. smegmatis∆aftB pMV261-Mt-aftC. A) Biosynthetic reaction 
scheme of products A and B formed in arabinofuranosyltransferase assays using the neoglycolipid Ara2 
acceptor. B) Arabinofuranosyltransferase activity was determined using the synthetic Ara2 acceptor in a cell-
free assay with and without EMB (1 mg/ml) as previously described (Lee et al., 1997). The products of the 
assay were resuspended prior to scintillation counting (10 %) and the remaining subjected to TLC using silica 
gel plates (5735 silica gel 60F254, Merck) in CHCl3:CH3OH:H2O:NH4OH (65/25/3.6/0.5, v/v/v/v) with the 
reaction products visualised by autoradiography. The TLC autoradiogram is representative of several 
independent experiments. 
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We then developed an arabinofuranosyltransferase assay using the synthetic acceptor α-D-
Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf-O-(CH2)8NH2 
(Ara5) (See figure 2.20B) and DP[14C]A as a sugar donor (Lee et al., 1998). 
TLC/autoradiographic analysis of the products, which are only synthesised in the presence of 
Ara5, when assayed with M. smegmatis membranes resulted in the formation of a single 
product X (Figure 2.19A) through the transfer of a single [14C]Araf residue, with a 
retardation factor (Rf) consistent with a synthetic Ara6 acceptor (Appelmelk et al., 2008) 
standard (Figure 2.19B). Interestingly, addition of EMB in several experiments, even at high 
concentrations of up to 1 mg/ml to the reaction mixture did not inhibit the synthesis of this in 
vitro synthesised [14C]Araf-Ara5 (Figure 2.19A, Product X), illustrating that the Ara5 
acceptor was not extended via an EMB-sensitive α(1→5) arabinofuranosyltransferase. 
Interestingly, membranes prepared form the M. smegmatis∆aftC strain were unable to 
synthesise the in vitro product to the same level of activity that was observed with wild type 
membranes prepared from M. smegmatis (Figure 2.19A). This was not surprising, since our 
earlier in vivo and in vitro studies would have expected residual Ara6 product formation, 
considering that M. smegmatis∆aftC possesses β(1→2) arabinofuranosyltransferase activity. 
Assays performed with membranes from the M. smegmatis∆aftC pMV261-Mt-aftC 
complemented strain, gave a similar profile to that of wild type M. smegmatis (Figure 2.19).  
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Figure 2.19:  Arabinofuranosyltransefrase activity utilising an Ara5 acceptor and membranes prepared 
from M. smegmatis, M. smegmatis∆aftC and M. smegmatis∆aftC pMV261-Mt-aftC. A) AraT activity was 
determined using the synthetic Ara5 acceptor in a cell-free assay with and without EMB (1mg ml-1). The 
products reflective of three independent enzymes and assayed were resuspended prior to scintillation counting 
(10%) and the remaining subjected to TLC using silica gel plates (5735 silica gel 60F254 Merck) in 
isopropanol/actetic acid/water 8/1/1 v/v/v), with the reaction product X visualised with autoradiograpy. The 
TLC autoradiogram is representative of three different independent experiments. B) Ara5 and Ara6 (Appelmelk 
et al., 2008) acceptor standards were subjected to TLC as above, and the reaction products were visualised by 
staining with α-naphthol followed by charring. 
 
To establish that the Ara5 acceptor is being utilised by two different 
arabinofuranosyltransferases, presumably establishing β(1→2) and  α(1→3) linkages, assays 
similar to that used before were scaled up and product X extracted and purified through 
preparative TLC for each membrane preparation. GC/MS analysis of the partially per-O-
methylated, per-O-acetylated alditol acetate derivatives of product X in assays preformed 
with M. smegmatis membranes revealed the addition of β(1→2) (Rt 15.52 min; m/z 129, 
130,161,190) and α(1→3) (Rt 15.83 min; m/z 118, 129, 130, 190, 202, 233) linked Araf 
residues (Figure 2.20A and B). Therefore, the product migrating below Ara5 and co-incident  
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Figure 2.20: GC/MS characterisation of in vitro synthesised product X from the 
arabinofuranosyltransferase assays utilising the Ara5 acceptor. A) GC/MS analysis of the partially per-O-
methylated, per-O-acetylated alditol acetate derivative of product X obtained from assays containing 
membranes prepared from either M. smegmatis, M. smegmatis∆aftC or M. smegmatis∆aftB pMV261-Mt-aftC. 
B) Panel illustrates the structure(s) of product X. 
with the Ara6 acceptor standard on TLC (Figure 2.19A and B) is in fact a mixture of two 
products. The addition of β(1→2)-linked Araf residues can be attributed to the function of 
AftB. The presence of α(1→3)-linked Araf residues in this assay using an Ara5 acceptor 
clearly highlights the role of a novel arabinofuranosyltransferase(s) capable of functioning in 
an α(1→3) capacity. Importantly, there is a complete removal of α(1→3) activity when the 
Ara5 acceptor is incubated with membranes prepared from M. smegmatisΔaftC (Figure 
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2.20A). However, β(1→2) activity is clearly present in M. smegmatisΔaftC (Figure 2.20A). 
In addition, M. smegmatisΔaftC complemented with pMV261-Mt-aftC restores α(1→3) 
arabinofuranosyltransferase activity to wild type M. smegmatis (Fig 2.20A). The results 
clearly establish both from in vivo and in vitro experiments that AftC catalyses the addition 
of an α(1→3)-Araf unit via an α(1→3) arabinofuranosyltransferase and that this enzyme is 
also resistant to EMB (Figure 2.19A). 
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2.2.14. Discussion 
The mAGP represents one of the most important cell wall components of the 
Corynebacterianeae and is essential for the viability of M. tuberculosis (Gande et al., 2004; 
Mills et al., 2004; Pan et al., 2001; Vilcheze et al., 2000). It is therefore not surprising that 
one of the most effective anti-mycobacterial drugs, EMB, targets its synthesis through 
inhibition of AG biosynthesis. However, the emergence of MDR-TB and XDR-TB has 
accelerated the need to discover new drug targets (Brennan & Nikaido, 1995). One of the 
strategies is to identify genes involved in AG biosynthesis. This strategy was previously used 
to identify the presence of a new “priming” enzyme, now termed AftA, which would link the 
initial Araf unit with the C-5 OH of a β(1→6) linked Galf of a pre-synthesised galactan core 
(Alderwick et al., 2005b). 
Although, the previously described Emb (Alderwick et al., 2005b) and AftA (Alderwick et 
al., 2006c) are arabinofuranosyltransferases, the proteins cannot functionally replace each 
other. Thus, despite some functional relationship, these glycosyltransferases have inherent 
specific features, as evident from the insensitivity of AftA towards EMB. The single Cg-Emb 
(Alderwick et al., 2005b; Radmacher et al., 2005) and Mt-Emb proteins are sensitive towards 
EMB (Belanger et al., 1996; Telenti et al., 1997). The number of 
arabinofuranosyltransferases that are required for mycobacterial arabinan biosynthesis has 
been a matter of speculation to date, depending on how the arabinan chains are assembled. 
The primary structure of AG (Besra et al., 1995; Daffé et al., 1990) would suggest at least 
five distinct arabinofuranosyltransferases are required for the complete formation of AG. 
Interestingly, M. smegmatis embA and embB mutants were found to possess reduced amounts 
of the non-reducing terminal disaccharide β-D-Araf-(1→2)-a-D-Araf and result in the 
removal of the dominant terminal non-reducing Ara6 branched motif in the mutant being 
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replaced by a linear Ara4 motif. The authors of this study concluded that the M. smegmatis 
embA and embB mutants result in a lack of 3-arm branching off the main α(1→5)-arabinan 
chain proximal to the non-reducing and attachment site of mycolic acids in AG (Escuyer et 
al., 2001). Initially, it was proposed that the β-D-Araf-(1→2)-α-D-Araf disaccharide was 
assembled using EmbA and EmbB. However, the identification of AftB in this study and the 
development of an in vitro assay (Lee et al., 1997) suggests that EmbA/B act as α(1→5) 
arabinofuranosyltransferases. 
This study has identified Rv3805c, which has now been termed AftB, as a novel retaining 
arabinofuranosyltransferase, and is likely to form a new family which is distinct from the 
inverting arabinofuranosyltransferase enzymes (EmbA, B, C, and AftA) in GT-83/85 
families (Coutinho & Henrissat, 1999).  More precisely, AftB adds to the non-reducing end 
of the arabinan domain of AG β(1→2) Araf residues, as shown through both in vivo and in 
vitro experiments. For instance, incubation of membranes prepared from C. glutamicum with 
DP[14C]A and the disaccharide neoglycolipid acceptor resulted in the appearance of two 
trisaccharide products (A and B), which equate to the transfer of both α(1→5) and 
β(1→2)Araf residues, respectively. Through further chemical characterisation of the products 
by TLC, ES-MS, and glycosyl linkage analyses, an α(1→5) linked trisaccharide product 
could only be identified in assays conducted with membranes prepared from C. 
glutamicumΔaftB. This clear loss of β(1→2)Araf activity corroborates the cell wall analysis 
of the C. glutamicumΔaftB mutant, where the loss of β(1→2) linked Araf residues could also 
be observed. We also attempted to inhibit AftB activity by incubation of the assay 
components in the presence of high concentrations of EMB (up to 1 mg/ml), a known 
inhibitor of the Emb proteins in M. tuberculosis and C. glutamicum. In doing so, analysis of 
the corresponding products synthesised from C. glutamicum membranes following EMB 
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treatment clearly show evidence of an EMB resistant β(1→2) arabinofuranosyltransferase 
activity and an EMB sensitive α(1→5) arabinofuranosyltransferase activity. In addition, since 
it has previously been established that the EMB-resistant AftA introduces the priming Araf 
residue at the 8th, 10th and 12th Galf residue of the galactan backbone, it can be concluded that 
the bulk α(1→5)Araf stems of AG represent the primary target of EMB. It is interesting to 
note that EMB resistance is simply not due to AftB being a retaining 
arabinofuranosyltransferase, in contrast to the inverting arabinofuranosyltransferase Mt-
EmbA and Mt-EmbB, since AftA, which is also an inverting arabinofuranosyltransferase, is 
also EMB resistant (Alderwick et al., 2006c).  It is noteworthy that deletion of aftB in C. 
glutamicum results in only a weak phenotype (Figure 2.2B).  In M. tuberculosis, mycolic 
acids are attached to the terminal β(1→2)Araf and penultimate α(1→5)Araf residue of the 
Ara6 motif of AG (McNeil et al., 1991). This appears to be similar in C. glutamicum since, in 
the absence of terminal β(1→2) Araf residues, mycolic acids are still bound to AG, thus 
emphasizing, in this respect, the cell wall similarity of these bacteria. However, in C. 
glutamicum a maximal 5% of the mycolic acids are covalently attached to AG (Puech et al., 
2001), whereas this value is about 10% in M. tuberculosis (McNeil et al., 1991). The fact that 
the aftB deletion mutant of C. glutamicum possesses less AG bound mycolic acids, also 
results in an increased abundance of TMCM. This situation can be entirely different in M. 
tuberculosis due to the essentiality of aftB in M. tuberculosis (Sassetti et al., 2003) and 
requires further investigation. 
A modified scheme for terminal cell wall arabinan biosynthesis in Corynebacterianeae is 
presented in Figure 2.21. It is possible that the AftB protein is responsible for the successive 
addition of two β(1→2) Araf residues at a 3,5-Araf branched residue. Although, this may be 
a reasonable inference from the in vivo structural work with the aftB deletion strain, it has not 
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been completely verified by our in vitro assay.  Therefore, it is formally possible that the 
AftB-dependent addition of one β(1→2) Araf residue is required, before a second GT-C 
related arabinofuranosyltransferase adds the second terminal β(1→2) Araf residue as shown 
in Figure 2.21. 
 
 
Figure 2.21: Proposed mycobacterial arabinan biosynthesis and the role of AftB and AftC. For reasons of 
simplicity it is shown that one of the β(1→2) linked Araf residues is added by AftB, whilst the second β(1→2) 
linked Araf residue may be catalysed by AftB or via an unknown GT-C arabinofuranosyltransferase (AftD), 
presumably closely related to AftB.  
 
This study has also identified MSMEG2785 (also Rv2673 and NCgl1822), which we have 
termed AftC, as a novel branching arabinofuranosyltransferase. More precisely, AftC 
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catalyses the addition of α(1→3) Araf residues as shown through both in vivo and in vitro 
experiments, ultimately resulting in 3,5-Araf residues after further α(1→5) extension, 
characteristic of AG. For instance, incubation of membranes prepared from M. smegmatis 
with DP[14C]A and a linear α(1→5)-Ara5 neoglycolipid acceptor resulted in the synthesis of 
an Ara6 product. Further chemical characterisation of the product, by glycosyl linkage 
analysis, established that the α(1→5)-Ara5 acceptor was extended via an EMB resistant 
α(1→3) arabinosfuranosyltransferase, giving rise to 3-linked Araf residues and corroborating 
our earlier cell wall analysis of the M. smegmatis∆aftC mutant. Since, it is now established 
that only α(1→5) arabinofuranosyltransferase(s) are EMB-sensitive it can be further 
speculated that EmbA and EmbB function in the assembly of the linear α(1→5) arabinan 
segments as presented in Figure 2.21. This is in accordance with previous data (Besra et al., 
1995; Daffé et al., 1990) and phenotypes of EmbA and EmbB (Escuyer et al., 2001; Zhang et 
al., 2003) and Cg-Emb (Alderwick et al., 2005b) mutants. It is clear that further studies are 
required to establish the precise role of EmbA and EmbB in mycobacteria. 
The analysis of the M. smegmatis∆aftC mutant to date and based on the Ara:Gal ratio would 
suggest that the residual arabinan segment in the mutant consists of approximately five Araf 
residues: β-D-Araf-(1→2)-α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf-
located at three branches on the galactan chain (Alderwick et al., 2005b; Besra et al., 1995). 
This is consistent with the recent primary structure of AG (Bhamidi et al., 2008), with a 
‘non-variable’ terminal non-reducing Ara17 motif, introduction of a 3,5-Araf residue distal to 
this non-reducing end by AftC and further extension by a linear α(1→5)Araf domain (Figure 
2.21). The latter appears to be variable (up to 12/13 residues). However, based on M. 
smegmatis∆aftC and the subsequent Ara:Gal compositional analysis, a dominant Ara22/Ara23 
motif would be consistent with recent (Bhamidi et al., 2008) and previous (Besra et al., 
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1995) structural data on AG and this is represented in terms of biosynthetic considerations in 
Figure 2.21.  
The arabinofuranosyltransferases of the Emb family (EmbC, EmbA and EmbB) (Belanger et 
al., 1996; Berg et al., 2005; Escuyer et al., 2001; Telenti et al., 1997), AftA (Alderwick et 
al., 2006c), AftB and AftC, possess some sequence similarity. This relates to a modified 
glycosyltransferase motif, which is defined in the GT-C glycosyltransferase superfamily as 
either DXD, EXD, DDX, or DEX (Liu & Mushegian, 2003). The most distant is probably 
AftA with only one negatively charged D residue, however possessing an adjacent polar Q 
residue (Alderwick et al., 2006c). In AftB there are two adjacent D residues (Figure 2.1B), 
which due to our mutational study are likely to be directly involved in glycosyl hydrolysis 
and transfer. Also, the high number of charged amino acyl residues of the strongly conserved 
loop region following the first TM helix might contribute to the proper orientation of 
substrates at the catalytic centre. The glycosyltransferase motif of 
arabinofuranosyltransferases so far identified is always located in a periplasmic loop region, 
which connects TM III-IV in EmbC, TM III-IV in AftA, and TM I-II in AftB (Figure 2.1B & 
C). A further feature common of the Emb, AftA and AftB proteins is that they consist of an 
N-terminal region, which has a number of hydrophobic segments spanning the TM, and a 
large C-terminal domain, which in Emb has been demonstrated to be located towards the 
periplasmic side (Seidel et al., 2007c). The number of TMs is different amongst these 
proteins, but the involvement of these TMs could be considered as being important for the 
translocation of DPA, the lipid linked substrate of these glycosyltransferases. The weak 
structural identities of the membrane embedded part of the arabinofuranosyltransferases, 
indicates that transport and presentation of DPA to the catalytic site might be different for 
these enzymes. A "Pro-motif" as identified in the Emb proteins (Berg et al., 2005) is not 
present in AftB and AftA. This motif is typical for polysaccharide co-polymerases and is 
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assumed to control the chain length in polysaccharide biosynthesis. Its absence in AftA and 
AftB seems plausible, since these enzymes add only singular Araf residues, but the Emb 
proteins presumably add a number of α(1→5) linked Araf residues to form the inner chain of 
the AG domain. 
To conclude, AftB and AftC represent novel arabinofuranosyltransferases in 
Corynebacterianeae, such as M. tuberculosis, which are responsible for the addition of the 
terminal β(1→2) linked Araf residues and  branching α(1→3) Araf residues, respectively. 
The genomic organisation in the genomes of the Corynebacterianeae sequenced is intriguing, 
revealing high synteny of the M. tuberculosis aftB and aftC locus to the maps of all other 
Mycobacterium and Corynebacterium species.  The identification of new cell wall 
biosynthetic drug targets is of great importance, especially with the emergence of MDR-TB 
and XDR-TB. These newly discovered DPA dependent arabinofuranosyltransferases 
represent, along with straightforward in vitro enzyme assays, promising candidates for 
further exploitation as potential drug targets.  
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3. Identification and characterisation of a crucial branching α(1→3)   
.arabinofuranosyltransferase involved in LAM bisynthesis  
3.1. Introduction 
TB affects a third of mankind and causes 1.7 million fatalities annually (Dye et al., 2006). 
The spread of TB has been facilitated in recent decades, due to the susceptibility of HIV 
infected individuals to Mycobacterium tuberculosis (Kaye & Frieden, 1996). The problem 
has been compounded by the emergence of MDR-TB and XDR-TB strains (Shah et al., 
2007). M. tuberculosis resides within the family of  Corynebacteriaceae. A common feature 
of this family is that they possess an unusual cell wall architecture dominated by an essential 
heteropolysaccharide termed AG, which is linked to both mycolic acids and peptidoglycan, 
forming the mAGP complex (Besra et al. 1995; Daffé et al., 1993; McNeil et al., 1991). The 
formation of the arabinan domain of AG results from the subsequent addition of Araf 
residues by a set of unique AraTs. The front line drug EMB has been shown to target at least 
three AraTs (EmbA, EmbB and EmbC) (Belanger et al., 1996; Telenti et al., 1997), but 
shows no inhibitory effects against the other recently identified cell wall AraTs, such as AftA 
(Alderwick et al., 2006), AftB (Chapter 2) and AftC (Chapter 2).  In the previous chapter, we 
successfully deleted MSMEG2785 (Ms-aftC) (Birch et al., 2008), and showed that this leads 
to expression of a severely truncated AG structure with branching defects in its arabinan 
domain.  
 
Apart from AG, mycobacteria contain several other glycoconjugates. LAM, which contains 
an arabinan domain that is structurally similar to that of AG, is a major component of the cell 
wall. It consists of a core mannan domain covalently linked to a mannosyl-phosphatidyl-
myo-inositol anchor, which makes it structurally similar to its biochemical precursor LM 
(Berg et al., 2007; Besra et al., 2007; Morita et al., 2004). Both LAM and LM exhibit 
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immunomodulatory functions that may influence the host immune response (Jozefowski et 
al., 2007). Species-specific differences in the “capping-motifs” of the non-reducing termini 
of the arabinan domain, for which three variants exist, i.e. AraLAM, PI-LAM and ManLAM 
(Gilleron et al., 1997; Khoo et al., 1995; Khoo et al., 2001; Nigou et al., 1997; Nigou et al., 
1999), have been shown to be important for this function.  
 
The arabinan domain of LAM is attached to an, as yet unidentified, region of the mannan 
backbone and is thought to be synthesised in a similar manner to that of arabinan found in 
AG ( Berg et al., 2007; Besra et al., 2007; Morita et al., 2004). To date, only one AraT has 
been implicated in the biosynthesis of LAM. This enzyme, EmbC, has also been shown to be 
targeted by EMB, but to a lesser extent than the cell wall core AraTs, EmbA and EmbB 
(Mikusova et al., 1995; Zhang et al., 2003). The formation of the arabinan domain of LAM 
requires an α(1→3) AraT in a similar manner to AG, thus resulting in the branched motif of 
LAM. Here we investigated the potential role of AftC in LAM biosynthesis. By structural 
analysis of LAM from a M. smegmatis∆aftC mutant we demonstrate that AftC carries dual 
functionality and is responsible for introducing 3,5-Araf branches into LAM, in addition to 
AG. Furthermore, we show, by treating an M. smegmatis∆aftC mutant with EMB, that EmbC 
is involved in the very early steps of the LAM arabinan core synthesis and that truncation of 
this domain modulates the immunological properties of the molecule. 
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3.2. Results 
3.2.1. Effects of aftC inactivation on LM/LAM biosynthesis 
M. smegmatis wild type (WT) (Figure 3.1, Lane 1) and M. smegmatis∆aftC lipoglycans 
(Figure 3.1, Lanes 2-4) were purified using conventional methods (Nigou et al., 1997), 
resulting in the recovery of a highly purified lipoglycan with an intermediate size between M. 
smegmatis LAM and LM, now termed AftC-LAM (Figure 3.1, Lane 3). Complementation of 
M. smegmatis∆aftC with Ms-aftC restored the lipoglycan profile to WT M. smegmatis 
(Figure 3.1, Lane 5). Plasmid borne Mt-aftC also resulted in complementation of the mutant 
(Figure 3.1, Lane 6). The molecular weight of AftC-LAM was investigated by negative-ion 
matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry 
(MS). The mass of WT-LAM and AftC-LAM exhibited broad unresolved peaks centered at 
m/z 15000 and 8000, respectively, indicating a weight decrease of ~7 kDa for the mutant 
LAM (Figure 3.2, A and B).  
                            
Figure 3.1: SDS-PAGE analysis of lipoglycans extracted from M. smegmatis and M. smegmatis∆aftC. Lane 
1, lipoglycans extracted from M. smegmatis; Lane 2, lipoglycans extracted from M. smegmatis∆aftC; Lane 3, 
purified AftC-LAM from M. smegmatis∆aftC and Lane 4, purified LM from M. smegmatis∆aftC; Lane 5, 
lipoglycans extracted from M. smegmatis∆aftC pMV261-Ms-aftC and Lane 6, lipoglycans extracted from M. 
smegmatis∆aftC pMV261-Mt-aftC. 
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Figure 3.2: MALDI-TOF-MS analysis of purified WT-LAM (A) and AftC-LAM (B) extracted from M. 
smegmatis and M. smegmatisΔaftC respectively. MALDI-TOF-MS spectra were acquired in the linear 
negative mode with a delayed extraction using 2,5-dihydrobenzoic acid as a matrix. 
 
3.2.2. Structural characterisation of AftC-LAM 
The ratio of Ara to Man in WT-LAM and AftC-LAM was determined using gas 
chromatography (GC) of alditol acetate derivatives (Birch et al., 2008) (Figure 3.3, A and C). 
WT-LAM, had a molar ratio of Ara:Man of 2.7:1, which is consistent with previously 
reported data (Zhang et al., 2003), whereas for AftC-LAM the Ara:Man ratio was 0.59:1 
(Figure 3.3, A and C). Complementation of M. smegmatis∆aftC with either Ms-aftC or Mt-
aftC, restored the Ara:Man ratio to that of the wild type LAM (Fig. 3.3, E and G). In M. 
smegmatis, LAM consists approximately of 71 Ara, 27 Man, and 1 Ins units (Petzold et al., 
2005; Zhang et al. 2003). The loss of 7kDa for AftC-LAM equates to 45 Ara residues, 
suggesting that AftC-LAM contains one or more short arabinan domains of up to ~16 Ara 
residues.  
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Figure 3.3: GC and GC/MS analysis of purified lipoglycans extracted from M. smegmatis (A and B), M. 
smegmatis ΔaftC (C and D), M. smegmatis ΔaftC pMV261- Ms-aftC (E and F), and M. smegmatis ΔaftC 
pMV261-Mt-aftC (G and H). The glycosyl composition of lipoglycans extracted were analyzed by GC after 
derivatization to alditol acetates. Glycosyl linkage analysis was performed after per-O-methylation and 
derivatization to partially per-O-methylated alditol acetates. Briefly, lipoglycan samples were per-O-methylated 
using dimethyl sulfinyl carbanion, hydrolyzed using 2 M TFA, reduced using NaBD4, and per-O-acetylated. 
The resulting per-O-methylated alditol acetates were solubilized in CHCl3 before analysis by GC/MS. 
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The 1H-NMR spectrum of WT-LAM (Figure 3.4A) was much more complex than the 
anomeric region of AftC-LAM (Figure 3.4B), Indeed, the AftC-LAM 1D 1H spectrum 
exhibits three major well-defined resonances characterised by several overlapping resonances 
arising from six different classes of glycosidic residues.  
                              
Figure 3.4: Two-dimensional NMR spectra of WT-LAM and AftC-LAM purified from M. smegmatis and 
M. smegmatis∆aftC. Structural characterisation of WT-LAM A) and AftC-LAM B). 1H, 13C HSQC NMR 
spectra were acquired in D2O at 313K. Expanded regions (δ 1H: 5.0-5.30, δ 13C: 101-111) are shown. 
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Based on our data for WT-LAM and previously published work (Nigou et al., 1997), the 13C 
resonance at δ101 ppm that correlated to an anomeric proton at δ5.15 ppm with a 1JH1,C1 
coupling constant of approximately 170 Hz  was assigned as 2,6-Manp. The resonances at 
δ105 and δ102.3, correlating to protons at δ5.07 and δ4.90 were assigned as t-Manp and 6-
Manp, respectively. The t-β-Araf residues corresponded to δ103.4 with 1H at δ5.16. The 
well-separated spin systems for 2-α-Araf attached to the 3-position (2-α-Araf→3, δ108.2, 
δ5.27 ppm) and 5-position (2-α-Araf→5, δ108.5, δ5.20) of the 3,5-Araf were also visible in 
the spectra of WT-LAM. Several spin systems were observed (δ110.3 and δ5.19 ppm, δ110.3 
and δ5.14 ppm and δ110.3 and δ5.11 ppm) assigned to 5-α-Araf in different chemical 
environments, with one overlapping set of 3,5-α-Araf (δ110.2-δ5.12) for WT-LAM. As 
reported two distinct chemical shifts of t-α-Araf could occur for the respective arms of a 
branched 3,5-α-Araf, as observed for 2-α-Araf→3 and 2-α-Araf→5 (Nigou et al., 1997). In 
AftC-LAM (Figure 3.4B) the resonances associated with the mannan core (t-Manp, 6-Manp 
and 2,6-Manp) are conserved but resonances associated with Araf residues are notably less 
abundant. In particular, 2-α-Araf→3 is absent and the complex set of signals for the different 
5-α-Araf are now much more simplified due to the loss of 3,5-α-Araf (Figure 3.4B). GC/MS 
of per-O-methylated alditol acetate derivatives confirmed this result in that it showed an 
unaltered glycosidic linkage profile for the mannan backbone of both WT- and AftC-LAM 
and a complete loss 3,5-Araf and significant reduction in t-Araf, 2-Araf and 5-Araf-linkages 
for the latter LAM (Figure 3.3 B and D). Complementation of M. smegmatis∆aftC with either 
Ms-aftC or Mt-aftC restored the glycosyl linkage profile to that of WT (Figure 3.3, F and H), 
demonstrating that MSMEG2785 (Ms-aftC) and Rv2673 (Mt-aftC) are functional 
orthologues. Overall, the compostional analysis suggests that, as compared to WT-LAM, 
AftC-LAM has an unaltered mannan domain composed of an α(1→6)-Manp backbone 
substituted by t-Manp units at O-2 positions, and to which is attached one or more short 
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α(1→5)-linked linear arabinan chain (in total representing approximately 12-15 Araf units) 
terminating in a single β(1→2) Ara residue (Figure 3.5). 
    
Figure 3.5: Structural representation of WT-LAM and AftC-LAM. Mannose and arabinose residues are 
displayed in green and blue, respectively. Lipoglycans are represented in their triacylated form and capping 
motifs have been removed for clarity. 
Chapter 3 
 117 
3.2.3. Effect of ethambutol on AftC-LAM formation 
EMB blocks cell wall arabinan biosynthesis by targeting the Emb proteins (Belanger et al., 
1996; Telenti et al., 1997). Although EmbC is known to be involved in LAM arabinan 
biosynthesis (Zhang et al., 2003), its precise role is as yet inconclusive. We exploited the 
phenotype of M. smegmatis∆aftC and the structural properties of AftC-LAM to investigate 
this role. For this, we treated [14C]-glucose labeled cultures of M. smegmatis with sub-
inhibitory concentrations of EMB, extracted the lipoglycans and performed a radiochemical 
quantification of [14C]-incorporated sugars. SDS-PAGE analysis of the [14C]-LM/LAM pool 
of WT M. smegmatis revealed 2 broad bands corresponding to LAM and LM migrating to 
their expected sizes (Figure 3.6A, Lane 1) and an Ara:Man ratio of 1.2:1 (Figure 3.6B, Lane 
1). Subsequent analysis of the [14C]-LM/LAM lipoglycan pool from M. smegmatis∆aftC, 
resulted in labeling of AftC-LAM and LM (Figure 3.6A, Lane 2) and an Ara:Man ratio of 
0.5:1 (Figure 3.6B, Lane 2). Addition of EMB at 0.5 µg ml-1 resulted in a decrease in the size 
of the AftC-[14C]-LAM, an accumulation of [14C]-LM (Figure 3.6A, Lane 3) and a 
corresponding change in the Ara:Man ratio of 0.3:1 (Figure 3.6B, Lane 3). Since AftC-LAM 
contains an intact mannan core, the only possible effect of EMB, is by directly inhibiting 
EmbC activity (addition of the terminal β(1→2) Araf residues by AftB is insensitive to EMB 
(Alderwick et al., 2006)), thus showing its involvement in the very early stages of LAM 
arabinan biosynthesis and inhibition of an α(1→5) AraT. Notably, we observed that residual 
[14C]-Ara labeling always remained upon EMB treatment (Figure 3.6B, Lane 3), suggesting 
that another AraT possibly adds the first Araf residue to LM, akin to AftA in AG 
biosynthesis (Alderwick et al., 2006).  
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Figure 3.6: SDS-PAGE A) and total sugar analysis B) of [14C]-labeled lipoglycans extracted from M. 
smegmatis and M. smegmatis∆aftC treated with EMB. Growing cultures of M. smegmatis and M. 
smegmatis∆aftC were labeled with [14C]-glucose and their lipoglycans extracted and analysed by SDS-PAGE 
(A). Lane 1, M. smegmatis, Lane 2, M. smegmatis∆aftC and Lane 3, M. smegmatis∆aftC + 0.5 µg ml-1 EMB. 
The above lipoglycans were hydrolysed in 2 M TFA and analysed by TLC to determine the total sugar 
composition (B). Lane 1, M. smegmatis, Lane 2, M. smegmatis∆aftC and Lane 3, M. smegmatis∆aftC + 0.5 µg 
ml-1 EMB. 
 
3.2.4. AftC-LAM displays pro-inflammatory properties 
LMs, in contrast to LAMs, are potent pro-inflammatory lipoglycans (Doz et al., 2007; Nigou 
et al., 2008; Quesniaux et al., 2004b; Vignal et al., 2003). This difference has been attributed 
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to the presence of the arabinan domain in LAM which masks the “bioactive” mannan core 
(Guerardel et al., 2002; Vignal et al., 2003). To investigate the consequence of the aftC 
mutation on the pro-inflammatory activity of LAM, we compared WT- and AftC-LAM for 
release of TNF-α by human THP1 cells. Consistent with earlier studies (Vignal et al., 2003), 
truncated AftC-LAM, as compared to WT-LAM, exhibited an increased pro-inflammatory 
activity (Figure 3.7A). LM is a known agonist for TLR2 (Briken et al., 2004). Therefore, we 
investigated the ability of WT- and AftC-LAM to activate this receptor. HEK293 cells 
expressing TLR2 were stimulated with increasing amounts of LAM after which TLR2-
dependent IL-8 production was determined. As shown in Figure 3.7B, AftC-LAM induced a 
much stronger TLR2 activation than did WT-LAM (~10-fold). This result demonstrates that 
the presence of the full-length arabinan domain somehow hampered TLR2 activation. 
Previously, it has been reported that immune stimulatory activity of some M. smegmatis 
LAM preparations may have been caused by lipopeptide contamination (Nigou et al., 2008). 
To investigate this issue, both WT and AftC-LAM were pre-treated with H2O2 (a procedure 
that inactivates lipopeptides (Morr et al., 2002; Zahringer et al., 2008)), after which they 
were re-tested for their activity on HEK293 TLR2 cells. As shown in Figure 3.7, pre-
treatment with H2O2 substantially reduced the activity of both WT- and AftC-LAM. 
However, in contrast to WT-LAM, which lost all of its activity, a substantial part of the 
activity arising from AftC-LAM was sustained for up to 168 h of treatment (Figure 3.7C). 
This was not due to the inactivation of the H2O2 itself, since addition of fresh H2O2 after 96 h 
did not further reduce the activity (Figure 3.7C). Therefore, we conclude that both LAM 
preparations were probably contaminated with lipopeptides to a certain extent. Nevertheless, 
inactivation of these molecules with H2O2, clearly demonstrated that AftC-LAM was able to 
activate TLR2, whereas WT-LAM (PILAM) became completely inactive for concentrations 
up to 100 µg/ml (Figure 3.7D). 
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Figure 3.7: TNF-α  production by human THP-1 cells and IL-8 production by HEK293 TLR-2 cells in response 
to WT-LAM and AftC-LAM. A) Human THP-1 cells were incubated with 1 µg ml-1 (black bars) or 10 µg ml-1 
(white bars) WT- or AftC-LAM. TNF-α was quantified after 24 h by ELISA. (B-D) HEK293 cells transfected with 
TLR2 were stimulated with: B) increasing amounts of WT- or AftC-LAM, with LPS (50 ng ml-1), with Pam3CSK4 
(50 ng ml-1) or with H2O as a negative control; C) 50 µg ml-1 of WT- or AftC-LAM (with and without 1% hydrogen 
peroxide (±H2O2) for the indicated time period), with LPS (50 ng ml-1), Pam3CSK4 (50 ng ml-1) (±H2O2 for 48 h) or 
with H2O as a negative control; D) with increasing amounts of WT- or AftC-LAM (treated with H2O2 for 168 h). In 
all cases, cells were stimulated for 24 h at 37oC, after which the supernatants were harvested and analysed for IL-8 by 
ELISA. E) Binding of DC-SIGN-Fc to WT- (▲) or AftC-LAM (■) as determined by ELISA. Absorption was 
measured at 490 nm. In all panels, data are expressed as the mean ± s.d. from 1 representative of 3 independent 
experiments.     
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To determine whether the increased pro-inflammatory activity of AftC-LAM indeed 
coincided with a more exposed mannan domain, the ability of WT- and AftC-LAM to 
interact with an Fc construct harboring the extracellular domain of the C-type lectin DC-
SIGN was investigated. DC-SIGN is highly expressed on dendritic cells and recognises high-
mannose structures (Appelmelk et al., 2003; Feinberg et al., 2001) including LM (Pitarque et 
al., 2005) but not PILAM (Maeda et al., 2003). As shown in Figure 3.7E, the reactivity of 
DC-SIGN-Fc towards AftC-LAM was stronger as compared to the reactivity against WT-
LAM, demonstrating that the mannan core of AftC-LAM was more accessible. 
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3.2.5. Discussion 
The data described unequivocally demonstrate that AftC is responsible for introducing 3,5-
Araf branching in the LAM arabinan domain of M. smegmatis and proposes a new model for 
LAM biosynthesis (Figure 3.8). Furthermore, we show, for the first time, that EmbC is 
involved in the very early stages of LAM arabinan biosynthesis and that with the truncation 
of the arabinan domain LAM gains the ability to activate TLR2. Although the structure of the 
arabinan domain of LAM is well understood, less is known of the enzymes involved in its 
biosynthesis. One important reason is that C. glutamicum, a preferred model organism to 
study mycobacterial AG and LM biosynthesis (Alderwick et al., 2006; Seidel et al., 2007; 
Birch et al., 2008) does not produce a convoluted LAM, as present in mycobacteria.  During 
our investigation of various putative GT-C glycosyltransferases, we deleted msmeg2785 
(AftC) from M. smegmatis, which resulted in a phenotype that displayed a severely truncated 
AG (Chapter 2) (Birch et al., 2008). In this chapter, we re-visited this mutant in an attempt to 
investigate the potential role of AftC in LAM biosynthesis. Chemical analysis revealed that 
LAM isolated from the aftC mutant contained an unaltered mannan core, but with one or 
more simple arabinan moieties of approximately 12-16 Araf units composed of α(1→5)-
linkages terminating in a single β(1→2) fashion. It is reasonable to conclude from our data 
that AftC is not involved in early arabinan LAM biosynthesis, since a more pronounced 
truncation of LAM would then be expected. AftC has dual functionality, in terms of its 
involvement in the biosynthesis of both AG and LAM. Attempts to generate an aftC deficient 
strain of M. tuberculosis has this far proved unsuccessful, highlighting the essentiality of aftC 
in M. tuberculosis (Sassetti et al., 2003) and the species’ intolerance to cell-wall changes. 
Hence, AftC represents an excellent drug target. 
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EmbC has long been implicated in the biosynthesis of mycobacterial LAM and has been 
shown to be a target of the front line drug EMB (Mikusova et al., 1995; Zhang et al., 2003). 
However, speculation around its precise enzymatic function has remained controversial. By 
utilising the unique phenotype of M. smegmatisΔaftC, we now provide unequivocal evidence 
that EmbC is an α(1→5) AraT, which is inhibited by EMB (Figure 3.8).  
 
                 
 
Figure 3.8:  Mycobacterial LAM biosynthesis and the role of AftC. The GT-A/B family of 
glycosyltransferases perform sequential glycosidic transfer of mannose residues utilising the high energy 
nucleotide GDP-Man, to a PI based anchor in the cytoplasm. The GT-C family of glycosyltransferases then 
continue LM and LAM biosynthesis by elaborating Ac1PIM4 with mannose and arabinose residues. MptA, 
MptB and Rv2181 are the only known ManTs involved in core mannan biosynthesis, for which they utilise the 
lipid linked substrate polyprenylphosphomannose (PPM) as the sugar donor. Decaprenyl-1-
monophosphoarabinose (DPA) is utilised by an unknown AraT to prime LM at an, as yet, unidentified position. 
EmbC and AftC are the other two identified AraTs which mature the final LAM molecule before species 
specific capping occurs.  
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We now propose a working model, whereby an as yet unidentified GT-C AraT, primes the 
mannan backbone with singular Araf residues in much the same way was as AftA primes the 
galactan backbone of AG (Alderwick et al., 2006). Subsequently, EmbC extends the 
arabinan chain in an α(1→5) fashion before AftC branches the polysaccharide with an 
α(1→3) Araf residue and the domain is further matured by a combination of AraTs including 
AftC, AftB and perhaps other as yet unidentified enzymes (Figure 3.8). 
Several mycobacterial cell-wall lipoglycans are pro-inflammatory stimuli of the host immune 
response. Both LM and LAM are members of a family of mycobacterial lipoglycans that all 
contain a conserved MPI anchor (Briken et al., 2004). Interestingly, LM, besides being a 
potent inducer of pro-inflammatory cytokines, also displays strong anti-inflammatory 
properties and represses lipopolysaccharide (LPS)-induced cytokine responses in 
macrophages (Quesniaux et al., 2004b). Recently, by making use of LM preparations, 
separated by their degree of acylation, it was demonstrated that these pro- and anti-
inflammatory properties are, at least in part, dependent on the degree of acylation (Doz et al., 
2007; Gilleron et al., 2006). Whereas, tri- and tetra-acylated LM forms displayed strong pro-
inflammatory properties, mono- and di-acylated molecules did not (Gilleron et al., 2006). 
Besides the degree of acylation, additional structural features of MPI-anchored lipoglycans 
determine their biological activity. Recently, it was shown that the chain length of the 
mannan core of MPI-anchored lipoglycans directly correlated with their ability to activate 
TLR2 (Nigou et al., 2008). Whereas lipoglycans with short oligomannopyranosyl backbones, 
such as the PIMs, were marginally active, the TLR2-activating potency of lipoglycans with 
longer backbones, i.e. LM, was strongly enhanced (Nigou et al., 2008). In addition to 
mannan chain length, the type of substitution of the mannan core was found to be critical, 
with activity being retained in the case of Manp substitutions but absent when the core was 
substituted with Araf residues (Nigou et al., 2008). This was evidently clear for 
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mycobacterial LAMs, which carry a bulky arabinan domain. Although their LM core would 
in principal allow for TLR2 activation, the LAMs were found to be inactive (Nigou et al., 
2008). The assumption that the arabinan domain is directly involved in “silencing activity” is 
further sustained by the observation that chemical degradation of the arabinan domain 
restores the pro-inflammatory properties of LAM (Vignal et al., 2003). Our results are in 
agreement with these findings as AftC-LAM, which expresses a severely truncated arabinan 
domain, exhibited an increased pro-inflammatory activity (Figure 3.7). Since WT and AftC-
LAM did not differ in their pattern of acylation or core mannan composition, the increased 
pro-inflammatory activity must be directly related to the shortening of the arabinan domain. 
Exactly how the arabinan domain prevents TLR activation is currently not fully understood.  
One thought is that the arabinan domain exerts its inhibitory effect by steric hindrance 
(Vignal et al., 2003). Although several lines of evidence point to this direction, the exact 
mechanism and the level at which this occurs remains unclear. In several mycobacterial 
species, the non-reducing termini of the branched arabinan domain are modified by capping 
motifs consisting of either oligomannosyl, i.e. ManLAMs, or PILAM units such as in M. 
smegmatis (Khoo et al., 1995). Whereas reports on the immune stimulatory properties of 
ManLAMs are consistent and unambiguously demonstrate that these types of LAMs are 
inactive (Nigou et al., 2008; Vignal et al., 2003), some controversy exists on the activity of 
PILAMs. Early reports demonstrate that PILAM is pro-inflammatory and signals via TLR2 
(Chatterjee et al., 1992; Gilleron et al., 1997; Tapping et al., 2003; Underhill et al., 1999; 
Vignal et al., 2003). However, the mechanism by which a low degree of inositol-phosphate 
capping would confer this pro-inflammatory activity has never been explained. One 
hypothesis is that the myo-inositol-phosphate motif in the MPI-anchored lipoglycans may 
mimic the inositol-phosphate caps on PILAMs thereby conferring activity. However, the 
notion that the unsubstituted PI caps are unlikely to mimic the acylated MPI anchor plus the 
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observation that PIMs are only marginally active, clearly demonstrate that the PI motif alone 
does not confer activity (Vignal et al., 2003). Interestingly, in a more recent study, Nigou et 
al. (2008) demonstrated that highly purified PILAMs from M. smegmatis and M. fortuitum 
were equivalent in activity to ManLAMs. Therefore, in contrast to what was previously 
suggested, the authors concluded that the presence of PI caps did not make LAM pro-
inflammatory and they suggested that the activity in earlier experiments was probably due to 
lipopeptide contamination. Even though contaminant lipopeptides may not be detected by the 
current analytical methods, trace amounts of these molecules (<0.1%) are enough to 
influence the outcome of much more sensitive biological assays. We therefore determined 
the effect of H2O2 treatment on the TLR2-stimulating activity of both WT and AftC-LAM. 
As shown in Figure 3.7C, treatment with H2O2 severely reduced the activity of WT-LAM 
(PILAM) suggesting that the earlier observed activity was indeed due to lipopeptide 
contamination. In contrast, although the activity of AftC-LAM was also substantially 
reduced, a stable part of the activity was insensitive to H2O2 treatment (Figure 3.7C). 
Although, we cannot exclude that H2O2 also acts on LAM and may thereby abrogate its 
activity, the observation that the residual activity of AftC-LAM stabilised after 4 days of 
treatment, instead of gradually declining further, argues against this notion. Furthermore, 
H2O2 treatment fully inactivated the lipopeptide Pam3CSK4, demonstrating that inactivated 
lipopeptides do not display any residual activity (Figure 3.7C). Overall, these data strongly 
suggest that the pro-inflammatory activity observed in some PILAM preparations was indeed 
the result of contaminating lipopeptides. Nevertheless, based on these experiments, we 
conclude that truncation of the arabinan domain by the aftC mutation resulted in an increased 
pro-inflammatoryactivityofAftC-LAM.
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4. Identification of a rhamnopyransolyltransferase (RptA) which utilises a novel 
decaprenolphosphorhamnose substrate 
4.1. Introduction 
A particularly interesting feature of C. glutamicum is the presence of terminal 
rhamnopyranose (t-Rhap) residues attached to the C2 position of α(1→5) linked Araf 
residues in the arabinan domain of AG (Alderwick et al., 2005). The biological function of 
these residues remains to be clarified, nevertheless, they are a feature of the corynebacterial 
cell wall and the biosynthesis of which, needs to be addressed. The current paradigm of AG 
biosynthesis follows a linear pathway, which is built upon a decaprenyl pyrophosphate lipid 
carrier. The unique disaccharide linker and galactan domain is synthesised by a variety of 
GT-A and GT-B family of glycosyltransferases, all of which utilise a nucleotide diphosphate 
activated sugar substrate for transferase activity. It has been hypothesised (Alderwick et al., 
2007; Alderwick et al., 2006; Berg et al., 2007), that a major shift in the biosynthetic 
machinery takes place upon the initiation of arabinan polymerisation. AftA, Emb, AftC and 
AftB all belong to the GT-C family of glycosyltransferases and all of which utilise DPA as 
the sole lipid activated phospho-sugar donor for arabinose transfer into the cell wall. Since, t-
Rhap residues are present in the arabinan component of the cell wall, the enzyme(s) 
responsible for its addition are likely to belong to the GT-C family of glycosyltransferase, 
and through deduction, one which utilises a lipid-phosphate derived rhamnose substrate, 
similar to DPA. Herein, we present the putative protein NCgl0543 as a distinct t-
rhamnopyranosyltransferase of the GT-C superfamily, which is responsible for the transfer of 
t-Rhap residues to the arabinan domain to form the branched 2,5-linked Araf motifs of C. 
glutamicum. In addition, we have identified a novel decaprenol-mono-phosphorylrhamnose 
and discuss its role in substrate presentation for AG biosynthesis in C. glutamicum. 
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4.2. Results 
4.2.1. Genome comparison of the NCgl0543 (rptA) locus 
An examination of the genome sequence of C. glutamicum revealed that there are fourteen 
glycosyltransferases of the GT-C family. The function of AftA has been identified 
(Alderwick et al., 2006), AftB, AftC, MptA (Mishra et al., 2007), and that of MptB (Mishra 
et al., 2008) which act as membrane-bound glycosyltransferases using polyprenylated-
phospho-arabinosyl- and mannosyl-sugar donors, respectively, in the synthesis of AG and 
LAM. The above mentioned genes are also present in M. tuberculosis illustrating that they 
are required to build the elementary cell wall structure of the Corynebacterianeae (Dover et 
al., 2004). 
An, as yet, uncharacterised GT-C glycosyltransferase of C. glutamicum is encoded by the 
putative protein NCgl0543. Orthologues of this gene, with identities exceeding 34%, are 
present in C. glutamicum R, Corynebacterium efficiens, Corynebacterium glucuronalyticum 
(ATCC 51867), and Corynebacterium amycolatum SK46, the latter two saprophytic 
organisms being human skin pathogens (Letek et al., 2006; Tauch et al., 2008). The genomic 
organisation surrounding NCgl0543 is largely syntenic and is preceded by a putative tRNA 
pseudouridine synthase and downstream of NCgl0543 is a membrane protein of unknown 
function (pfam class DUF690). There are no orthologues of NCgl0543 present in 
Corynebacterium diphtheriae, Corynebacterium jeikeium nor Corynebacterium urealyticum 
DSM 7109 (Cerdeno-Tarraga et al., 2003; Tauch et al., 2005; Tauch et al., 2008). 
NCgl0543 of C. glutamicum is a large polytopic membrane protein of 799 amino acid 
residues and is predicted to possess 13 transmembrane-spanning helices (TMH) (Figure 
4.1A). It is further characterised by a periplasmic carboxyterminal extension of 237 aa, 
similar to the C-terminal features of AftA (Alderwick et al., 2006), AftB, and the Emb 
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proteins (Alderwick et al., 2006; Berg et al., 2005; Seidel et al., 2007; Telenti et al., 2007). A 
particularly highly conserved region is present at the end of the long loop connecting TMH 3 
and TMH 4. This region is schematically shown in Figure 4.1A, as is part of its sequence 
(Figure 4.1B). This sequence resembles the glycosyltransferase GT-C family DXD motif 
(Liu & Mushegian, 2003), as it contains a number of basic and acidic residues, with the latter 
being shown in mutational studies to be essential for glycosyltransferase activity using 
polyprenylated phospho-sugar donors (Berg et al., 2007; Seidel et al., 2007b). 
 
     
 
Figure 4.1: Hypothetical spatial organisation and partial sequence of the putative protein NCgl0543. A) 
The hypothetical schematic organisation of the putative protein NCgl0543 is shown spanning the membrane 13 
times with the carboxy terminal end consisting of 237 amino acids and located in the periplasm. Also shown is 
the long loop of 168 amino acids connecting TMH 3 and TMH 4. The black star locates the putative 
glycosyltransferase region given in B and the white star a conserved region, and also present in the putative 
protein Rv3779, in the periplasmic part of the protein. B) Illustrates the part of the loop region, where acidic 
and basic residues are highlighted. Although, the overall topology of the M. tuberculosis putative protein 
Rv3779 and its orthologs are somewhat different to that of the corynebacterial proteins, the loop region is 
strongly conserved in the Coynebacterianeae and this is indicated for selected mycobacterial species underneath 
the sequence alignement. Shown are aa 127 - 188 of the M. tuberculosis sequence, and aa 184 - 235 of the C. 
glutamicum sequence. On top of the sequence comparison the predicted secondary structure is given, with L 
indicating a loop region, H a helical structure, and E an extended sheet structure. The abbreviations are as 
follows: C. glu., Corynebacterium glutamicum ATCC13032; C. glR. Corynebacterium glutamicum strainR; C. 
eff., Corynebacterium efficiens; C. gly., Corynebacterium glucuronalyticum; C. amy., Corynebacterium 
amycolatum; M. mar., Mycobacterium marinum (ATCC BAA-535); M. tub., Mycobacterium tuberculosis; M. 
par., Mycobacterium paratuberculosis; M. lep., Mycobacterium leprae. 
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4.2.2. Construction of C. glutamicumΔrptA 
In an attempt to delete NCgl0543 in C. glutamicum, the non-replicative vector 
pK19mobsacBΔNCgl0543 was constructed. This was introduced into C. glutamicum via 
electroporation and kanamycin-resistant clones obtained indicating integration in the 
chromosome by homologous recombination (Schafer et al., 1994). Using the sucrose 
resistance provoked by the sacB gene a second homologous recombination event was 
selected. A total of 9 clones were analysed by PCR and in 2 of them a wild type reversion at 
the NCgl0543 locus was restored, whereas a deletion of NCgl0543 was obtained in the 7 
remaining clones. These numbers indicate that loss of NCgl0543 is not detrimental to cell 
growth or viability. As a result, and based on the results described below, one clone was 
subsequently termed C. glutamicumΔrptA and confirmed by PCR to have Cg-rptA deleted, 
whereas controls with C. glutamicum wild type resulted in the expected larger amplification 
product. 
4.2.3. In vitro growth phenotype of C. glutamicumΔrptA 
Growth of wild-type C. glutamicum and C. glutamicumΔrptA was compared in liquid 
mineral salt medium CGXII and rich medium BHIS (Eggeling & Bott, 2005). Both strains 
exhibited comparable growth rates of 0.36 ± 0.03 h-1 on mineral salt medium CGXII and 0.60 
± 0.05 h-1 on rich medium BHIS. Thus, C. glutamicumΔrptA does not exhibit an apparent 
growth defect indicating some degree of tolerance to the deletion of Cg-rptA. For further 
analyses, C. glutamicumΔrptA was transformed with a plasmid encoding Cg-rptA, as well as 
with a plasmid encoding Rv3779 of M. tuberculosis to result in C. glutamicumΔrptA 
pVWEx-Cg-rptA and C. glutamicumΔrptA pVWEx-Rv3779. 
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Figure 4.2: Strategy to delete Cg-aftC using the deletion vector pK19mobsacB∆rptA. This vector carries 18 
nucleotides of the 5' end of Cg-rptA and 36 nucleotides of its 3' end thereby enabling the in-frame deletion of 
the entire Cg-rptA gene. The arrows marked P1 and P2 locate the primers used for the PCR analysis to confirm 
the absence of Cg-rptA. Distances are not drawn to scale. The results of the PCR analysis with the primer pair 
P1/P2 are shown on the right. Amplification products obtained from the wild type (wt) were applied in the 
middle lane and that of the deletion mutant in the right lane. ‘St’ marks the standard.  
 
4.2.4. Glycosyl compositional analysis of cell walls from C. glutamicum, C. 
glutamicum∆rptA, C. glutamicum∆rptA pVWEx-Cg-rptA, and C. 
glutamicum∆rptA pVWEx-Rv3779 
To study the function of a corynebacterial rptA deletion mutant, defatted cells were analysed 
quantitatively for AG esterified corynemycolic acids. Wild type C. glutamicum exhibited the 
known profile of CMAMES as previously described (Alderwick et al., 2005). Furthermore, 
cell wall bound CMAMEs were not significantly altered in C. glutamicum∆rptA, which is 
contrary to the deletion of other GT-C glycosyltransferases in C. glutamicum (Alderwick et 
al., 2005; Alderwick et al., 2006). Analysis of cell wall associated lipids in several 
independent experiments highlighted no change in the lipid profiles of the Cg-rptA deletion 
mutant compared to that of C. glutamicum. This was confirmed quantitatively through 
[14C]acetate labeling of cultures and equal loading of radioactivity of extractable free lipids 
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from C. glutamicum, C. glutamicum∆rptA and the complemented C. glutamicum∆rptA strain 
using plasmid pVWEx-Cg-rptA. These results demonstrate that, unlike Cg-emb or Cg-aftA 
(Alderwick et al., 2005; Alderwick et al., 2006), Cg-rptA has little or no involvement in the 
structure or biosynthesis of cell wall bound/extractable lipids in C. glutamicum.  
The cell wall core (mAGP) was prepared from C. glutamicum and C. glutamicum∆rptA as 
described (Alderwick et al., 2005; Besra et al., 1995; Daffé et al. 1990) and the ratio of Rha, 
Ara to Gal in mAGP determined by gas chromatography (GC) analysis of alditol acetates 
(Alderwick et al., 2005; Besra et al., 1995; Daffé et al. 1990 (Figure 4.2). The glycosyl 
compositional analysis of wild type C. glutamicum revealed a relative molar ratio of 
Rha:Ara:Gal of 21:71:31 which is in accordance with previous data ( Alderwick et al., 2005) 
(Figure 4.2). The C. glutamicum∆rptA mutant yielded a molar ratio of Rha:Ara:Gal 
(1:71:31), with a significant reduction in Rha content and no relative change in the Ara:Gal 
ratio (Figure 4.2). Complementation of C. glutamicum∆rptA with pVWEx-Cg-rptA restored 
the Rha:Ara:Gal ratio to that of wild type C. glutamicum (Figure 4.2). Interestingly, 
complementation with pVWEx-Rv3779 did not complement and yielded a phenotype 
identical to that of C. glutamicum∆rptA. 
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Figure 4.3:  GC analysis of cell walls of C. glutamicum, C. glutamicum∆rptA and C. glutamicum∆rptA 
pVWEx-Cg-rptA. Samples of purified cell walls were hydrolysed with 2M TFA, reduced, per-O-acetylated and 
analysed as described under “Materials and Methods” (Alderwick et al., 2005; Besra et al., 1995). 
Abbreviations: Ara, arabinose; Gal, galactose; Rha, rhamnose. 
 
4.2.5. Glycosyl linkage analysis of cell walls from C. glutamicum, C. glutamicum∆rptA, 
C. glutamicum∆rptA pVWEx-Cg-rptA, and C. glutamicum∆rptA pVWEx-Rv3779 
Gas chromatography mass spectrometry (GC/MS) analysis of per-O-methylated alditol 
acetate derivatives prepared from C. glutamicum and C. glutamicum∆rptA indicated a loss of 
t-linked Rhap residues with a corresponding loss of 2,5-linked Araf residues (Figure 4.4).  
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Complementation of C. glutamicum∆rptA with plasmid-encoded pVWEx-Cg-rptA restored 
the glycosyl linkage profile to that of wild type C. glutamicum (Figure 4.4). Furthermore, as 
demonstrated by our total sugar analysis and cell wall sugar linkage analysis, Rv3779 was 
unable to complement C. glutamicum∆rptA by pVWEx-Rv3779. These results demonstrate 
that the putative protein NCgl0543 is involved in the biosynthesis of C. glutamicum AG 
through the addition of t-Rhap residues to the C2 position of the 5-linked backbone domain 
of specific Araf residues.  
4.2.6. Recognition of a rhamnose lipid-linked sugar donor, decaprenyl-P-rhamnose 
Initial assays involved wild type membranes from C. glutamicum and either 
UDP[14C]GlcNAc, dTDP-[14C]Rha, UDP-[14C]Gal or p[14C]Rpp as sugar donors for AG 
biosynthesis. Samples of the radioactive lipids from each assay were applied to TLC plates 
which were then developed in CHCl3/CH3OH/NH4OH/H20 (65:25:0.5:3.6) and 
autoradiograms obtained (Figure 4.5).  
As expected a series of polar glycolipids (GL-1 to -4) were observed corresponding to 
GlcNAc-P-polyprenyl (GL-1), Rha-GlcNAc-P-polyprenyl (GL-2), Gal-Rha-GlcNAc-P-
polyprenyl (GL-3), Gal-Gal-Rha-GlcNAc-P-polyprenyl (GL-4) and DPA/DPR consistent 
with previous studies utilising M. smegmatis membranes (Mikusova et al., 1996). 
Interestingly, the inclusion of dTDP-[14C]-Rha also resulted in the synthesis of a more apolar 
rhamnose-labeled lipid X product, in comparison to GL-2-4 (Figure 4.5).  
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Figure 4.4: GC/MS analysis of cell walls of C. glutamicum, C. glutamicum∆rptA and C. glutamicum∆rptA 
pVWEx-Cg-rptA. Samples of per-O-methylated cell walls were hydrolysed with 2M TFA, reduced, per-O-
acetylated and analysed as described under “Materials and Methods” (Alderwick et al., 2005; Besra et al., 
1995) 
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Figure 4.5: Analysis of [14C]GlcNAc, [14C]Rha, [14C]Gal and [14C]Ara labeled glycolipids in C. 
glutamicum. Membranes from C. glutamicum were prepared, mixed with decaprenyl-1-monophosphate and 
labeled with either UDP-[14C]GlcNAc, dTDP-[14C]Rha, UDP-[14C]Gal or p-[14C]Rpp. Radiolabeled glycolipids 
were extracted, analysed by TLC and visualised by autoradiography as described in “Materials and Methods”.  
Abbreviations: GL-1, GlcNAc-P-P-polyprenyl; GL-2, Rha-GlcNAc-P-P-polyprenyl; GL-3, Gal-Rha-GlcNAc-
P-P-polyprenyl; GL-4, Gal-Gal-Rha-GlcNAc-P-P-polyprenyl; Lipid-X, putative decaprenol-1-monophosphate-
rhamnopyranose; DPA, β-D-arabinofuranosyl-1-monophosphoryldecaprenol; DPR, β-D-ribofuranosyl-1-
monophosphoryldecaprenol. 
 
This lipid X was sensitive to acid and resistant to mild-base treatment indicating that this 
product was also a polyprenyl-P based lipid. Importantly, an increase in the synthesis of lipid 
X, based on TLC and densitometry, was found when assays were repeated with membranes 
prepared from C. glutamicum∆rptA (lipid X, 4300 cpm) compared to C. glutamicum (lipid X, 
3057 cpm), indicating that lipid X was probably the lipid-linked sugar donor for the GT-C 
glycosyltransferase RptA in this study (Figure 4.6).  Furthermore, the synthesis of lipid X 
was unaffected by the addition of tunicamycin (C. glutamicum lipid X, 3222 cpm; C. 
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glutamicum∆rptA lipid X, 4203 cpm) which inhibits GlcNAc phosphotransferase activity of 
Rv1302, thus leading to a marked decrease in GlcNAc-P-polyprenyl (Gl-1) and higher GLs 
(e.g. >GL-2) (Figure 4.6).  
                         
Figure 4.6: Analysis of [14C]Rha base stable lipids in C. glutamicum and C. glutamicum∆rptA and the 
effect of tunicamycin. Membranes from C. glutamicum and C. glutamicum∆rptA were prepared, mixed with 
decaprenol-1-monophosphate and labeled with dTDP-[14C]Rha. [14C]Rha-labeled glycolipids were extracted, 
analysed by TLC and visualised by autoradiography as described in “Materials and Methods”. Abbreviations: 
GL-1, GlcNAc-P-P-polyprenyl; GL-2, Rha-GlcNAc-P-P-polyprenyl; GL-3, Gal-Rha-GlcNAc-P-P-polyprenyl; 
GL-4, Gal-Gal-Rha-GlcNAc-P-P-polyprenyl; Lipid-X, putative decaprenol-1-monophosphate-rhamnopyranose. 
 
The basic assay mixture was scaled-up containing cold dTDP-Rha and the lipid X extracted 
for subsequent characterisation by treatment with mild base. Negative-ion electro-spray mass 
spectrometry (ES-MS) revealed a major signal (M-H)- at m/z 777 for decaprenyl phosphate 
(Figure 4.7A inset), and a product ion at m/z 924 corresponding to decaprenyl-P-rhamnose 
(Figure 4.7A). We also observe mass ions at m/z 934 and m/z 936, which could indicate 5 
and 6 fully saturated isoprene units out of a possible 10. Similar observations have previously 
been reported in other Corynebacteriaceae glycolipids, such as the apparent mycolate 
transporter Myc-PL (Besra et al., 1994). Altogether, the above dTDP-Rha labeling, 
sensitivity to acid, resistance to base and to tunicamycin, and analysis by ES-MS, confirmed 
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that lipid X was prenylated-P-rhamnose (Figure 4.7B), and is therefore the likely substrate of 
the membrane bound rhamnosyltransferase RptA. 
 
                
Figure 4.7: Mass spectrometry analysis and identification of decaprenyl-1-monophosphorylrhamnose. A) 
Electrospray mass spectometry (in the negative mode) of decaprenol-1-phosphorylrhamnose. B) Structure of 
decaprenol-1-phosphorylrhamnose. 
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4.3. Discussion 
It is clear, from this present study, that Cg-rptA is non-essential and is involved in the 
addition of t-Rhap residues to a 5-linked Araf backbone giving rise to branched 2,5-linked 
Araf residues. We also report a Rha:Ara molar ratio of 21:71 in C. glutamicum AG (Figure 
4.3), which equates to approximately 7 t-Rhap residues per arabinan tricosamer. This 
significant amount of rhamnose in the cell wall must not be dismissed, and more so, the 
functional significance must be elucidated. Rhamnose is present in the cell walls of many 
Gram-positive bacteria such as Staphylococcus, Streptococcus, Bacillus and Pseudomonas 
(Weidnemaier & Peschel, 2008). In Pseudomonas aeruginosa, L-rhamnose is present in the 
form of mono or di substituted rhamnolipids, and these virulence factors are thought to act by 
disrupting lipid membranes by acting as a surfactant (Van Delden & Iglewski, 1998). In 
other Gram-positive bacteria, rhamnose is present in the cell wall as part of the carbohydrate 
moieties of teichoic acids and other cell-wall glycopolymers (Baddiley, 1972). However, 
since C. glutamicum is non-pathogenic, the introduction of t-Rhap residues is probably 
related to either (i) structural integrity or (ii) a mechanism to cap and end arabinan synthesis 
and provide a control point for the extent of mycolation of the "terminal" arabinan units. 
Cg-rptA shares approximately 40% sequence similarity with the putative M. tuberculosis 
protein Rv3779. Although, the total length of the proteins differ by 133 aa, there are 
remarkable structural similarities, such as the high identity at the sequence level in the GT-C 
loop, which is located between TMH 3 and 4 in C. glutamicum (Figure 4.1) and TMH 4 and 
5 in M. tuberculosis Rv3779. This loop is followed by 10 TMHs in C. glutamicum, which are 
present and similarly arranged in the M. tuberculosis orthologue. Interestingly, within the 
final periplasmic region, there is also a similar stretch of aa residues indicated as an open star 
in Figure 4.1A. Since the carboxy terminal periplasmic domain is suggested to play a role in 
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substrate recognition, which in the case of the GT-C glycosyltransferases is a growing 
polysaccharide, we speculate that both Cg-RptA and the putative Rv3779 protein recognise a 
related substrate, such as an arabinan oligosaccharide and distinct sugar donors, since the 
putative protein, Rv3779, failed to complement C. glutamicum∆rptA.  
NCgl0543 is part of the rfb locus and its genomic organisation is well retained in 
Corynebacterianeae. Orthologues of this locus, which include rfbE, NCgl0197, NCgl0195, 
rfbD (NCgl0198), are present in C. glutamicum. RfbE has similarity to an ATP-dependent 
export carrier and is tentatively annotated as being a polysaccharide export ATP-binding 
protein, and rfbD as a polysaccharide export ABC transporter permease (Cole et al., 1998). 
We have found that the galactosyltransferase NCgl0195 (Alderwick et al., 2008; Mikusova et 
al., 2006) is essential in C. glutamicum and is involved in GL-3 and GL-4 biosynthesis. Due 
to the function of Cg-RptA, and its similarity to the putative protein Rv3779, we speculate 
that the rfb locus is essential for polysaccharide biosynthesis and resultant export to the 
periplasm.  
The biosynthesis of high energy nucleotide derived sugar substrates of Corynebacteriaceae 
glycosyltransferases, such as UDP-α-D-Galf (Weston et al., 1997), dTDP-Rhap (Ma et al., 
1997) has been well characterised. These substrates are utilised by GT-A/B 
glycosyltransferases in the cytoplasm of the cell to form a preliminary linear galactan 
polysaccharide before being exported to the periplasm, by an as yet unidentified flippase. At 
this point, further polysaccharide biosynthesis employs glycosyltransferases belonging to the 
GT-C family which make use of prenylated phosphosugar substrates (Liu & Mushegian, 
2003; Berg et al., 2007). In Corynebacterianeae, decaprenol (C50) and, to a lesser extent 
octahydroheptaprenol (C35), are the predominant lipid carriers for peptidoglycan, 
arabinogalactan and mannan biosynthesis. Decaprenyl phosphate is glycosylated by 
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arabinose and ribose to form β-D-arabinofuranosyl-1-monophosphoryldecaprenol (DPA) and 
β-D-ribofuranosyl-1-monophosphoryldecaprenol (DPR), respectively (Wolucka et al.,1994). 
It is also glycosylated by mannose to form β-D-mannosyl-1-monophosphoryldecapreol 
(DPM or PPM) (Gurcha et al., 2002; Yokoyoma & Ballou, 1989) and glucose to form β-D-
glucosyl-1-monophosphoryldecaprenol (GPM) (Schultz & Elbein, 1974). To date, this is the 
first report of a GT-C rhamnosyltransferase (RptA). Furthermore, this is also the first report 
of a rhamnosylated monophosphodecaprenol, which is the substrate for RptA and novel with 
respect to DPA, DPR and DPM. Finally, the discovery of Cg-rptA has shed new light on the 
glycosyltransferases which are key to building the cell wall AG of Corynebacterianeae. 
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5. Conclusion and future work 
M. tuberculosis is a major cause of illness and death worldwide and with the advent of MDR- 
and XDR-TB strains discovery of new chemotherapeutic agents is paramount (Brennan & 
Nikaido, 1995). Mycobacteria have an intricate cell wall and maintenance of its integrity is 
essential for the survival of the bacilli, and as such, numerous anti-tubercular drugs target its 
biosynthetic machinery.  One such drug, EMB, inhibits synthesis of the arabinan, which 
forms an integral component of AG and LAM, the two dominating heteropolysaccharides 
located in the mycobacterial cell wall. In this regard, the last two decades have seen 
considerable effort concentrated towards the elucidation of the enzymes involved with in 
their biosynthetic pathways.  
The number of arabinofuranosyltransferases that are required for mycobacterial arabinan 
biosynthesis has been a matter of speculation to date depending on how and where the 
arabinan chains are assembled. In terms of AG, the primary structure (Besra et al., 1995; 
Daffé et al., 1990) would suggest at least five distinct arabinofuranosyltransferases are 
required for the complete formation of the three AG arabinan domains. The availability of 
the complete genome sequence of M. tuberculosis H37Rv, as well as the decoding of other 
Actinomycetales genomes such as C. glutamicm proved crucial in forming our experimental 
hypothesis. Carrying out comparative genomic analysis of Corynebacterineae genome 
sequences, and employing surrogate experimental model systems such as C. glutamicum and 
M. smegmatis, has enabled us to study the molecular genetics of mycobacterial cell wall 
biosynthetic processes, which are otherwise essential in M. tuberculosis. This strategy was 
previously used to identify the presence of a new “priming” enzyme, now termed AftA, 
which would link the initial Araf unit with the C-5 OH of a β(1→6) linked Galf of a pre-
synthesised galactan core (Alderwick et al., 2005b). 
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The studies reported in this thesis have identified Rv3805c, which has now been termed 
AftB, as a novel retaining arabinofuranosyltransferase, which adds to the non-reducing end 
of the arabinan domain of AG β(1→2) Araf residues. Deletion of its orthologue NCgl2780 in 
the closely related species C. glutamicum produced a viable mutant with a decreased 
abundance of cell wall bound mycolic acids, consistent with a partial loss of mycolylation 
sites. Glycosyl linkage analysis of arabinogalactan revealed the complete loss of terminal 
β(1→2) linked  Araf residues which was fully restored upon complementation with a plasmid 
expressing Cg-AftB or Mt-AftB but not with muteins of Mt-AftB, where the two adjacent 
aspartic acid residues, which have been suggested to be involved in glycosyltransferase 
activity, were replaced by alanine. In addition, the use of C. glutamicum and C. 
glutamicum∆aftB in an in vitro assay utilizing the sugar donor DPA together with a 
neoglycolipid acceptor as substrate, confirmed AftB as a terminal β(1→2) 
arabinofuranosyltransferase, which was also insensitive to EMB. 
Interestingly, Escuyer et al. (2001) reported, M. smegmatis embA and embB mutants 
possessing reduced amounts of the non-reducing terminal disaccharide β-D-Araf-(1→2)-a-D-
Araf, resulting in the absence of the dominant terminal non-reducing Ara6 branched motif in 
the mutant being replaced by a linear Ara4 motif. The authors of this study concluded that the 
M. smegmatis embA and embB mutants result in a lack of 3-arm branching off the main 
α(1→5)-arabinan chain proximal to the non-reducing and attachment site of mycolic acids in 
AG (Escuyer et al., 2001), leading to the supposition that the β-D-Araf-(1→2)-α-D-Araf 
disaccharide was assembled using EmbA and EmbB. 
The results presented in this thesis do not reflect the proposed roles of the known AraTs 
propounded by Escuyer et al. (2001), in fact the complete biochemical and molecular 
characterisation of AftB in this study and the development of an in vitro assay (Lee et al., 
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1997) suggests that EmbA/B may act as α(1→5) arabinofuranosyltransferases, although 
further definitive characterisation is required. Due to the inherent absence of a LAM-like 
molecule in C. glutamicum, we were unable to determine the involvement of Mt-AftB in 
both AG and LAM arabinan biosynthetic pathways. In terms of future studies, it would be 
interesting to generate an aftB mutant in M. smegmatis to assess whether or not AftB has dual 
functionality, with regard to LAM biosynthesis, and is responsible for β(1→2) capping in 
LAM, akin to our studies of M. smegmatis AftC (see below).  
In addition, our current studies have also identified MSMEG2785 (Rv2673 and NCgl1822), 
which we have termed AftC, as a novel branching arabinofuranosyltransferase. In vivo and in 
vitro experiments demonstrated that AftC catalyses the addition of α(1→3) Araf residues, 
ultimately resulting in 3,5-Araf residues after further α(1→5) extension, characteristic of 
AG. It was shown that incubation of membranes prepared from M. smegmatis with DP[14C]A 
and a linear α(1→5)-Ara5 neoglycolipid acceptor resulted in the synthesis of an Ara6 
product. Further chemical characterisation of the product by glycosyl linkage analysis 
established that the α(1→5)-Ara5 acceptor was extended via an EMB resistant α(1→3) 
arabinosfuranosyltransferase, giving rise to 3-linked Araf residues. Since, it is now 
established that only α(1→5) arabinofuranosyltransferase(s) are EMB-sensitive it can be 
further speculated that EmbA and EmbB function in the assembly of the linear α(1→5) 
arabinan segments. This is in accordance with previous data (Besra et al., 1995; Daffé et al., 
1990) and phenotypes of EmbA and EmbB (Escuyer et al., 2001; Zhang et al., 2003) and Cg-
Emb (Alderwick et al., 2005b) mutants. It is clear that further studies are required to 
establish the precise role of EmbA and EmbB in mycobacteria. 
Given that M. smegmatis possesses a LAM structure similar to M. tuberculosis, and the 
arabinan domain is structurally similar to that of AG, we investigated the potential dual 
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functionality of AftC. The formation of the arabinan domain of LAM requires an α(1→3) 
AraT resulting in the branched motif of LAM. By structural analysis of LAM from a M. 
smegmatis∆aftC mutant, we demonstrated that AftC carries dual functionality and is 
responsible for introducing 3,5-Araf branches into LAM, in addition to AG. Furthermore, it 
was shown by treating an M. smegmatis∆aftC mutant with EMB, that EmbC is involved in 
the very early steps of the LAM arabinan core synthesis and that truncation of this domain 
modulated the immunological properties of the molecule.  AftC-LAM exhibited enhanced 
pro-inflammatory activity due to its ability to activate TLR2, thus further work using this 
truncated LAM could shed light on the structure-function relationship of TLR2 activation by 
mycobacterial lipoglycans. It would be interesting to examine whether the generation of aftC 
mutants in M. bovis BCG and M. marinum is in fact feasible and if these could be used in 
infection studies involving mice and zebrafish, respectively.  
This study also characterised a further ORF from C. glutamicum encoding a distinct t-
rhamnopyranosyltransferase from the GT-C superfamily of glycosyltransferases, now termed 
RptA. Disruption of NCgl0543 in C. glutamicum and subsequent biochemical and molecular 
analyses demonstrated that the enzyme is responsible for the transfer of t-Rhap residues to 
the arabinan domain to form the branched 2,5-linked Araf motifs of C. glutamicum. The 
introduction of t-Rhap residues is probably related to either structural integrity or a 
mechanism to cap and end arabinan synthesis, providing a control point for the extent of 
mycolation of the "terminal" arabinan units. Cg-rptA shares approximately 40% sequence 
similarity with the putative M. tuberculosis protein Rv3779 and there are remarkable 
structural similarities, such as the high identity at the sequence level in the GT-C loop. 
Interestingly, within the final periplasmic region, there is also a similar stretch of amino acid 
residues and given that the carboxy terminal periplasmic domain is suggested to play a role 
in substrate recognition, we speculated that both Cg-RptA and the putative Rv3779 protein 
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recognise a related substrate, such as an arabinan oligosaccharide but utilising distinct sugar 
donors, since the putative protein, Rv3779, failed to complement C. glutamicum∆rptA. A 
recent investigation by Scherman et al. (2009) presented evidence that Rv3779 exhibited 
polyprenyl-phosphomannopyranose synthase activity. However, a very recent investigation 
carried out in the same laboratory presented conflicting data, which clearly establishes 
Rv3779 as a polyprenyl-phospho-N-acetylgalactosamine transferase, the enzyme responsible 
for modifying the interior 3,5-Araf branch motifs by the addition of terminal GalN units 
(Skovierova et al., 2010). Based on the findings reported in this thesis for RptA (Chapter 4), 
the latter is the more likely role of Rv3779 since its natural substrate is polyprenyl-phospho-
N-acetylgalactosamine (polyprenyl-P-GalNAc) for which the equivalent is polyprenyl-P-
Rhap in C. glutamicum (Chapter 4). Furthermore, the absence of GalN units in the AG of M. 
smegmatis correlates with a clear lack of a Rv3779 homolog in the M. smegmatis genome. 
Our apparent negative observation of a clear phenotypic change upon over expression of 
Rv3779 in M. smegmatis and the inability of Rv3779 to complement the C. glutamicum∆rptA 
mutant, presents conclusive evidence that C. glutamicum and M. tuberculosis share similar 
AG modifying activities. The role of GalN modifications in the AG of M. tuberculosis 
remains unknown. 
As noted previously, glycosyltransferases involved in galactan and early PIM biosynthesis 
utilise high-energy sugar donor substrates and belong to the GT-A/B family present in the 
cytoplasm of the cell. Upon transition from galactan to arabinan biosynthesis, and early PIM 
to higher PIM biosynthesis, there is a change to GT-C family of glycosyltransferases, which 
make use of polyprenol phosphate substrates (Liu & Mushegian, 2003; Berg et al., 2007).  
With this is mind and the fact that rhamnosyl residues are most likely added in the periplasm, 
we set about looking for lipid linked sugar donor akin to DPA (Wolucka et al., 1994) and 
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DPM (Gurcha et al., 2002; Yokoyoma & Ballou, 1989). This is the first report of a 
rhamnosylated monophosphodecaprenol, which is the substrate for RptA.  
To conclude, AftB and AftC represent novel AraTs in Corynebacterianeae, which are 
responsible for the addition of the terminal β(1→2) linked Araf residues and  branching 
α(1→3) Araf residues into arabinan, respectively. The identification of new cell wall 
biosynthetic drug targets is of great importance, especially with the emergence of MDR-TB 
and XDR-TB. Since AftB and AftC are EMB insensitive, these newly discovered DPA 
dependent AraTs represent promising candidates for further exploitation as potential drug 
targets. The disruption of the biosynthesis of mycobacterial AG and LAM formation by 
small molecule inhibition would potentially have a catastrophic effect on the structural 
integrity, composition and permeability of the TB cell wall. The molecular mechanism and 
biochemistry of the GT-C superfamily of glycosyltransferases are poorly understood. 
Considering that 80% of all pharmacological drug targets are located in the cytoplasmic 
membrane of cells, further investigation into these polytopic membrane bound enzymes is 
warranted. It is envisaged that the studies reported in this thesis could be expanded in terms 
of future experiments exploring: (i) over expression of recombinant 
arabinofuranosyltransferases, (ii) the development of a sensitive and selective AraT assay 
suitable for high-throughput screening of a chemical library, (iii) X-ray crystallographic 
structural studies, and (iv) in silico drug design. 
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6. Materials and Methods 
6.1. Chemicals, reagents and growth conditions 
All chemicals and solvents were purchased from Sigma-Aldrich (Dorset, UK), Biorad (CA, 
USA) and Fischer Chemicals (UK) unless otherwise stated, and were of AnalR grade or 
equivalent. Enzymes were obtained from Sigma-Aldrich (Dorest, UK), Roche (Lewes, UK) 
or New England Biolabs (Boston, USA) and were of the highest grade available. 
6.2. Bacterial growth conditions 
C. glutamicum ATCC 13032  and E. coli DH5αmcr were grown in Luria-Bertani broth (LB, 
Difco) at 30°C and 37°C, respectively. The recombinant strains generated in this thesis were 
grown on complex brain–heart infusion medium LBHIS (5 g tryptone, 5 g NaCl, 2.5 g yeast 
extract, 18.5 g brain heart infusion (Difco), and 90.1 g sorbitol per litre). Kanamycin and 
ampicillin were used at a concentration of 50 µg/ml. The minimal medium CGXII was used 
for C. glutamicum (Eggeling & Bott, 2005). Samples for lipid and cell wall analysis were 
harvested after reaching an OD 3, followed by a saline wash and freeze drying. 
M.  smegmatis strains were grown in tryptic soy broth (TSB; Difco), containing 0.05% 
Tween 80 (TSBT). M.  smegmatis and mycobacteriophages were also propagated on 
Middlebrook 7H9 broth (Difco), supplemented with 0.2% glycerol and 0.05% Tween 80.  
For phage infection experiments Tween 80 was omitted in all media. Solid media were made 
by adding 1.5% agar to the above-mentioned broths. The concentrations of antibiotics used 
for M.nsmegmatis were 100µg/ml- for hygromycin and 20µg/ml- for kanamycin.  
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6.2.1. Construction of C. glutamicum mutants 
6.2.1.1. Construction of C. glutamicumΔaftB and complementing strains 
M. tuberculosis H37Rv DNA was obtained from the NIH Tuberculosis Research Materials 
and Vaccine Testing Contract at Colorado State University. All mutant strains in C. 
glutamicum were constructed at Institute for Biotechnology Research Centre, Juelich, 
Germany.  
The vectors made were pMSX-Cg-aftB (NCgl2780), pMSX-Mt-aftB (Rv3805c), and 
pK19mobsac∆aftB (NCgl2780). To enable deletion of Cg-aftB, cross-over PCR was applied 
to generate the fragments carrying fused sequences adjacent to the gene in question. Cross-
over PCR was applied with primer pairs AB and CD (Table 1.4) and C. glutamicum genomic 
DNA as template. Both amplified products were used in a second PCR with primer pairs AD 
to generate a fragment consisting of sequences adjacent to Cg-aftB, which was blunt end-
ligated with SmaI-cleaved pK19mobsacB. All plasmids were confirmed by sequencing. The 
chromosomal deletion of Cg-aftB was performed, using two rounds of positive selection 
(Schafer et al., 1994), and its successful deletion was verified by use of different primer 
pairs. Plasmid pMSX-Mt-aftB and pMSX-Cg-aftB were introduced into C. glutamicumΔaftB 
by electroporation with selection to kanamycin resistance (25 µg/ml). 
To express M. tuberculosis aftB in C. glutamicum, the primer pair EF was used, with the 
restriction sites NdeI and XhoI underlined, using M. tuberculosis H37Rv chromosomal DNA 
as a template. The purified PCR fragment was ligated with accordingly digested pMSX to 
give pMSX-Mt-aftB. pMSX was prepared from pEKEx2 (Eikmanns et al., 1991) to generate 
a derivative providing an appropriate ribosome binding site together with a C-terminal His 
tag. It was created by the individual cleavage of pEKEx2 with NdeI and XhoI, each followed 
by Klenow treatment and religation. The intermediate construct was SalI/DraI-cleaved, 
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treated with mung bean nuclease, and ligated with the XbaI/MroI fragment from pET22b, 
which before use was treated with the Klenow fragment to eventually yield pMSX. To 
overexpress Cg-aftB, the primer pair GH was used to amplify C. glutamicum aftB, which was 
ligated with NdeI- and XhoI-cleaved pMSX to generate pMSX-Cg-aftB. 
Table 1.4: Primers used for the generation of knock-out mutants and complemented strains.  
Primer name Sequences (5’→3’) 
A ACGCCAAGCTTTGCTAGTCGCTGCGTTTGGTTC 
B CCCATCCACTAAACACTGGGGGCTAAACGTCATGAG 
C CCCATCCACTAAACACTGGGGGCTAAACGTCATGAG 
D GCCAGTGAATTCGGCGCGCAGCGTTGGTATC 
E GTATGAGCATATGGTCCGGGTCAGCTTGTGG 
F ATTGCCCCTCACTCGAGCTCCCGCGGTGGCGGG 
G ATGTGGCCATATGACGTTTAGCCCCCAGCGTC 
H TGTTTACTCGAGCTGAGAGCTATATAAAGGTTCTCCGC 
I CGTTAAGCTTCGATCTTGTTGATGTGTGGCATCACACG 
J CCCATCCACTAAACTTAAACAGCGCCATCAACAACATGG 
K TGTTTAAGTTTAGTGGATGGGTGATCCAACGCACGACCATC 
L GCATGGATCCACGCATACCGAGGGAAAGATCTTC 
M CGTTGAATTCGGTTCCAGTAGCACCTGCGAAAGG 
N CCCATCCACTAAACTTAAACACAATCCATAGTGTCGTCAGCATC 
O TGTTTAAGTTTAGTGGATGGGCCGGATCCAACGAAGCC 
P GCTTTCTAGAATGCGGGCAACCGCGCAGTGTG 
Q GATGAATCTAGAAAGGGAGATATAGATGCTGACGACACTATG 
R CTACTTTCTAGATTAGTTAGGGACCGTATGCGGC 
S GATAATCTAGAAGGGAGATATAGGTGGGCCTGTGGTTCG 
T GCCGTACTTTCTAGACTAGGAGTGTGTTGCTGCG 
U GAACCGCAGGTGTATGAAGCACACGTG 
V GGCAGATTACGCTGCAGTTCTTTCTGCG 
MS2785LL TTTTTTTTCCATAAATTGGATCCGCTGACCGACCTCATC 
MS2785LR TTTTTTTTCCATTTCTTGGCGAGCCCGAGCTTGAAGTTG 
MS2785RR TTTTTTTTCCATAGATTGGTTCCTGCTGCTGTCCCTTGG 
MS2785RR TTTTTTTTCCATCTTTTGGCGAACTCAGCGGCGATTCAC 
Site-specific mutations were introduced in Mt-aftB using appropriate mutagenic primers and 
pMSX-Mt-aftB as the double-stranded template (QuikChange kit, Stratagene). After linear 
amplification of the newly synthesized strands and DpnI digestion of parental strands, 
plasmids pMSX-Mt-aftB-D29A and pMSX-Mt-aftB-D30A were generated carrying the 
mutations as indicated. All plasmids were verified by sequencing. 
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6.2.1.2. Construction of C. glutamicumΔaftC and complementing strains 
The genes analysed were Rv2673 and NCgl1505 from M. tuberculosis and C. glutamicum, 
respectively, termed aftC. To construct the deletion vector pK19mobsacBDaftC (NCgl1822), 
cross-over PCR was applied with primer pairs IJ and KL and C. glutamicum genomic DNA 
as template. Both amplified products were used in a second PCR with primer pairs IL to 
generate a 656 bp fragment consisting of sequences adjacent to Cg-aftC, which was ligated 
with BamHI–HindIII-cleaved pK19mobsacB. All plasmids were confirmed by sequencing. 
The chromosomal deletion of Cg-aftC was performed using two rounds of positive selection 
(Schafer et al., 1994) and its successful deletion was verified by use of two different primer 
pairs. 
6.2.1.3. Construction of C. glutamicumΔrptA and complementing strains 
The vectors made were pVWEx-Cg-rptA, pVWEx-Rv3779, and pK19mobsacBrptA. To 
construct the latter deletion vector, crossover PCR was applied with primer pairs MN and OP 
and C. glutamicum genomic DNA as a template. Both amplified products were used in a 
second PCR with primer pair AD to generate a 587-bp fragment consisting of sequences 
adjacent to NCgl0543, which was treated with EcoRI and XbaI and ligated with 
pK19mobsacB to yield pK19mobsacBrptA. To enable the expression of NCgl0543, the 
primer pair QR was used to amplify rptA of C. glutamicum, which was treated with XbaI and 
ligated to yield pVWEx-Cg-rptA. The primer pair ST was used to amplify Rv3779 from M. 
tuberculosis. The resulting fragment was treated with XbaI to yield pVWEx-Rv3779. The 
correct orientation and the sequence identities were confirmed for all plasmids by sequencing.  
The chromosomal deletion of the NCgl0543 gene was performed, as described previously, 
using two rounds of positive selection (Schafer et al., 1994) and its successful deletion was 
verified by use of primer pair UV. This yielded the expected fragment of 837 bp in the 
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deletion mutant and was termed C. glutamicum rptA and a fragment of 3,179 bp in wild-type 
C. glutamicum. 
6.2.2. Construction of M. smegmatis mutants 
6.2.2.1. Construction of M. smegmatis∆aftC and complementing strains 
Approximately 1 kb of upstream and downstream flanking sequences of MSMEG2785 were 
PCR amplified from M. smegmatis mc2155 genomic DNA using the primer pairs MS2785LL/ 
MS2785LR and MS2785RL/MS2785RR, respectively. Following restriction digestion of the 
primer incorporated Van91I sites, the PCR fragments were cloned into Van91I-digested 
p0004S. The ligation mixture was transformed into E. coli Top10 cells and selected on LB 
agar with hygromycin at 37° overnight.  Recovered plasmids were digested with PacI and 
ligated with PacI-digested phAE159 to yield the knockout plasmid pDMSMEG2785. The 
ligated knock-out plasmid and the temperature-sensitive mycobacteriophage phAE159 were 
then packaged into λ phage heads and transduced into E. coli HB101, as described previously 
(Bardarov et al., 2002), to yield phasmid DNA of the knockout phage phDMSMEG2785. The 
recovered phasmid was then transformed into M. smegmatis via electroporation and cells 
grown at 30°C for 3 days to yield phage particles. Generation of high titre phage particles 
involved 200 µl of 0.8 OD600nm culture of M. smegmatis mixed into 5 ml molten 7H9 soft 
agar and overlaid on a basal layer of 7H9 agar. The phage stock was serially diluted (10-1 - 
10-10) with MP buffer (50mM Tris.HCl pH7.8, 150mM MgSO4, 2mM CaCl2) and 10 µl of 
each dilution spotted onto the solidified overlay of M. smegmatis. Plates were incubated at 
the permissive temperature of 30°C for 3 days, after which, the plaque forming units were 
counted and phage titre calculated (pfu = number of pfu in spot x dilution factor x 100).  
Original phage stock was then diluted to yield approximately 500 plaques per plate and 
mixed with 200 µl M. smegmatis in molten 7H9 agar, which was overlaid on solid 7H9 agar. 
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Plates were incubated at 30°C for 3 days, resulting in a “lacy pattern”.  The high titre phage 
was then collected and filtered through a 0.45µm filter (Stover et al., 1991). 
To perform specialized transduction, M. smegmatis cultures were grown to an OD600nm 0.8 in 
50 ml of TSB (0.05% Tween 80). Harvested cells were then washed three times with 50ml 
MP buffer and finally resuspended in 5 ml MP buffer. 0.5 ml of cells was then mixed with 
0.5 ml of the optimum high titre lysate (1010 pfu/ml) and incubated overnight at 37°C (Stover 
et al., 1991; Bardarov et al., 2002). Cells were harvested and resuspended in 25 ml TSB and 
recovered overnight at 37°C, followed by plating onto TSB agar plates with hygromycin B. 
Plates were incubated at 37°C for 1-2 weeks. Deletion of MSMEG2785 in one hygromycin-
resistant transductant was confirmed by Southern blot. To enable expression of MSMEG2785 
and Rv2673, in the deletion mutant, these were amplified using primer pairs designed for 
subsequent cloning into the mycobacterial-shuttle vector pMV261 (Stover et al., 1991). All 
cloned fragments were verified by sequencing. 
6.2.2.2. Southern blot analysis 
Southern blot analyis was used to confirm gene knock-out mutants and was performed as 
specified in the Roche Applied Science kit manual. SacI digested genomic DNA from M. 
smegmatis wild-type and M. smegmatisΔaftC strains were subjected to gel electrophoresis to 
separate the fragments, producing a laddering effect. In the mutant strain the aftC gene had 
been replaced with a hygR gene. There were two SacI restriction sites in the wild-type and 
three in the mutant due to the presence of the hygR gene marker. PCR products of 1 kb of 
aftC left and right flanking regions were used as probes. Following SacI digestion, one 
fragment was observed for wild-type and two fragments for M. smegmatisΔaftC. Following 
gel electrophoresis, the gel was depurinated (0.2M HCL, 15min) and denatured (1.5M NaCl, 
0.5M NaOH, 15 min). The gel was then washed to return to pH 7.4 and the DNA 
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subsequently transferred to positively charged nitrocellulose membrane via capillary action 
with 20 x SSC (3M sodium citrate. pH 7.0). DNA on membrane was then covalently bound 
by UV-crosslinking. The membrane was finally rinsed with distilled water and air-dried. 
Probe preparation involved boiling, snap freezing and labeling with digoxigenin-dUTP, using 
the DIG High Prime DNA labeling and Detection Start Kit (Roche), as described in the kit 
manual. The membrane was exposed to the probe at 65°C overnight, followed by washing 
and finally immunodetected with the antibody for 30 min at 25°C.  The hybridized probes 
were visualized with the chemiluminescence.  
6.2.3. mAGP purification procedures 
After cultivation the thawed C. glutamicum/M. smegmatis cells were resuspended in 
phosphate buffered saline containing 2% Triton X-100 (pH 7.2) and disrupted by sonicaton 
(MSE Soniprep 150, 12 micron amplitude, 60s ON, 90s OFF for 10 cycles, on ice). The cell 
debris was centrifuged at 27,000 xg (Besra et al., 1995; Daffé et al., 1990). The pelleted 
material was extracted three times with 2% SDS in phosphate buffered saline at 95°C for 1 hr 
to remove associated proteins, successively washed with water, 80% (v/v) acetone in water, 
and acetone, and finally dried under compressed N2 to yield a highly purified cell wall 
preparation (Besra et al., 1995; Daffé et al., 1990).  
6.2.3.1. Acid hydrolysis and alditol acetate derivatisation 
Cell wall preparations (1 mg) were hydrolysed in 250 µl of 2 M trifluoroacetic acid (TFA) at 
120°C for 2 h (Besra et al., 1995; Daffé et al., 1990). After drying under compressed N2, 
sugar residues were reduced with 50 µl NaB2H4 (10 mg/ml in ethanol:1M NH3 OH (1:1)) and 
the resultant alditols per-O-acetylated using 100µl acetic anhydride with heating  at 100 °C 
for 1 hr. After cooling, the reaction mix was combined with 100µl toluene and dried under 
compressed N2. The resulting alditol acetates were partitioned between 2 ml H2O and 2 ml 
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CHCl3, mixed, centrifuged and the organic phase dried under compressed N2. Alditol 
acetates were examined by GC as described in section 6.2.4. 
6.2.3.2. Glycosidic linkage analysis 
Cell wall preparations (10 mg) were suspended in 0.5 ml dimethyl sulfoxide (anhydrous) and 
100 µl of 4.8 M dimethyl sulfinyl carbanion (generated by mixing NaH (2.4 g) with 
anhydrous DMSO (20 ml) and heated at 50°C with strirring for 3 h) (Besra et al., 1995; 
Daffé et al., 1990). The reaction mixture was stirred at room temperature for 1 hr and then 50 
µl of CH3I was slowly added and the suspension stirred for a further 1 hr. A further 100 µl of 
4.8 M dimethyl sulfinyl carbanion and 50 µl CH3I was added and the process repeated for a 
total of three times. The reaction mixture was then diluted with an equal volume of water and 
the entire contents dialysed against 10 L of water, overnight (1000 kDa MWCO Spectra/Por 
membrane 6, Spectrum labs, UK). The dialysed retentate was dried in a Savant SpeedVac 
SC110. The resulting per-O-methylated cell wall samples were resuspended in 2 ml of 
H2O/DMSO (1:1, v/v) and applied to a C18 Sep-Pak cartridge (Alltech, Deerfield, USA), 
which was pre-equilibrated sequentially with 20 ml ethanol, 5 ml H2O, 5 ml acetonitrile, 5 ml 
ethanol and 10 ml H20. The material bound to the Sep-Pak was washed with 5 ml H2O, 8 ml 
H2O/acetonitrile (4:1, v/v) and then eluted with 2 ml acetonitrile and 2 ml ethanol, the latter 
eluants were pooled and dried in a Savant SpeedVac SC110. The per-O-methylated cell walls 
were hydrolysed, reduced and per-O-acetylated as described in chapter 6.2.3.1. Per-O-
methylated and per-O-acetylated alditol acetates were examined by GC/MS as described in 
chapter 6.2.4 
6.2.4. GC and GC/MS 
GC analysis was performed using a Thermoquest Trace GC 2000. Samples were injected in 
the splitless mode. The column used was a DB225 (Supelco) ID 0.10 mm, length 10 m and df 
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0.05 µm. The oven was programmed to hold at an isothermal temperature of 275 °C for a run 
time of 15 min.  
GC/MS was carried out on a Finnigan Polaris/GCQ PlusTM. The column used was a BPX5 
(Supleco). Injector temperature was set at 50ºC, held for 1 min and then increased to 110ºC at 
20ºC/min. The oven was held at 110ºC then ramped to 290ºC at 8ºC/min and held for 5 min 
to ensure all the products had eluted from the column. All the data were collected and 
analyzed using Xcaliber (v.1.2) software. 
6.3. Extraction and visualisation of lipids 
6.3.1. Cell wall associated lipid extraction 
Cells were grown as described in section 6.2, harvested, washed and freeze-dried. Cell wall 
associated free lipids were extracted twice from 100 mg of dried cells using 2 ml of 
CHCl3/CH3OH/H2O (10:10:3, v/v/v) for 3 hr at 50 °C. Organic extracts were combined with 
1.75 ml CHCl3 and 0.75 ml H2O, mixed and centrifuged at 1500 x g for 5 mins. The lower 
organic phase was recovered, back washed twice with 2 ml of CHCl3/CH3OH/H2O (3:47:48, 
v/v/v), dried and resuspended with 200 µl of CHCl3/CH3OH/H2O (10:10:3, v/v/v). A 10 µl 
aliquot was subject to TLC analysis, using silica gel plates (5554 silica gel 60F254, Merck) 
developed in CHCl3/CH3OH/H2O (60:16:2, v/v/v). TLC plates were charred, using 5% 
molybdophosphoric acid (MPA) in ethanol at 100oC to reveal free lipids. MPA was used for 
the detection of all lipids. Lipid species were revealed by charring the plates with a heat gun. 
α-Naphthol (α-NAP) was used for the detection of all glycolipids. α-NAP solution was 
prepared from 6 g of α -naphthol dissolved in 25 ml of sulfuric acid and 450 ml ethanol. 
Glycolipid species were revealed by gently charring the plates with a heat gun. The Dittmer 
and Lester reagent was prepared according to the modified procedure of Muthing & Radloff 
(1998) for the detection of phospholipids and glycophospholipids. Solution A consisted of 40 
Chapter 6  Materials and Methods 
160 
g molybdenum VI oxide dissolved in 1 L of boiling sulfuric acid, solution B contained 1.7 g 
of solid molybdenum dissolved into 0.5 L of solution A. Solutions A and B were then mixed 
with H2O to give a final solution in the ratio of solution A:solution B:H2O, 1:1:4. Plates were 
sprayed with the stain and left to develop for 5 min at room temperature. 
6.3.2. Exported (media filtrate) lipid extraction 
Exported lipids were analysed in a similar manner to that in C. glutamicum cells were 
cultured as described above. Once the A600 reached ~0.5, cultures were labelled with 1 µCi 
[1,2-14C]acetic acid (specific activity 50-62 mCi/mmol, GE Healthcare, UK) and further 
incubated for 8 hr. Cells were harvested by centrifugation at 27,000 x g for 30 min and the 
supernatant carefully removed and dried using a Savant SpeedVac SC110. The residue was 
resuspended into 2 ml of CHCl3/CH3OH/H2O (10:10:3, v/v/v) for 3 hr at 50 °C. Organic 
extracts were combined with 1.75 ml CHCl3 and 0.75 ml H2O, mixed and centrifuged at 
1,500 x g for 5 mins. The lower organic phase was recovered, back washed twice with 2 ml 
of CHCl3/CH3OH/H2O (3:47:48, v/v/v), dried and resuspended with 200 µl of 
CHCl3/CH3OH/H2O (10:10:3, v/v/v). An aliquot of each extraction was subjected to 
scintillation counting using 10 ml EcoScint and analysed by TLC using silica gel plates 
(5554 silica gel 60F254, Merck) developed in CHCl3/CH3OH/H2O (60:16:2, v/v/v). TLCs 
were exposed to X-ray film (Kodak X-Omat) for 2 days to visualise radiolabelled lipids by 
autoradiography.  
6.3.3. Cell wall bound lipid extraction 
Cells were grown as described, harvested, washed and freeze-dried. Cells (100 mg) were 
extracted by two consecutive extractions with 2 ml of CHCl3/CH3OH/H2O (10:10:3, v/v/v) 
for 3 hr at 50°C. The bound lipids from the de-lipidated extracts were released by the 
addition of 2 ml of 5% aqueous solution of tetra-butyl ammonium hydroxide (TBAH), 
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followed by overnight incubation at 100 °C. After cooling, water (2 ml), CH2Cl2 (4 ml) and 
CH3I (500 µl) were added and mixed thoroughly for 30 min. The lower organic phase was 
recovered following centrifugation and washed three times with water (4 ml), dried and 
resuspended in diethyl ether (4 ml). After centrifugation, the clear supernatant was again 
dried and resuspended in CH2Cl2 (100 µl). An aliquot (10 µl) from each strain was subjected 
to TLC, using silica gel plates (5554 silica gel 60F254, Merck), developed in petroleum 
ether/acetone (95:5, v/v) and charred using 5% MPA in ethanol at 100 oC to reveal 
CMAMES/MAMES and compared to known standards (Gande et al., 2004). 
6.3.4. Analysis of AftB muteins  
Recombinant C. glutamicum strains deleted of the chromosomal Cg-aftB copy, but carrying 
either pMSX, pMSX-Mt-aftB, pMSX-Mt-aftB-D29A or pMSX-Mt-aftB-D30A were each 
grown in LB up to an OD of 4. Cells were harvested by centrifugation, washed and 
resuspended in 30 ml of 50 mM TrisHCl pH 7.4 buffer, containing 200 mM NaCl and 50 
mM imidazole, and disrupted by probe sonication. Centrifugation at 27,000 x g resulted in a 
clear supernatant, which was applied to a 1 ml HiTrap™ Chelating HP column (GE 
Healthcare) using an ÅTKA chromatography system. The column was initially washed with 
10 ml of the aforementioned buffer and bound proteins subsequently eluted with 2 ml of the 
same buffer, but containing 500 mM imidazole. Eluted proteins were precipitated, dried, and 
resuspended in 10 µl loading buffer and SDS-PAGE carried out on a 10% polyacrylamide 
gel, which was subsequently stained using 0.05% Coomassie-G250 in 10% acetic acid and 
25% isopropanol. Bands of interest were excised and subjected to in-gel digestion with 
trypsin before peptide mass fingerprinting. Peptides were extracted by sequential addition of 
water (12 µl) and 0.1% (v/v) trifluoroacetic acid (TFA) in 30% (v/v) acetonitrile (10 µl), and 
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analyzed manually, using an Applied Biosystems Voyager STR MALDI-TOF mass 
spectrometer. 
6.4. Extraction and Purifications of lipoglycans 
Lipoglycans were extracted from delipidated cells as described previously (Nigou et al., 
1997; Mishra et al., 2008). Dried cells were resuspended in water, disrupted by sonication 
(MSE Soniprep 150, 12 micron amplitude, 60s ON, 90s OFF for 10 cycles, on ice) and an 
equal volume of ethanol was added and the mixture heated under reflux, followed by 
centrifugation and recovery of the supernatant. This extraction process was repeated five 
times and the combined supernatants, containing lipoglycans, neutral glycans and proteins 
were dried, followed by hot-phenol-H2O treatment. The aqueous phase was dialysed against 
water, performed using a low molecular weight cut off dialysis tubing, (Spectra/Por 
membrane 6, MWCO 3,500 kDA from Spectrum Labs). The retentate was dried, resuspended 
in water and digested with α-amylase, DNase, RNase, chymotrypsin and trypsin, and 
dialysed once again to remove residual impurities and enzymes. 
The crude lipoglycan extract was dried and resuspended in buffer A (50 mM ammonium 
acetate and 15% propan-1-ol) and subjected to Octyl Sepharose CL- 4B HIC (2.5 cm x 50 
cm) (Leopold & Fischer, 1993). The column was washed initially with 4 column volumes of 
buffer A to ensure removal of neutral glycans followed by buffer B (50 mM ammonium 
acetate and 50% propan-1- ol). The eluent was collected and concentrated to approximately 1 
ml and precipitated using 5 ml of ethanol. The sample was dried using a Savant Speedvac 
and then resuspended in buffer C (0.2 M NaCl, 0.25% sodium deoxycholate (w/v), 1 mM 
EDTA and 10 mM Tris-HCl, pH 8) to a final concentration of 200 mg/ml. 
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The sample was gently mixed and left to incubate for 48 h at room temperature. The sample 
was then loaded onto a 200 ml Sephacryl S-200 column previously equilibrated with buffer 
C. The sample was eluted with 400 ml of buffer C at a flow rate of 3 ml/h, collecting 1.5 ml 
fractions. 
The fractions were monitored by SDS-PAGE using Pro-Q emerald glycoprotein stain and 
individual fractions pooled and dialyzed extensively against buffer D (10 mM Tris-HCl, pH 
8, 0.2 M NaCl, 1 mM EDTA) for 72 h with frequent changes of buffer. The samples were 
further dialyzed against deionized water for 48 h with frequent changes of water, lyophilized 
and stored at - 20°C. 
6.4.1. NMR spectroscopic analysis of WT-LAM and AftC-LAM.  
NMR spectra of LAM samples were recorded on a Bruker DMX-500 equipped, with a 
double resonance (1H/X)-BBi z-gradient probe head. All samples were exchanged in D2O 
(D, 99.97% from Euriso-top, Saint-Aubin, France), with intermediate lyophilization, and then 
dissolved in 0.5 ml D2O and analyzed at 313K. The 1H and 13C NMR chemical shifts were 
referenced relative to internal acetone at 2.225 and 34.00 ppm, respectively. All the details 
concerning NMR sequences used and experimental procedures were described previously 
(Gilleron et al., 1999; Gilleron et al., 2000). 
6.4.2. SDS PAGE 
The method used in this study was the discontinuous gel method using a Hoefer “mighty 
small” SE200 vertical slab gel system. Resolving gels of either 12 % or 15% acrylamide 
(w/v) and a stacking gel of 6 % (w/v) acrylamide were prepared and cast in the apparatus 
according to the manufacturer’s specifications and and run at 300 mV and 20 mA/gel until 
completion. Lipoglycan samples (10 µg) were analysed on 15% polyacrylamide gels and 
Chapter 6  Materials and Methods 
164 
visualised using Pro-Q Emerald Glycoprotein stain (Invitrogen) according to the 
manufacturer’s protocol. Protein samples (usually 10–20 µg) were run on 12% 
polyacrylamide gels and visualised by immersing gels in 20 ml Coomassie brilliant blue R-
250 (CBB) stain (5 % glacial acetic acid, 0.0025 % CBB (w/v), 50 % methanol) and left for 
3-4 hr on a rotating platform. Excess stain was removed by rinsing in destaining solution 
(10% glacial acetic acid in 40% methanol).  
6.5. Cell free [14C]-labeling assays 
6.5.1. Preparation of C. glutamicum and M. smegmatis membranes 
Pelleted cells, wet weight 5 g were resuspended in 50 mM MOPS (pH 7.9), 5 mM β-
mercaptoethanol and 10 mM MgCl2. Resuspended cells were sonicated (MSE Soniprep 150, 
12 micron amplitude, 60s ON, 90s OFF for 10 cycles, on ice), centrifuged at 23000 x g for 20 
mins at 4°C, and the resulting supernatant re-centrifuged at 100,000 x g for 90 mins at 4°C to 
isolate cell membranes which were collected and concentrated to a protein concentration of 
15-20 mg/ml in 50 mM MOPS (pH 7.9), 10 mM MgSO4, 5 mM β-mercaptoethanol (Chapter 
6.5.3). 
6.5.2. Preparation of C. glutamicum and M. smegmatis cell wall material 
Cells (10 g) were resuspended in 35 ml of 50 mM MOPS (pH 7.9), 10 mM MgSO4, 5 mM β-
mercaptoethanol and subject to probe sonication (MSE Soniprep 150, 12 micron amplitude, 
60s ON, 90s OFF for 10 cycles, on ice). The cell slurry was centrifuged at 27, 000 x g for 20 
min at 4 °C, the pellet was recovered and the resulting supernatant further centrifuged at 
100,000 x g for 90 min at 4 °C. The pellet from the 27, 000 x g spin was resuspended in 24 
ml 50 mM MOPS (pH 7.9), 10 mM MgSO4, 5 mM β-mercaptoethanol and 32 ml of Percoll 
(Sigma-Aldrich), mixed thoroughly and centrifuged at 27, 000 x g for 60 min at 4 °C. The 
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upper band (corresponding to C. glutamicum cell wall “P60” material) was removed, washed 
with 50 mM MOPS (pH 7.9), 10 mM MgSO4, 5 mM β -mercaptoethanol with further 
centrifugation to remove Percoll and the final cell wall fraction resuspended in 50 mM 
MOPS (pH 7.9), 10 mM MgSO4, 5 mM β-mercaptoethanol to a final protein concentration of 
8 – 10 mg/ml (Chapter 6.5.3). 
6.5.3. Estimation of protein concentration 
The concentration of total protein present in cell wall material and membranes were 
measured using the Bicinchoninic protein assay (BCA) kit (Pierce). The assay was performed 
according to the manufacturer’s protocol. The assay was calibrated over the range 2.5 – 5.0 
µg/ml by using a range of standards derived from a 2 mg/ml stock solution of bovine serum 
albumin (BSA) (Pierce). Samples, standards and blanks were assayed in triplicate. Samples 
were also diluted 1 in 5 to ensure a reading was obtained within the limits of the standard 
curve. The assay was incubated at 37 °C for 30 min and the colorimetric change was 
measured at 562 nm. 
6.5.4. Arabinofuranosyltransferase assays 
6.5.4.1. Arabinofuranosyltransferase activity with membrane preparations of C. 
glutamicum, C. glutamicum∆aftB, and C. glutamicum∆aftB pMSX-Mt-aftB  
Membranes were prepared as described previously (Alderwick et al., 2006; Lee et al., 1997) 
and resuspended in 50 mM MOPS (pH 7.9), containing 5 mM β-mercaptoethanol and 10 mM 
MgCl2 (buffer A) to a final concentration of 15-10 mg/ml. The neoglycolipid acceptor α-D-
Araf-(1→5)-α-D-Araf-O-C8 (stored in C2H5OH) and DP[14C]A (Lee et al., 1995; Lee et al., 
1998) (stored in CHCl3/CH3OH, 2:1, v/v) were aliquoted into a 1.5 ml Eppendorf tube to a 
final concentration of 2 mM and  200,000 cpm (90 µM), respectively, and dried under 
nitrogen. The basic arabinofuranosyltransferase assay was carried out as described previously 
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(Lee et al., 1997) with modifications. IgePalTM (Sigma-Aldrich) was added (0.1%, v/v) with 
the appropriate amount of buffer A (final volume 80 µl). Tubes were sonicated for 15 min to 
resuspend lipid linked substrates and then mixed with the remaining assay components, 
which included membrane protein (1 mg) from either C. glutamicum, C. glutamicumΔaftB or 
C. glutamicum∆aftB pMSX-Mt-aftB, 1 mM ATP, 1 mM NADP and in some cases EMB (0-1 
mg/ml). Assays were incubated for 1 h at 37 °C and quenched by the addition of 533 µl 
CHCl3/CH3OH (1:1, v/v). After mixing and centrifugation at 27,000 x g for 15 min at 4 °C, 
the supernatant was removed and dried under nitrogen. The residue was then resuspended in 
700 µl of CH3CH2OH/H2O (1:1, v/v) and loaded onto a 1 ml SepPak strong anion exchange 
cartridge (Supelco), pre-equilibrated with CH3CH2OH/H2O (1:1, v/v). The column was 
washed with 2 ml CH3CH2OH and the eluate collected, dried and partitioned between the 
two phases, arising from a mixture of n-butanol (3 ml) and water (3 ml). The resulting 
organic phase was recovered following centrifugation at 3,500 x g and the aqueous phase 
again extracted twice with 3 ml of water-saturated n-butanol. The pooled extracts were back-
washed twice with n-butanol-saturated water (3 ml). The n-butanol fraction was dried and 
resuspended in 200 µl n-butanol. The extracted radiolabeled material was quantified by liquid 
scintillation counting using 10 % of the labelled material and 5 ml of EcoScintA (National 
Diagnostics, Atlanta). The incorporation of [14C]Araf was determined by subtracting counts 
present in control assays (incubations in the absence of acceptor). The remaining labeled 
material was subjected to TLC using silica gel plates (5735 silica gel 60F254, Merck) 
developed in CHCl3:CH2OH:H2O:NH4OH (65:25:3.6:0.5, v/v/v/v). TLC-autoradiograms 
were obtained by exposing TLCs to Kodak X-Omat film for 3 days. 
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6.5.4.2. Analysis of arabinofuranosytransferase reaction products prepared   from C. 
glutamicum and C. glutamicum∆aftB membranes 
Large-scale reaction mixtures containing cold DPA (200 µg, 0.75 mM) (Lee et al., 1997) and 
50 mM of the acceptor α -D-Araf-(1→5)-α-D-Araf-O-C8 were mixed and given an initial 
incubation at 37 °C with membranes prepared from either C. glutamicum (EMB also added 
to reaction mixtures at a concentration of 100 µg/ml) or C. glutamicum∆aftB for 1 h. The 
assays were replenished with fresh membranes (1 mg) and re-incubated for 1 h at 37 °C with 
the entire process repeated thrice. Products were extracted from reaction mixtures by n-
butanol/water phase separation as described earlier to extract products. Products were applied 
to preparative TLC plates, developed in CHCl3:CH3OH:H2O:NH4OH (65:25:3.6:0.5, v/v/v/v) 
and sprayed with 0.01% 1,6-diphenylhexatriene in petroleum-ether:acetone (9:1, v/v), and 
the products localized under long-wave (366 nm) UV light (Lee et al., 1997). The plate was 
then re-developed in toluene to remove the reagent and the bands recovered from the plates 
by extraction with n-butanol. The butanol phases were washed with water saturated with n-
butanol and the dried products subjected to 1H-NMR, ES-MS and GC/MS as previously 
described (Lee et al., 1997). 
6.5.4.3. Arabinofuranosyltransferase activity with membrane preparations of M. 
smegmatis, M. smegmatis pMV261-Mt-aftC, M. smegmatis∆aftC and M. 
smegmatis∆aftC pMV261-Mt-aftC 
Membranes were prepared as described previously (Lee et al., 1997; Alderwick et al., 2006a) 
and re-suspended in 50 mM MOPS (pH 7.9), containing 5 mM β-mercaptoethanol and 
10mM MgCl2 (buffer A) to a final concentration of 15–10 mg/ml. -The neoglycolipid 
acceptors used in this study were α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-Araf-(1→5)-α-D-
Araf-(1→5)-α-D-Araf-O-(CH2)8NH2 (Ara5,) and α-D-Araf-(1→5)-α-D-Araf-O-(CH2)7CH3 
(Ara2) (Lee et al., 1995; 1998). The acceptors (either Ara2 or Ara5) and DP[14C]A (Lee et al., 
1995; 1998) (stored in CHCl3/CH3OH, 2:1, v/v) were aliquoted into 1.5 ml Eppendorf tubes 
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to a final concentration of 2mM and 200 000 cpm (90 mM), respectively, and dried under 
nitrogen. The arabinofuranosyltransferase assay was carried out as described previously (Lee 
et al., 1997) with modifications. IgePalTM (Sigma-Aldrich) was added (0.1%, v/v) with the 
appropriate amount of buffer A (final volume 80 ml). Tubes were sonicated for 15 min to re-
suspend lipid linked substrates and then mixed with the remaining assay components, which 
included membrane protein from either M. smegmatis, M. smegmatis∆aftC, M. smegmatis 
pMV261-Mt-aftC and M. smegmatis∆aftC pMV261-Mt-aftC. 
M. smegmatis pMV261-Mt-aftC M. smegmatis∆aftC or M. smegmatis∆aftC pMV261-Mt-
aftC (1 mg), 1 mM ATP, 1 mM NADP and in some cases EMB (0–1 mg ml-1). Assays were 
incubated for 1 h at 37°C and quenched by the addition of 533 ml CHCl3/CH3OH (1:1, v/v). 
After mixing and centrifugation at 27 000 g for 15 min at 4°C, the supernatant was removed 
and dried under nitrogen. The residue was then re-suspended in 700ml of CH3CH2OH/H2O 
(1:1, v/v) and loaded onto a 1 ml SepPak strong anion exchange cartridge (Supelco), pre-
equilibrated with CH3CH2OH/H2O (1:1, v/v). The column was washed with 2 ml 
CH3CH2OH and the eluate collected, dried and partitioned between the two phases arising 
from a mixture of n-butanol (3 ml) and water (3 ml). The resulting organic phase was 
recovered, following centrifugation at 3500 g, and the aqueous phase again extracted twice 
with 3 ml of water- saturated n-butanol. The pooled extracts were back-washed twice with n-
butanol-saturated water (3 ml). The n-butanol fraction was dried and re-suspended in 200 ml 
butanol. The extracted radiolabelled material was quantified by liquid scintillation counting, 
using 10% of the labelled material and 5 ml of EcoScintA (National Diagnostics, Atlanta). 
The incor- poration of [14C]Araf was determined by subtracting counts present in control 
assays (incubations in the absence of acceptor). The remaining labelled material was 
subjected to thin-layer chromatography (TLC) using either isopropanol/ acetic acid/water 
(8:1:1, v/v/v) for the assays utilizing the Ara5 acceptor or CHCl3/CH2OH/H2O/NH4OH 
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(65:25:3.6:0.5, v/v/v/v) in the case of the Ara2 acceptor on aluminum- backed Silica Gel 60 
F254 plates (Merck, Darmstadt, Germany). Autoradiograms were obtained by exposing 
TLCs to X-ray film (Kodak X-Omat) for 3 days. 
6.5.4.4. Characterization of a(1→3)-arabinofuranosyltransferase activity with 
membranes prepared from M. smegmatis, M. smegmatis∆aftC and M. 
smegmatis∆aftC pMV261-Mt-aftC 
Large-scale reaction mixtures containing cold DPA (200 mg, 0.75 mM) (Lee et al., 1997) 
and 50 mM of the acceptor Ara5 were mixed and given an initial incubation at 37°C with 
membranes prepared from either M. smegmatis, M. smegmatis∆aftC or M. smegmatis∆aftC 
pMV261-Mt-aftC for 1 h. The assays were replenished with fresh membranes (1 mg) and re-
incubated for 1 h at 37°C with the entire process repeated thrice. Products were extracted 
from reaction mixtures by n-butanol/water phase separation as described earlier to extract 
products. Products were applied to preparative TLC plates, developed in isopropanol/acetic 
acid/water (8:1:1, v/v/v) and sprayed with 0.01% 1,6- diphenylhexatriene in petroleum-
ether/acetone (9:1, v/v), and the products localised under long-wave (366 nm) UV light (Lee 
et al., 1997). The plate was then re-developed in toluene to remove the reagent and the bands 
recovered from the plates by extraction with n-butanol. The n-butanol phases were washed 
with water saturated with n-butanol and the dried products subjected to GC (Sassaki et al., 
2005) and GC/MS as described (Lee et al., 1997; Alderwick et al., 2006a). 
6.5.4.5. [14C]-carbohydrate labeling of C. glutamicum and C. glutamicumΔrptA  
glycolipids. 
Cells (10 g) from C. glutamicum and C. glutamicumΔrptA were resuspended in 35 mL of 50 
mM MOPS (pH 7.9), 10 mM MgSO4, 5 mM β-mercaptoethanol (buffer A) and subjected to 
probe sonication for 60 s on and 90 s off (repeated for a total of 10 cycles). The cell slurry 
was centrifuged at 27,000  g for 20 min at 4°C; the pellet was recovered and the resulting 
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supernatant further centrifuged at 100,000   g for 90 min at 4°C. Purified C. glutamicum 
membranes were recovered and resuspended in buffer A to a final concentration of 15–20 
mg/mL. The pellet from the 27,000  g spin was resuspended in 24 mL of buffer A and 32 
mL of Percoll, mixed thoroughly, and centrifuged at 27,000g for 60 min at 4°C. The upper 
band (corresponding to C. glutamicum cell wall “P60” material) was removed, washed with 
buffer A with further centrifugation to remove Percoll, and the final cell wall fraction 
resuspended in buffer A to a final concentration of 8–10 mg/mL.  
The initial, standard reaction to measure incorporation of [14C]GlcNAc from UDP-
[14C]GlcNAc, [14C]Rha from dTDP-[14C]Rha, [14C]Gal from UDP-[14C]Gal, and [14C]Ara 
from p[14C]Rpp were as follows. Decaprenol phosphate (50 µg, 5 mg/mL stored in ethanol, 
10 µL) was dried under nitrogen and was resuspended by the addition of 50 µL of a 1% 
IgePal CA-630 (Sigma Aldrich) solution in buffer A and sonicated. The basic assay mix 
consisted of 2 mg of membranes and 0.5 mg cell wall “P60” from either C. glutamicum or C. 
glutamicumΔrptA, 1 mM ATP, and 1 mM NADP in a final volume of 160 µL of buffer A 
and initiated by the addition of either 100,000 cpm UDP-[14C]GlcNAc (ammonium salt; 
Amersham, Bucks, United Kingdom, specific activity 214 mCi/mmol), 200,000 cpm dTDP-
[14C]Rha (enzymatically synthesized as described in Mikusova et al. (1996) specific activity 
300 µCi/µmol kindly donated by Prof Michael McNeil, Colorado State University), UDP-
[14C]Gal (ammonium salt; Amersham, Bucks, United Kingdom, specific activity 257 
mCi/mmol) and 50,000cpm p[14C]Rpp (enzymatically synthesized as described in section 
6.6.2, specific activity 250 µCi/µmol). Reactions were incubated at 37°C for 2 hr and 
quenched by the addition of CHCl3/CH3OH (1066 µl, 1:1, v/v) and mixed at room 
temperature for 30 min. The samples were then centrifuged at 27,000  g at room 
temperature for 20 min and the supernatant was removed from the pelleted material and H2O 
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(230 µl) and CHCl3 (537 µl) added to the previously extracted supernatant, mixed at room 
temperature for 30 min and then centrifuged at 5,000  g. The lower organic fraction was 
recovered and washed twice with CHCl3/CH3OH/H2O (613 µl, 3:47:48, v/v/v). After 
centrifugation at 5,000  g for 10 min, the lower organic fraction was recovered and dried 
under compressed nitrogen. The resulting extract was resuspended in CHCl3/CH3OH (100 µl, 
2:1, v/v). An aliquot (10 µl) from each assay was subjected to scintillation counting and the 
remainder of the sample analyzed by TLC using silica gel plates (5735 silica gel 60F254, 
Merck), developed in CHCl3/CH3OH/NH4OH/H2O (65:25:0.5:3.6, v/v/v/v) and visualized by 
autoradiography by exposure of Kodak X-Omat AR film to the TLC plates to reveal 
incorporation of either [14C]GlcNAc, [14C]Rha, [14C]Gal or [14C]Ara into solvent extractable 
lipids. 
6.5.4.5.1. Preparation of p[14C]Rpp 
Radiolabelled p[14C]Rpp was prepared as described (Hove-Jensen, 1985), but with 
modifications. 200 µCi  [14C]-D-glucose (0.7 µmoles, Amersham) was dried under 
compressed N2 and resuspended in 400 µl of 50 mM HEPES (pH 7.6), 5 mM MgCl2 and 0.5 
mM MnCl2. ATP (1 mM) and β-NADP (4 mM) was added to the reaction mixture before the 
addition of 5 units of hexokinase powder (Sigma Aldrich, UK) and the reaction mixture was 
incubated at room temperature for 5 min. Glucose-6-phosphate dehydrogenase (5 units, 
Sigma Aldrich, UK) was added and incubated for 5 min at room temperature before the 
addition of 6-phosphogluconate dehydrogenase (5 units, Sigma Aldrich, UK) and further 
incubated at 37 °C for 5 min. Phosphoriboseisomerase (5 units, Sigma Aldrich, UK) was then 
added and the reaction mixture incubated at 30 °C for 5 min. PRPP synthetase was prepared 
as described in Huang et al. (2005). 
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6.5.4.6. Chemical identification of decaprenol-1-monophosphate-rhamnopyranose. 
Membranes from C. glutamicum or C. glutamicumΔrptA were assayed as described above, 
but with or without the addition of 50 µg/mL tunicamycin. Decaprenylmonophosphate (50 
µg, 5 mg/ml stored in CHCl3/CH3OH (2:1, v/v)), was dried under nitrogen and resuspended 
by the addition of 107 µl of a 1% IgePal CA-630 (Sigma Aldrich) solution in buffer A and 
sonicated. The basic assay mix consisted of 2 mg of membranes, 0.5 mg cell wall “P60”, 1 
mM ATP, 1 mM NADP in a final volume of 160 µl and initiated by the addition of 5 mM of 
dTDP-Rha or 200,000 cpm of dTDP-[14C]Rha chemically synthesized as previously 
described (enzymatically synthesized as described in Mikusova et al., (1996) specific activity 
300 µCi/µmol kindly donated by Prof Michael McNeil, Colorado State University) and 
incubated at 37 °C for 1 h. Assays performed using dTDP-[14C]Rha were processed as 
described above, whereas assays performed using cold dTDP-Rha were replenished by the 
addition of a further 2 mg of membranes and 0.5 mg of cell wall “P60” with further 
incubation at 37°C for 1 h. This process was repeated for a total of three additions with a 
final assay volume of 250 µL. Assays were quenched by the addition of CHCl3/CH3OH 
(3330 µl, 1:1, v/v), 1.6 M NaOH (250 µl) and mixed at room temperature for 30 min. The 
samples were then centrifuged at 27,000  g at room temperature for 30 min and the 
supernatant was removed from the pelleted material. H2O (720 µl) and CHCl3 (1678 µl) was 
added to the previously extracted supernatant, mixed at room temperature for 30 min and 
then centrifuged at 5,000  g. The lower organic fraction was recovered and washed twice 
with 1.92 ml of CHCl3/CH3OH/H2O (1.92 ml, 3:47:48, v/v/v). After centrifugation at 5,000 
 g for 10 min, the lower organic fraction was recovered and dried under nitrogen. The 
resulting extract was resuspended in CHCl3/CH3OH (100 µl, 2:1, v/v) and analyzed by 
electrospray mass spectrometry (ES-MS) in the negative mode on a Micromass LCT mass 
spectrometer. 
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6.5.5. Treatment of M. smegmatis and M. smegmatis∆aftC with sub-inhibitory 
concentrations of EMB and subsequent lipoglycan analysis.  
M. smegmatis and M. smegmatis∆aftC were grown in 100 mL TSB as described above. Once 
an O.D600 of 0.4 was reached, EMB was added to cultures of M. smegmatis∆aftC at a 
concentration of 0 and 0.5 and 1.0 µg ml-1. After a further 2 h incubation, 66 µCi of [U-14C]-
D-glucose (specific activity 300 mCi/mmol, ARC radiochemicals) was added to all cultures 
and incubated for a further 48 h. Cells were harvested by centrifugation and the lipoglycans 
were extracted and analysed by SDS-PAGE, as described above. Further analysis on the 
[14C]-incorporated sugars was performed as described. Equal counts of extracted [14C]-
labelled lipoglycans (50,000 cpm) from each growing culture were then hydrolyzed by using 
100 µL of 2 M TFA for 1 h at 120°C, dried, resuspended in 2 mL of CHCl3/H2O (1:1, v/v), 
and the upper aqueous phase recovered and dried. The residual radiolabeled sugars were 
resuspended in 20 µL of H2O and subjected to TLC using cellulose-coated aluminum plates 
(HPTLC-Aluminum Cellulose, Merck) and developed three times in formic acid/H2O/tert-
butanol/methyl ethyl ketone (3:3:8:6, v/v/v/v). Sugars were visualized by TLC exposure to 
X-ray film (Kodak X-Omat) and quantified by densitometry. 
6.5.6. Treatment of WT-LAM, AftC-LAM and Pam3CSK4 with H2O2 
All immunomodulatory analyses were conducted by Jerome Nigou at the Department of 
Medical Microbiology and Infection Control, Amsterdam, Netherlands. WT-LAM, AftC-
LAM and Pam3CSK4 (Invivogen) were treated with H2O2 as described (Morr et al., 2002; 
Zahringer et al., 2008). WT-LAM and AftC-LAM (0.2 mg ml-1) and Pam3CysK4 (1 µg ml-1) 
were incubated in the dark at 4oC in the absence or presence of 1% H2O2. After incubation 
for various periods of time, the samples were snap-frozen, using liquid nitrogen, and 
lyophilized. 
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6.5.7. Cell culture 
The human myeloid THP-1 monocyte/macrophage human cell line was maintained in 
continuous culture with RPMI 1640 medium (Invitrogen), 10% fetal calf serum (Lonza) in an 
atmosphere of 5% CO2 at 37 °C, as non-adherent cells. Purified native or modified 
lipogycans as well as the other stimuli were added in duplicate or triplicate to 
monocyte/macrophage cells and then incubated for 20 h at 37 °C. HEK293 cells transfected 
with TLR2 (Mambula et al., 2002) were kept in DMEM (Invitrogen) containing 10% FCS, 
100 units ml-1 penicillin,100 µg ml-1 streptomycin, 0.5 mg ml-1 GW418, 2 mM L-glutamine, 
and 110 mg L-1 pyruvate.  
6.5.8. Cell stimulation assays 
Cells (HEK293 cells were first released by trypsinisation) were washed with and resuspended 
in culture medium at 1.25x106 cells ml-1. 80 µl (1x105 cells) was transferred to a 96-well U-
bottom plate (Greiner) and left for 2 h, followed by incubations in triplicate with H2O2-
treated WT-LAM, AftC-LAM, Pam3CSK4 or with LPS (from Salmonella enterica serovar 
Abortusequi (Sigma-Aldrich L5886)) in a final stimulation volume of 100 µl. Unstimulated 
cells served as controls. Culture supernatants were harvested after 24 h by centrifugation and 
stored at -80°C for cytokine measurements using enzyme-linked immunosorbent assay 
(ELISA). Human IL-8 and TNF-α concentrations were determined in ELISA according to 
the manufacturer’s instructions (Invitrogen and R&D systems, respectively). 
6.5.9. DC-SIGN-Fc ELISA 
WT-LAM and AftC-LAM (1 µg ml-1 in saline (100 µL) were coated on NUNC Maxisorp 
plates (Roskilde) overnight at 4oC. Plates were blocked with 1% bovine serum albumine 
(BSA) and serially diluted DC-SIGN-Fc (van Die I et al., 2003) was added for 2 h at room 
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temperature. Then the plates were washed four times with Tris-buffered saline with 1 mM 
MgCl2, 2 mM CaCl2, 0.05% Tween-80 (TSMT) and incubated with goat-anti-human IgG 
antibody conjugated with peroxidase (Jackson Immunoresearch). Plates were washed eight 
times with TSMT and developed using o-phenylenediamine dihydrochloride and absorption 
measured at 490 nm.  
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